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Abstract 
 
Much of the mammalian genome is composed of repetitive elements, consisting of tandem 
and interspersed repeats. Heterochromatinisation of pericentromeric tandem satellite 
repeats plays an important role in centromere formation and maintenance of genome 
stability. Additionally, several human diseases are caused by microsatellite repeat 
expansion. Among different classes of interspersed repeats, retro-elements LINEs and SINEs 
are considered to contribute to genome evolution; however they also pose a potential 
threat to genome stability. Hence it appears essential that repetitive elements are 
transcriptionally silenced, which occurs via heterochromatinisation. To further understand 
heterochromatin formation, this thesis investigated: (i) the frataxin (FXN) gene which 
contains a GAA-repeat expansion causing FXN silencing which in turn leads to the 
neurodegenerative disease Friedreich’s ataxia (FRDA); (ii) the effect of proteasome 
inhibition on the transcription of heterochromatinised DNA repeats. Here, the silenced FXN 
gene was shown to be upregulated by treatment of FRDA patients with the HDAC inhibitor, 
nicotinamide. This upregulation was accompanied by reduction of the heterochromatin 
histone modification H3K9me3. Moreover, the proteasome was found at the 
heterochromatinised FXN gene in cells derived from patients, consistent with the hypothesis 
that, in FRDA, proteasomal degradation of a stalled RNAPII might contribute to FXN 
silencing. Although proteasome inhibition did not upregulate FXN transcription, it caused 
transcriptional activation of pericentromeric satellite repeats which appeared to be 
independent of cell-cycle perturbations and was accompanied by delocalisation of HP1α 
from chromocentres without detectable changes in the levels of histone modifications. 
Proteasome inhibition also increased the number of chromocentres per cell consistent with 
destabilisation of chromocentres. This effect of proteasome inhibition in upregulation of 
pericentromeric repeats was shown to be at least partly dependent on activation of heat 
shock transcription factor and binding of this factor to a consensus sequence within the 
pericentromeric satellite repeat region.  
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CHAPTER 1: General Introduction 
 
1. Chromatin structure 
In the nuclei of eukaryotic cells DNA is complexed with proteins to form nucleosomes which 
are the basic subunits of chromatin. Eukaryotic nucleosome is formed by 146 base pairs of 
DNA wrapped around octamers of the four core histone proteins H2A, H2B, H3 and H4. Each 
histone consists of a globular domain and a flexible N-terminal tail, which protrudes from 
the surface of a nucleosome (Figure 1.1A) (Kornberg, 1974; Luger, Mader, Richmond, 
Sargent, & Richmond, 1997). Adjacent nucleosomes are joined by a varying length of linker 
DNA which interacts with histone H1 triggering chromatin compaction (Woodcock, 
Skoultchi, & Fan, 2006). Until recently it was believed that chromatin compaction occurs 
through a hierarchical packaging model where nucleosomes form a 10nm thick “beads-on-a-
string” conformation, which coil into a 30nm higher ordered fibre, which further compacts 
into 100-200nm fibres (Finch & Klug, 1976; F. Song et al., 2014; Tremethick, 2007; Widom, 
1992; Woodcock & Dimitrov, 2001). However, recent study (Ricci, Manzo, Garcia-Parajo, 
Lakadamyali, & Cosma, 2015) using super resolution nanoscopy combined with computer 
simulation, argues against this ordered fibre structure, suggesting that nucleosomes are 
arranged into distinct domains called nucleosome clutches alongside the chromatin fibre. 
Each nucleosome clutch, which consists of heterogeneous number of nucleosomes, is 
separated by a nucleosome depleted region.  The larger and denser clutches, contain more 
nucleosomes and are enriched with histone H1, forming the closed chromatin structure - 
heterochromatin. On the contrary, smaller and less dense clutches are associated with RNA 
polymerase II (RNAPII) and forms a more open chromatin structure - euchromatin (Ricci et 
al., 2015) (Figure 1.1B).  
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Figure 1.1: Nucleosome and chromatin structure. (A) Nucleosome: The nucleosome is 
formed by the wrapping of 146bp DNA around octamers of the four core histone proteins 
H2A, H2B, H3 and H4. Each histone consists of a globular domain and N-terminal tails which 
protrude from the surface of the nucleosome (B) Chromatin structure: Chromatin is formed 
by nucleosome clutches. Each nucleosome clutch, which consists of a varying number of 
nucleosomes, is separated by nucleosome depleted regions. RNAPII is preferentially 
associated with smaller clutches and nucleosome depleted regions representing 
euchromatin regions whereas H1 is enriched in larger clutches representing 
heterochromatin regions. A is adapted from  (Tsankova, Renthal, Kumar, & Nestler, 2007).  B 
is based on the (Ricci et al., 2015) 
 
 
 
Nucleosome 
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2.   Heterochromatin 
Originally the eukaryotic genome was first seen to be divided into two major compartments, 
by examining different DNA staining in an interphase cell nucleus under the microscope.  
Lightly stained areas of nucleus are known as euchromatin and darkly, densely stained areas 
comprise the heterochromatin (Heitz, 1928) (Figure 1.2).   
 
 2.1 Properties of heterochromatin  
There are significant differences both structurally and functionally between 
heterochromatin and euchromatin. Euchromatin is rich in transcriptionally active genes 
whereas highly compact heterochromatin is associated with transcriptional repression. A 
major role of the heterochromatin structure is to prevent the accessibility of dedicated 
machineries involved in transcription or other DNA based processes to the underlying DNA 
sequences. Other characteristics of heterochromatin include a reduced recombination rate, 
replication in late S-phase of the cell cycle and cluster formation primarily close to the 
nuclear periphery (Dillon & Festenstein, 2002).  
 
 
 
Figure 1.2: Mammalian cell nucleus (presented as grey) during interphase. Image of cells 
after DNA staining shows different compartment of the chromatin. The dark regions 
represent closed, transcriptionally silenced chromatin area (heterochromatin) whereas light 
region consist from transcriptional active, open chromatin area (euchromain) Adapted from 
(Yandim, Natisvili, & Festenstein, 2013).  
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Heterochromatin is further divided into facultative and constitutive heterochromatin 
(Natarajan & Schmid, 1971). Facultative heterochromatin is established through silencing of 
genes upon developmental cues therefore may form at various regions of the 
chromosomes. On the other hand, in most organisms, constitutive heterochromatin is 
considered as a more static structure, established at various repetitive DNA elements, 
therefore forming at the same genomic regions in all the cell types (Dillon, 2004).  
 
 
2.2 Heterochromatin regulation  
In multicellular organisms, heterochromatin is epigenetically regulated by various 
mechanisms including i) post-translational histone modifications ii) DNA cytosine 
methylation and iii) RNA interference.  
 
 
2.2.1 Histone modifications 
The histone consists of a globular domain and a flexible N-terminal tail, which protrudes 
from the surface of the nucleosome (Luger et al., 1997). Each histone can be a subject to 
post-translational modifications including acetylation, methylation, phosphorylation, 
ubiquitylation, sumoylation, ADP ribosylation, deiminitaion, proline isomerization (Bannister 
& Kouzarides, 2011)  and recently discovered crotonylation (Sabari et al., 2015). These 
modifications occur typically at the flexible N-terminal tail of core histones and are catalysed 
by numerous nuclear enzymes that act mainly on the lysine (K), arginine (R) or serine (S) 
residues. Nonetheless, some modifications have also been recently reported to occur on the 
globular histone domain (Bannister & Kouzarides, 2011). The diversity of histone 
modifications and their possible combinations contribute to the formation of the so called 
“histone code” which is thought to be established and regulated by the activity of “writers” 
and “erasers” which install and remove the modifications respectively. The main functions 
of these modifications are (i) changing the overall structure of chromatin by directly 
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affecting the hydrophobic or electrostatic state of histones or (ii) providing binding sites for 
chromatin “readers” which in turn can recruit additional chromatin modifiers and 
remodelling enzymes (Jenuwein & Allis, 2001). Importantly, the majority of the histone 
modifications appear to be reversible biochemical alterations, ensuring that chromatin 
regulation is a dynamic process that can respond to different cellular conditions (Kouzarides, 
2007). The common histone modifications and their effects on the transcription are shown 
in Table 1.  
This thesis will cover only acetylation and methylation of the N-terminal histone tails, which 
represent the most studied modifications.   
 
 
Histone modification Modified residue Transcriptional Activity 
Acetylation  H3 (K9, K14, K18, K56)  
H4 (K5, K8, K12, K16)  
H2A  
H2B (K5, K15, K16) 
 
Activation 
 
Methylation  
H3 (K4, K36, K79) 
H3 (K9, K27) 
H4 (K20) 
Activation 
Repression 
Phosphorylation H3 (S10) Activation 
Ubiquitination H2A (K119) 
H2B (K120) 
Activation 
Repression 
Sumoylation H4 (K5, K8, K12, K16) 
H2A (K125) 
H2B (K5, K15, K16) 
 
Repression 
Crotonylation H3 (K18) Activation 
 
Table 1: Common histone modifications and there effect on the gene transcription. Adapted 
from (Allis, 2007) and based on (Sabari et al., 2015) 
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2.2.1.1 Histone acetylation  
Histone acetylation was the first histone modification discovered present at various lysine 
residues of the N-terminal histone tails (Phillips, 1963). This histone modification is 
catalyzed by counteracting the action of two classes of enzymes with relative low substrate 
specificity: histone deacetylases (HDACs) and histone acetyltransferases (HATs) which 
remove and install acetyl groups from histones respectively.  Addition of acetyl groups to 
the histone N-terminal tails neutralises the positive charge of lysine residues, thereby 
weakening the attraction between DNA and the positively charged histones. This has the 
effect of opening up the chromatin structure which allows easier access of the 
transcriptional machinery to the underlying DNA sequences (Bannister & Kouzarides, 2011; 
Gorisch, Wachsmuth, Toth, Lichter, & Rippe, 2005; Tse, Sera, Wolffe, & Hansen, 1998; 
Zentner & Henikoff, 2013). Hence acetylation is primarily associated with the 
transcriptionally active state of chromatin with euchromatic regions being hyperacetylated 
in contrast with heterochromatin regions that are hypoacetylated (Halleck & Gurley, 1981; 
Hebbes, Thorne, & Cranerobinson, 1988; Jeppesen & Turner, 1993; Shahbazian & Grunstein, 
2007; Suka, Suka, Carmen, Wu, & Grunstein, 2001; Vaquero et al., 2004). Inhibition of the 
acetylation process or the components of the histone acetylation pathway is shown by 
multiple studies to cause heterochromatin disruption in mammalian cell lines (Robbins et 
al., 2005; Taddei, Maison, Roche, & Almouzni, 2001; L. P. Wu et al., 2008).  
Additionally, histone acetylation has also been shown to form a platform for recruitment of 
several bromodomain-containing proteins which can directly or indirectly regulate the 
transcription (Josling et al., 2012, Kanno et al., 2004, Dey et al., 2003). For example BRD4 
was shown to function as transcriptional regulator by recruiting positive transcription 
elongation factor complex (PTEFb) to the target sites (Jang et al., 2005, Yang et al., 2005) as 
well as interacting with elongating RNAPII (Kanno et al., 2014) resulting in the release of the 
RNAPII from the promoter proximal pausing. However, it is noteworthy that a study has also 
revealed the link between histone acetylation and transcriptional repression, which was 
shown to be mediated through BRD4 bromodomain proteins (Wu & Chiang, 2007).  
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2.2.1.2 Histone methylation  
Methylation of histone tails (at lysine and arginine residues) is a more complex 
phenomenon, compared to acetylation, since it is associated with both the active and the 
repressed chromatin state – depending on the type of methylation and the position of the 
methylated histone residue (Kouzarides, 2007). The outcome of the histone methylation is 
primarily creation of binding sites recognised by the chromatin ‘readers’ and alteration of 
hydrophobicity which in turn induces conformation changes of the histones (D. Y. Lee, 
Teyssier, Strahl, & Stallcup, 2005).  
The knowledge regarding the arginine methylation, which can exist only as mono and 
dimethylation (Bedford & Richard, 2005) is limited and will not be discussed further in this 
thesis.  
The lysine methylation can exist as mono, di and trimethylation. This covalent histone 
modification which involves the transfer of a methyl group (R-CH3) from S-adenosyl-L-
methionine (SAM) to the N – terminal histone tails, is carried out by evolutionarily 
conserved histone lysine methyltrasferases (HKMTs).  On the other hand, removal of the 
methyl group from histones is catalysed by histone lysine demethylases (HKDMs) (J. C. 
Black, Van Rechem, & Whetstine, 2012; Y. Shi & Whetstine, 2007; Shilatifard, 2006).  
Unlike enzymes involved in regulation of histone acetylation, HKMTs and HKDMs are highly 
specific to distinct histone residues. Among the many histone methylation sites identified to 
date, histone H3 trimethylation of residue K4 and K36 are primarily found in euchromatic 
regions (Hon, Hawkins, & Ren, 2009), whereas histone H3 methylation of residue K9 and 
histone H4 methylation of K20 are predominantly associated with constitutive 
heterochromatic regions (Kourmouli et al., 2004; Martens et al., 2005; Saksouk, Simboeck, & 
Dejardin, 2015; Schotta et al., 2004). More details regarding these modifications will be 
discussed in the following section. In contrast, the facultative heterochromatin regions are 
mostly linked with trimethylation on residue K27 on histone 3 (H3K27me3), which is 
established through EZH2 HKMT, known as part of Polycomb repressor complex 2 (PRC2). 
The H3K27m3 forms a platform for recruitment of PRC1 complex in order to form a compact 
chromatin structure therefore transcriptional silence facultative heterochromatin (Heard, 
2005; Plath et al., 2003; Simon & Kingston, 2013).  
 
30 
 
2.2.1.2.1 Formation and function of H3K4 methylation 
Among many histone modifications that are generally associated with transcriptional 
activation is histone 3 lysine 4 (H3K4) methylation (Santos-Rosa et al., 2002; Strahl, Ohba, 
Cook, & Allis, 1999). This mark exists as mono, di and tri-methylation and is catalysed by a 
single SET domain containing 1 (SET1) HKMTs in yeast and by a number homologues of the 
SET1-family in mammals including SET1A, SET1B, mixed lineage leukemia (MLL -1, -2, -3, -4) 
family of enzymes, SET and MYND domain containing 3 (SMYD3), SET domain-containing 
protein 7 (SETD7), small or homeotic discs 1 ASH1-like protein (ASH1L) (Briggs et al., 2001; 
Brinkmeier et al., 2015; Dou et al., 2006; Gu & Lee, 2013; Hamamoto et al., 2004; J. H. Lee, 
Tate, You, & Skalnik, 2007; Roguev et al., 2001; Soares, Radman-Livaja, Lin, Rando, & 
Buratowski, 2014; South, Harmeyer, Serratore, & Briggs, 2013; Yokoyama et al., 2004). 
Each methylation level has a distinct distribution and function. More specifically, H3K4me3 
is particularly enriched at active or poised promoters (close to the TSS) of genes and is 
established co-transcriptionally thought that HKMTs interact with the serine 5-
phosphorylated C-terminal domain of RNAPII (initiating RNAPII) (Ardehali et al., 2011; 
Krogan et al., 2003; J. H. Lee & Skalnik, 2008; Ng, Robert, Young, & Struhl, 2003).  
Following deposition, H3K4me3 mediates the recruitment of various factor that promote 
transcription, such as HATs, chromatin remodellers and the transcription factor II D (TFIID) 
(Clouaire, Webb, & Bird, 2014; Lauberth et al., 2013; Vermeulen et al., 2007; Wysocka et al., 
2006). On the other hand H3K4me2 is found downstream of the promoter, throughout the 
gene body and is associated with HDACs which in turn deacetylates histones (T. Kim & 
Buratowski, 2009; T. Kim, Xu, Clauder-Munster, Steinmetz, & Buratowski, 2012; C. L. Liu et 
al., 2005; Pokholok et al., 2005). Finally, H3K4me1 is mainly present at active, closed or 
poised enhancers with as yet unknown function (Shlyueva, Stampfel, & Stark, 2014).  
 
 
2.2.1.2.2 Formation and function of H3K36 methylation  
One of the histone modifications that regulates chromatin structure during transcription is 
histone H3 lysine 36 methylation (H3K36me). In yeast, all three methylation states, mono, di 
and tri are established by a single SET domain containing 2 (SET2) HKMT (Strahl et al., 2002). 
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However, the higher eukaryotes contain several HKMTs that show preference for different 
methylation levels. For example nuclear receptor SET domain-containing 1, 2, 3 (NSD1, -2, -
3) catalyses mono and dimethylation of H3K36 generating H3K36me1 and H3K36me2 
respectively, whereas SET2 has a specific trimethylase activity where it adds a methyl group 
to H3K36me2 thereby creating H3K36me3, which positively correlates with transcription 
rates (Wagner & Carpenter, 2012). Each methylation state of H3K36 has a different 
distribution within the cells, with an overall progressive shift from mono, to di and to tri 
methylation from the promoter to the 3’ end of active genes (Bannister et al., 2005; Bell et 
al., 2007).  
The SET2 mediated methylation of H3K36me3 is regulated by the Serine 2-phosphorylated 
C-terminal domain of RNAPII (elongating RNAPII), which directly interacts and recruits the 
SET2 HKMT to its target sites (Krogan et al., 2003; B. Li, Howe, Anderson, Yates, & Workman, 
2003; J. Li, Moazed, & Gygi, 2002; T. Xiao et al., 2003). Subsequently, the H3K36me3 serves 
as a binding site for HDAC complex recruitment which in turn deacetylates histones and re-
establishes the compact chromatin structure in the wake of transcribing RNAPII (Carrozza et 
al., 2005; Joshi & Struhl, 2005; B. Li et al., 2003). Furthermore, H3K36me3 also suppresses 
histone exchange as well as inhibiting the interaction of H3 with histone chaperones 
throughout the coding regions (Keogh et al., 2005; Venkatesh et al., 2012).   
Notably, the function of H3K36 methylation is not restricted to transcriptional activation as 
it has also been associated with various other processes, including DNA repair and 
alternative splicing (Fnu et al., 2011; Jha & Strahl, 2014; Kolasinska-Zwierz et al., 2009; Luco 
et al., 2010).   
 
2.2.1.2.3 Formation and function of H4K20 methylation  
Methylation of histone H4 lysine 20 is an evolutionarily conserved histone modification 
mark existing in mono, di and trimethylation states. Each state has a different biological 
function and is established by activity of distinct HKMTs (Jorgensen, Schotta, & Sorensen, 
2013). Monomethylation of H4K20 is catalysed by SET8/PR-Set7 and is predominantly 
associated with DNA replication (Abbas et al., 2010; Fang et al., 2002; Jorgensen et al., 2007; 
Nishioka et al., 2002; Tardat et al., 2010; S. M. Wu et al., 2010). On the other hand, 
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dimethylation of H4K20 is mediated by SUV420H1 (suppressor of variegation 4-20 
homologue – isoform 1)  and serves as a binding site for DNA damage recognition proteins 
and thereby facilitates DNA damage repair (Botuyan et al., 2006; Sanders et al., 2004; 
Schotta et al., 2008). Lastly, trimethylation of H4K20 is catalysed by the activity of 
SUV420H2 (suppressor of variegation 4-20 homologue – isoform 2) enzymes and is 
considered as another “hallmark” of constitutive heterochromatin (Benetti et al., 2007; 
Schotta et al., 2004; Schotta et al., 2008).  A mechanism of SUV420H2 targeting to 
heterochromatin regions is believed to occur through synergistic interactions with multiple 
heterochromatin proteins (M. Hahn et al., 2013; Schotta et al., 2004).  
The function of SUV420H2 in heterochromatin regions is not clear however evidence 
suggests that SUV420H2 induces chromatin compaction through interaction with 
heterochromatin proteins as well as cohesin recruitment to heterochromatin, a molecule 
important in chromatid cohesion and chromosome segregation (M. Hahn et al., 2013).  
 
 
 
2.2.1.2.4 Formation and function of H3K9 methylation 
The initial step of mammalian heterochromatin formation is proposed to occur through 
monomethylation of free histone H3 at the lysine 9 residue which is thought to take place 
before incorporation into chromatin within the cytoplasm. This reaction is catalysed by 
Prdm3 and Prdm16 HMTs, whose concomitant depletion was shown to disrupt 
heterochromatin structure (Pinheiro et al., 2012). The monomethylated H3K9 (H3K9me1) is 
then translocated from the cytoplasm to the nucleus and incorporated at heterochromatin 
sites where it is further di and trimethylated by H3K9-specific lysine methyl-transferases, 
SUV39H1/2 (suppressor of variegation 3-9 homologue; two isoforms -1 and -2) (Pinheiro et 
al., 2012; Rea et al., 2000).  
The activity of SUV39H is an important factor for the regulation of constitutive 
heterochromatin as loss of SUV39H was reported to impair mammalian heterochromatin (A. 
H. Peters et al., 2003; A. H. F. M. Peters et al., 2001).  
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Importantly, H3K9me3 is regarded as the “hallmark‟ of constitutive heterochromatin in the 
majority of eukaryotes and serves as a docking site for binding of heterochromatin protein 
(HP1) (Bannister et al., 2001; Guenatri, Bailly, Maison, & Almouzni, 2004; Lachner, O'Carroll, 
Rea, Mechtler, & Jenuwein, 2001; Mosch, Franz, Soeroes, Singh, & Fischle, 2011).  
 
2.2.2 Heterochromatin protein 1  
Heterochromatin protein 1 (HP1) is a highly conserved non-histone chromosomal protein, 
present in all eukaryotic organism, ranging from fission yeast to mammals, with the 
exception of budding yeast Saccharomyces cerevisiae (P. B. Singh et al., 1991).  In mammals 
it consists of three isoforms named HP1α, HP1β and HP1γ.  Structurally, all isoforms contain 
an N-terminal chromodomain (CD), a hinge domain and a C-terminal chromoshadow 
domain (CSD) (Figure 1.3A) (Canzio, Larson, & Narlikar, 2014; Hiragami & Festenstein, 2005). 
The CD functions as the chromatin-binding domain as it specifically recognises H3K9 
methylation, with the highest binding efficiency for H3K9me3 over H3K9me2 or H3K9me1 
(Bannister et al., 2001; Fischle et al., 2003; Lachner et al., 2001). On the other hand the CSD 
is responsible for HP1 dimerization and interaction with numerous proteins containing 
PXVXL (where P = Proline, V = Valine, L = Leucine and x is any amino acid) penta-peptide 
motif (Brasher et al., 2000; Cowieson, Partridge, Allshire, & McLaughlin, 2000; Thiru et al., 
2004), HDACs (C. L. Zhang, McKinsey, & Olson, 2002), DNA methyltransferases (DNMTs) 
(Bachman, Rountree, & Baylin, 2001; Fuks, Hurd, Deplus, & Kouzarides, 2003; Lehnertz et 
al., 2003) and  SUV39H (Aagaard et al., 1999; Bannister et al., 2001; Hiragami & Festenstein, 
2005; Yamamoto & Sonoda, 2003). Notably, previous reports concluded that the interaction 
of HP1 with SUV39H creates a positive feedback loop for formation and maintenance of 
heterochromatin as well as stimulating its spreading into adjacent regions (Figure 1.3B) (S. I. 
Grewal & Jia, 2007; Muller-Ott et al., 2014; Schotta et al., 2002). However, a recent study 
clearly showed that SUV39H1-HP1 binding is dispensable for H3K9me3 (Muramatsu et al., 
2013). Lastly, a variable length hinge region that connects the CD with CSD is less 
evolutionary conserved and was reported to binds to histone H1, DNA and RNA in order to 
enhance HP1 binding affinity for nucleosomes containing H3K9me3 (Badugu, Yoo, Singh, & 
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Kellum, 2005; Meehan, Kao, & Pennings, 2003; Muchardt et al., 2002; Nielsen et al., 2001; 
Smothers & Henikoff, 2001; T. Zhao, Heyduk, Allis, & Eissenberg, 2000).  
The interaction of HP1 with chromatin is not a static but rather a dynamic interaction 
affected by various cellular processes including differentiation and cell cycle (Cammas, 
Herzog, Lerouge, Chambon, & Losson, 2004; Cheutin et al., 2003; Festenstein et al., 2003; 
Minc, Allory, Worman, Courvalin, & Buendia, 1999). For example, although H3K9me3 is 
present throughout the cell cycle, HP1α was reported to get evicted from heterochromatin 
during the mitosis (Fischle et al., 2005).  
Despite the structural similarities, different HP1 isoforms have distinct localization patterns 
within cells, with HP1α and HP1β predominantly associated with heterochromatin regions 
(Wreggett et al., 1994), whereas HP1γ was found to be located both in euchromatic and 
heterochromatin regions (Fanti, Berloco, Piacentini, & Pimpinelli, 2003; Minc et al., 1999; 
Minc, Courvalin, & Buendia, 2000). Furthermore, different HP1 isoforms also have distinct 
cellular functions, as different phenotypes were detected in mice deficient for each HP1 
isoform (Abe et al., 2011; Aucott et al., 2008; Brown et al., 2010; Hiragami & Festenstein, 
2005; Minc et al., 1999; Nielsen et al., 2001). It is also noteworthy that functions of HP1 are 
not restricted to gene repression and heterochromatin formation, as growing evidence also 
indicates its role in transcriptional activation (Johansson, Stenberg, Pettersson, & Larsson, 
2007; Kwon et al., 2010; Mateescu, Bourachot, Rachez, Ogryzko, & Muchardt, 2008; 
Piacentini, Fanti, Berloco, Perrini, & Pimpinelli, 2003; Saint-Andre, Batsche, Rachez, & 
Muchardt, 2011; Vakoc, Mandat, Olenschock, & Blobel, 2005).  
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Figure 1.3: HP1 isoforms and Heterochromatin formation/spreading. (A) HP1 isoforms: 
Mammals contain three HP1 isoforms which contain N-terminal H3K9 binding 
chromodomain (CD), a linker hinge domain and a C-terminal chromoshadow domain (CSD) 
that is involved in HP1 dimerisation and protein binding. (B) Heterochromatin formation and 
spreading by combinatory activity of HP1 and SUV39H. SUV39H catalyse H3K9 methylation, 
which is recognised by HP1 protein. Once HP1 binds, it can cause spreading of H3K9me3 to 
adjacent nucleosomes via its direct association with SUV39H. In addition, HP1 via its 
chromoshadow domain is able to self-associate and lead to the spread of heterochromatin. 
Although this was a good model for heterochromatin formation, recent data argue against 
its veracity (Muramatsu et al., 2013). B Adapted from (Yandim et al., 2013).  
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2.2.3 DNA methylation  
DNA methylation is a highly conserved epigenetic modification of DNA, present in most 
eukaryotic organisms that impacts upon many cellular process including heterochromatin, 
gene expression and genome stability (Feng et al., 2010; Law & Jacobsen, 2010). In 
mammals it is mainly established within the CpG dinucleotide context where cytosine is 
covalently methylated on the fifth position (5-methylcytosine, 5mC) by activity of three 
distinct DNA methyltransferases, DNMT1, DNMT3a and DNMT3b (X. Cheng & Blumenthal, 
2008; Holliday & Pugh, 1975; Riggs, 1975). DNMT1 is the so called maintenance DNMT 
regulating faithful maintenance of methylation patterns upon DNA replication (Hermann, 
Goyal, & Jeltsch, 2004), whereas DNMT3a and DNMT3b are de novo DNMTs that catalyse 
new DNA methylation patterns predominantly during early development and 
gametogenesis (Okano, Bell, Haber, & Li, 1999) .  
Despite, the stable maintenance of DNA methylation patterns in somatic cells, passive or 
active DNA demethylation (genome-wide loss of 5mC) takes place during specific stages of 
development (H. Wu & Zhang, 2014).  
Importantly, 60-80% of human CpGs are methylated in somatic cells, many of which occur in 
heterochromatin regions (Z. D. Smith & Meissner, 2013). Consistently, many chromatin 
repressive factors (SUV39H1/2 and HP1) were reported to associate with DNMTs 
(DNMT3a/3b) (Cedar & Bergman, 2009; Lehnertz et al., 2003) . On the contrary, the CpG 
islands which are found in approximately 70% of annotated promoters, including all 
housekeeping and developmentally regulated genes are constantly hypomethylated 
(Deaton & Bird, 2011; Z. D. Smith & Meissner, 2013).  Moreover DNA methylation may 
affect gene transcription by physically blocking the access of proteins that bind to 
unmethylated CpGs or attract methyl-CpG-binding domain proteins (MBDs), which in turn 
form docking sites for number of chromatin remodelling factor such as HDACs (Dhasarathy 
& Wade, 2008; P. L. Jones et al., 1998b; R. P. Sharma, Gavin, & Grayson, 2010).  
Notably altered DNA methylation patterns have been associated with many diseases 
including cancer and neurodegenerative diseases (De Zhu, 2005; K. D. Hansen et al., 2011; 
Lopez-Serra & Esteller, 2012; H. Y. Lu, Liu, Deng, & Qing, 2013; Nishida, Kudo, Nagasaka, Ikai, 
& Goel, 2012; S. Sharma, Kelly, & Jones, 2010; H. Wood, 2013).  
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2.2.4 RNA interference  
RNA interference (RNAi) is a post-transcriptional gene silencing mechanism mediated 
through small RNA sequences (Castel & Martienssen, 2013). One class of these sequences 
include small interfering RNAs (siRNAs) which were shown to be required for constitutive 
heterochromatin formation in the fission yeast, S. Pombe (S. I. Grewal & Elgin, 2007; 
Reinhart & Bartel, 2002; Wassenegger, 2005). During this pathway dsRNA that generate 
from antisense transcription of heterochromatin regions is cleaved into siRNA by 
endoribonuclease activity of Dicer enzyme. These siRNAs are subsequently incorporated 
into a multi-protein complex, (RITS- RNA-induced transcriptional gene silencing) and target 
the heterochromatic regions where they recruit Clr4 (SUV39H homologue) which in turn 
catalyses H3K9me3 therefore inducing chromatin compaction and repression (Djupedal & 
Ekwall, 2009; Noma et al., 2004; Verdel et al., 2004; T. A. Volpe et al., 2002; Yu, Jih, Iglesias, 
& Moazed, 2014).  Notably, this mechanism is mainly studied in yeast. Despite the 
conservation of mechanisms involved in heterochromatin formation, evidence is sparse that 
RNAi components play role in heterochromatin formation in mammals.  
 
 
The summary of the main epigenetic factors that regulate transcriptionally repressed 
heterochromatin versus transcriptionally active euchromatin is shown in Figure 1.4. 
Importantly, local concentration of these factors and the presence of the binding sites at a 
given locus can greatly influence the final transcriptional state (Dillon & Festenstein, 2002; 
Yandim et al., 2013) 
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Figure 1.4: Summary of the factors regulating switching between heterochromatin and 
euchromatin. Euchromatin is associated with DNA histone acetylation, H3K4m and lack of 
DNA methylation. Heterochromatin is linked with DNA methylation, histone deacetylation, 
H3K4 demethylation, H4K20m, H3K9m, H3K27m and “glue” proteins including HP1 and 
PRC1. Adapted from (Yandim et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H4K20 methylation  
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3. Repetitive DNA Element  
The majority of the mammalian genome is known to consist of repetitive DNA elements and 
non-coding sequences including intragenic and regulatory sequences (E. S. Lander et al., 
2001; Waterston et al., 2002). More specifically, only 4% of the mouse genome comprises 
coding sequences, whereas 44% is repetitive and 52% noncoding DNA. Similar composition 
occurs in the human genome with 55% repetitive sequences. Heterochromatinisation of 
these elements is important for maintenance of both chromosome structure and genome 
integrity (Peng & Karpen, 2009; A. H. F. M. Peters et al., 2001; J. M. Peters, Tedeschi, & 
Schmitz, 2008; Pidoux & Allshire, 2005).  
Repetitive DNA elements are classified into two major categories; interspersed repetitive 
elements, which are singular repetitive elements that are distributed throughout the 
genome and tandem repetitive elements which are present in a head to tail orientation 
without sequences between repeating units (Martens et al., 2005; Padeken et al., 2015). 
Each of the categories is further divided into several subfamilies. Interspersed repetitive 
elements are mainly comprised of transfer DNA (tDNA), gene paralogues and all 
transposons. On the other hand tandem repetitive elements consist of ribosomal DNA 
repeats (rDNAs), gene tandems and satellite DNA repeats which are in turn divided into 
mini/micro-satellites and classic satellites. Classic satellite DNA repeats can be further 
subdivided based on their chromosomal distribution into telomeric, pericentromeric and 
centromeric satellites (Richard et al., 2008). A schematic representation of different class of 
repetitive DNA elements is shown in Figure 1.5. 
This thesis is mainly focused on transposons and satellite repeats. Hence their basic 
structure, function and regulation will be discussed in the following sections. 
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Repetitive DNA Elements 
Interspersed Repeats Tandem Repeats 
Transposons 
Retrotransposons 
Non-LTRs LTRs 
LINEs SINEs 
tDNAs Paralogues  
DNA Transposons 
Tandem Paralogues rDNAs  Satellite 
 
Classic Satellites Mini/Micro-satellites 
Pericentromeric Centromeric Telomeric 
Figure 1.5: Schematic representation of DNA repetitive elements. Based on the reviews (Padeken, Zeller, & Gasser, 2015; Richard, 
Kerrest, & Dujon, 2008)  
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3.1 Transposons  
Transposons are widespread mobile genomic sequences that have the ability to move to 
different parts of the genome through transposition. Based on their mechanism of 
transposition, transposons are broadly classified in two main groups, DNA transposons and 
retrotransposons. DNA transposons use a “cut and paste” mechanism to insert themselves 
into new genomic locations whereas retrotransposons use “copy and paste” mechanisms 
via RNA as an intermediate (Y. J. Kim, Lee, & Han, 2012; Smit, 1996; Wicker et al., 2007; 
Zamudio & Bourc'his, 2010).  
 
3.1.1 DNA transposons 
Structurally, DNA transposons consist of a gene encoding transposase that is flanked on 
both sides by Inverted Terminal Repeats (ITRs). The transposase, acting as an endonuclease, 
recognises and binds these ITRs to catalyse the excision of the transposon from the existing 
locus, which is subsequently integrated into a new genomic location. The cleavage of the 
two DNA stands forms Target Site Duplications (TSDs) sites, which comprises a distinctive 
mark per DNA transposon (Levin & Moran, 2011; Munoz-Lopez & Garcia-Perez, 2010). Based 
on the homology of the transposases, sequence of ITR and/or TSD, DNA transposons are 
divided into 10 different families. Among them, Tc1 represents the most common family 
(Feschotte & Pritham, 2007). 
 
3.1.2 Retrotransposons  
Retrotransposons are the second major class of transposons that are able to duplicate 
themselves in the host genome through an RNA intermediate which is first reverse 
transcribed into a complementary DNA (cDNA) followed by integration into a new random 
genomic location. These elements are divided in two categories, retrotransposons with long 
terminal repeats (LTR retrotransposons) and without LTR (non-LTR retrotransposons) 
(Goodier & Kazazian, 2008; Levin & Moran, 2011; Padeken et al., 2015). The LTR class of 
retrotransposons have structural and functional similarities with retroviruses (Grandbastien, 
2015) and will not be discussed further in this thesis. Non-LTR retrotransposons are ancient 
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genetic elements that are further subdivided into long interspersed nuclear elements 
(LINEs) and short interspersed nuclear elements (SINEs) (Han, 2010).  
 
 
 
3.1.2.1 Long interspersed nuclear elements (LINEs) 
LINEs are the autonomous class of non-LTR retrotransposons found preferentially in AT rich 
regions in eukaryotic genomes (E. S. Lander et al., 2001). Their size varies between 6-8 kb 
and they are transcribed (or are evolutionary remnants of what were previously transcribed) 
to RNA predominantly by RNAPII. LINEs can be further divided into several subcategories 
such as L1, L2 or L3. Among them LINE-L1 is the most abundant and the only active LINE 
element within the mammalian genome (Richard et al., 2008). It constitutes 17% of the 
human genome out of which 99.8% appears to be inactive due to internal rearrangement, 
mutations and 5’ end truncation (Knight, 2009; Konkel & Batzer, 2010; E. S. Lander et al., 
2001).  
Structurally LINE-L1 elements contain the following regions: i) 5’UTR region which serves as 
an RNAPII promoter and transcription factor binding site, (ii) two ‘open reading frames’ 
(ORFs), ORF1 and ORF2; ORF1 encodes a chaperone protein that binds to RNA whereas 
ORF2 encodes protein with endonuclease (EN) and reverse transcriptase activity (RT), both 
essential for cDNA synthesis and insertion respectively and iii) a 3’UTR polyadenylation site 
(Babushok & Kazazian, 2007; Erwin, Marchetto, & Gage, 2014) (Figure 1.6A).  
The transposition of the active LINE-L1 occurs in 3 steps: i) the endonuclease nicks the target 
double-stranded DNA, (ii) poly(T) sequence anneals with LINE-L1 mRNA poly (A) tail at the 
nick site and cDNA is synthesized by reverse transcriptase and (iii) LINE-L1 mRNA gets 
degraded followed by second start synthesis and ligation, which results in the insertion of a 
full or a partial new LINE copy into a new genomic location (Deininger & Batzer, 2002; Jurka, 
1997; Levin & Moran, 2011; Padeken et al., 2015).  
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3.1.2.2 Short interspersed nuclear elements (SINEs) 
SINEs are a non-autonomous class of retrotransposons found preferentially in GC rich 
regions in eukaryotic genomes (E. S. Lander et al., 2001). These elements are short (100-
400bp) pseudogenes containing RNAPIII promoters and are dependent on the molecular 
machinery encoded by LINE elements for their transposition in the host genome as these 
elements do not encode any proteins (Dewannieux, Esnault, & Heidmann, 2003; Ivics & 
Izsvak, 2010).  
SINEs are among the most abundant repetitive elements in the mammalian genome, 
represented mainly by Alu and MIR in primates and B1 (a homologue to Alu), B2, and ID in 
rodents (Zamudio & Bourc'his, 2010). Both Alu and B1 elements consist of two and one 
monomers respectively (Figure 1.6B) and are products of a 7SL RNA gene duplication which 
occurred 80 million years ago, whereas the remainder is derived primarily from tRNA genes 
(Daniels & Deininger, 1985; Kramerov & Vassetzky, 2005; Tsirigos & Rigoutsos, 2009).  
A summary of the structure, the length and the copy number of LINEL1 and SINEB1 
elements in the mouse genome is shown in Figure 1.6.  
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 Full-length repeat unit  Copy number 
LINE L1 ~6 kb >500 000 
SINE B1 300 bp >500 000 
 
Figure 1.6: Overview of characteristics of non-LTR retrotransposons LINE L1 and SINE B1 in 
the mouse genome. (A) Structural organisation of LINE L1 element. LINE L1 consists of a 
5’UTR which serves as an RNAPII promoter, two ORFs that encode chaperone proteins that 
bind to RNA, an endonuclease (EN) and a reverse transcriptase (RT) and a polyA tail. (B) 
Structural organisation of SINE B1 element. SINE B1 is a short pseudogene with encoding no 
proteins, it contains an RNAPIII promoter and polyA tail. (C) Table illustrating the repeat unit 
length and the copy number of LINE L1 and SINE B1 elements. C was adapted and modified 
from (Martens et al., 2005).  
 
 
 
 
 
 
polyA  ORF1        ORF2 
5’-UTR 3’-UTR 
polyA 
A 
B 
C 
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3.1.3 Regulation of Retrotransposons 
Although the majority of retrotransposons are inactive and unable to transpose due to 
mutations or truncations, some of them are still active and affect the mammalian genome in 
many different ways including altering gene expression and splicing, generating insertion 
mutations, creating and repairing DNA double-strand breaks,  generating genomic 
rearrangements (such as deletions, duplications and inversions) (Cordaux & Batzer, 2009). 
All these effects may contribute to genomic evolution; however they can also pose a 
potential threat to genomic stability. Therefore it is not surprising that retrotransposition 
has been associated with many diseases, such as cancer, β-thalassemia, Duchenne muscular 
dystrophy, cystic fibrosis (Belancio, Hedges, & Deininger, 2008; Callinan & Batzer, 2006; J. 
M. Chen, Stenson, Cooper, & Ferec, 2005; Deininger & Batzer, 1999; Gualtieri et al., 2013; 
Lanikova et al., 2013; Musova et al., 2006; Schneider, Duffield, Symer, & Burns, 2009; K. 
Yoshida, Nakamura, Yazaki, Ikeda, & Takeda, 1998).  
In order to protect the genome from these deleterious effects, cells have acquired several 
epigenetic mechanisms to prevent mobilization of retrotransposons. Interestingly, these 
mechanisms differ in cycling and postmitotic cells. In somatic cells, DNA methylation is the 
primary driving factor for the silencing, with generally these elements being 
hypemethylated whereas histone modifications play only a minor role (Bierhoff, Postepska-
Igielska, & Grummt, 2014; Hutnick, Huang, Loo, Ma, & Fan, 2010; O'Donnell & Burns, 2010; 
Rollins et al., 2006; Teneng, Montoya-Durango, Quertermous, Lacy, & Ramos, 2011; Turelli 
et al., 2014; Walsh, Chaillet, & Bestor, 1998).  
However in postmitotic cells, in addition to DNA methylation, long noncoding RNAs 
(lncRNAs) were shown to trigger upregulation of H4K20me3 via recruitment of SUV420H to 
the locus (Bierhoff, Dammert, et al., 2014). Some evidence also suggests RNA dependent 
silencing of retrotransposons (Faulkner et al., 2009). For example in human cells 
bidirectional transcripts from LINE L1 elements were revealed to generate siRNAs that 
suppress retrotransposition by an RNAi mechanism (N. Yang & Kazazian, 2006). Additionally 
in the germline and in human induced pluripotent stem cells (iPSCs) Piwi-interacting RNA 
(piRNA) that derives from retrotransposon transcripts were shown to associate with PIWI 
proteins and mediate de novo DNA methylation and subsequent silencing of 
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retrotransposons (Aravin et al., 2008; De Fazio et al., 2011; Kuramochi-Miyagawa et al., 
2008; Marchetto et al., 2013).  
 
Importantly, the expression of retrotransposons seems to be dynamic and stage specific 
according to a recent study, where LTR (IAP) and non-LTR (LINE L1) retrotransposons were 
shown to reactivate in both parental genomes after fertilization through gain of the active 
H3K4me3 mark and are repressed during early mouse embryogenesis (Fadloun et al., 2013).  
 
 
 
 
 
 
 
 
 
3.2 Satellite repeats  
Satellite repeats are characterized by large tandem repeats present as array blocks in the 
genome with lengths reaching several millions of nucleotides. These elements are 
categorised into three groups based on the length of the repeat unit. The first group 
consists of the classic satellites, which is further divided into telomeric, centromeric and 
pericentromeric repeats. The second and third category of satellite repeats consists of 
minisatellites and microsatellites respectively (Richard et al., 2008). The length of 
minisatellites repeat units is 10-60bp (Jeffreys, 1997; Jeffreys, Wilson, & Thein, 1985) 
whereas microsatellites are shorter with a repeat unit between 1-6bp long (Abdul-Muneer, 
2014; Ellegren, 2000).   
Telomeric repeats are comprised of a highly conserved hexameric 5’-TTAGGG-3’ repeat 
sequence whose array constitutes the ends of eukaryotic chromosomes, the telomeres 
(Meyne, Ratliff, & Moyzis, 1989; Moyzis et al., 1988; Wicky et al., 1996). This specific DNA 
motif is recognised by conserved DNA binding machineries that are recruited to telomeres 
and regulate their structure and function (Y. Huang, Liang, Liu, Huang, & Songyang, 2014; 
Palm & de Lange, 2008; Schoeftner & Blasco, 2009). 
Centromeric repeats are present at the centromere, whereas pericentromeric repeats form 
the regions flanking the centromeres called pericentromeres (Eymery, Callanan, & Vourc'h, 
2009). In contrast to the telomeric repeat, the DNA sequences of centromeric and 
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pericentromeric repeats are not conserved and differ significantly between species or even 
between chromosomes of the same species (Allshire & Karpen, 2008; Heslop-Harrison, 
Brandes, & Schwarzacher, 2003; Saksouk et al., 2015). For example the human centromere 
is comprised of arrays of 171 bp α-satellite repeats, whereas pericentromeres contain array 
of chromosome specific pericentromeric repeats including satellites I, II and III, β-satellite 
and γ-satellite (J. H. Kim et al., 2009; M. K. Rudd, Wray, & Willard, 2006; Vissel, Nagy, & 
Choo, 1992). On the other hand in mice the centromeric and pericentromeric repeats 
consist of minor satellite repeats and A/T-rich major satellite repeats respectively (Guenatri 
et al., 2004; Komissarov, Gavrilova, Demin, Ishov, & Podgornaya, 2011; Martens et al., 
2005). A summary of the location, structure, the length and the copy number of major and 
minor satellites in the mouse genome is shown in the Figure 1.7.   
Although telomeres have an important role in protecting chromosomal integrity (Murnane, 
2012; O'Sullivan & Karlseder, 2010), this thesis is mainly focused on centromeres and 
pericentromeres.   
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
 
 
                                                                  
 
 Full-length repeat unit Copy number 
Major satellite repeat 234  bp >200 000 
Minor satellite repeat  123 bp >50 000 
 
Figure 1.7:  Overview of characteristics of classic satellite repeats in the mouse genome. (A) 
Schematic representation of the location and the general organisation of major and minor 
satellite repeats in a mitotic mouse chromosome. (B) Table illustrating the repeat unit 
length and the copy number of major and minor satellite repeats.  Adapted and modified 
from (Martens et al., 2005). 
 
 
 
 
 
 
 
Telomere 
Telomere 
Pericentromere:   Major satellite 
Centromere:   Minor satellite 
A 
B 
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3.3  Regulation of centromeres and pericentromeres 
Centromeres and pericentromeres have distinct chromatin structures, both of which are 
important for kinetochore assembly and proper chromosomal segregation during cell 
division (Ekwall, 2007; Fukagawa & Earnshaw, 2014; Rosic, Kohler, & Erhardt, 2014; Vos, 
Famulski, & Chan, 2006; Westhorpe & Straight, 2013). 
 
3.3.1  Centromeres  
Centromeres contain the centromere-specific histone H3 variant CENP-A which consists of a 
structural as well as functional foundation for the kinetochore formation (B. E. Black & 
Bassett, 2008; Guse, Carroll, Moree, Fuller, & Straight, 2011; Hori, Shang, Takeuchi, & 
Fukagawa, 2013; Perpelescu & Fukagawa, 2011; Warburton et al., 1997). This histone 
variant is periodically interrupted by nucleosomes containing H3K4me2 that is normally 
associated with open chromatin structures (Bergmann et al., 2011; Stimpson & Sullivan, 
2011; Sullivan & Karpen, 2004). Furthermore H4K20me1 has been recently identified to be 
an important factor for functional centromere formation (Hori et al., 2014). Additionally 
these domains generally lack heterochromatin histone modifications, lack histone 
acetylation and contain DNA methylation, giving the centromere an unusual chromatin 
structure that differs from both euchromatin and heterochromatin (Choy, Acuna, Au, & 
Basrai, 2011; Gopalakrishnan, Sullivan, Trazzi, Della Valle, & Robertson, 2009; Jeppesen, 
Mitchell, Turner, & Perry, 1992; Luo & Preuss, 2003; Okano et al., 1999; Sullivan & Karpen, 
2004).  
Importantly, centromeres that consist of arrays of centromeric satellite repeats have been 
reported to be transcriptionally active in multiple organisms, including plants, vertebrates 
and invertebrates. The regulation of the transcription is not clear; however these non-
coding transcripts are believed to play an important role in centromere formation and 
function (Bouzinba-Segard, Guais, & Francastel, 2006; F. L. Chan & Wong, 2012; Choi et al., 
2011; Gent & Dawe, 2012; H. R. Lee, Neumann, Macas, & Jiang, 2006; Y. X. Li & Kirby, 2003; 
Ohkuni & Kitagawa, 2011; Pezer & Ugarkovic, 2008; Sadeghi, Siggens, Svensson, & Ekwall, 
2014; Scott, 2013; Topp, Zhong, & Dawe, 2004; L. H. Wong et al., 2007; Yan et al., 2006). For 
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example transcripts from minor satellite repeats and α-satellite repeats in mouse and 
human respectively were revealed to facilitate the recruitment of centromeric proteins such 
as CENP-C, INCENP, Survivin and aurora B kinase (AUBK) to centromeres (F. L. Chan et al., 
2012; Y. Q. Du, Topp, & Dawe, 2010; Ferri, Bouzinba-Segard, Velasco, Hube, & Francastel, 
2009; L. H. Wong et al., 2007).  
Moreover, some studies also suggest that the balance of the centromeric transcription is 
equally important factor for centromere activity. Loss of centromeric transcript was 
accompanied by defective incorporation of CENP-A in centromeres during mitotic exit 
leading to a gradual centromere inactivation (Bergmann et al., 2011; F. L. Chan et al., 2012). 
Similarly, overexpression of these transcripts caused displacement of CENP-A as well as 
failure of further recruitment of these molecules to centromere resulting to centromere 
inactivation (Bergmann et al., 2012).  
 
3.3.2  Pericentromeres  
Pericentromeres are regions of the chromosomes that display constitutive heterochromatin 
structure. It is though vital for these regions to be maintained in a highly condensed 
chromatin state in order to provide a structural support for the centromere and to ensure 
genome stability in eukaryotic cells (Allshire, Nimmo, Ekwall, Javerzat, & Cranston, 1995; 
Kellum & Alberts, 1995; A. H. Peters et al., 2001; Vos et al., 2006).  
As mentioned in the previous section, pericentromeric regions are comprised of arrays of 
pericentromeric satellite repeats without conservation of their DNA sequence among 
different species. However, the common features between different pericentromeric 
regions are (i) the repetitive nature of these elements that might be an important factor for 
heterochromatin formation by an unknown mechanism (Garrick, Fiering, Martin, & 
Whitelaw, 1998; Henikoff, 1998) and (ii) the combination of specific repressive epigenetic 
modifications, including DNA methylation, histone hypoacetylation, H3K9me3, H3K64me3, 
H4K20me3 and associated HP1α/β proteins that cause pericentromeric 
heterochromatinisation (Bannister et al., 2001; S. I. S. Grewal & Moazed, 2003; Lange et al., 
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2013; Lehnertz et al., 2003; Probst & Almouzni, 2011; Saksouk et al., 2015; Schotta et al., 
2004) .  
 
Recent studies have confirmed the transcription of pericentromeric satellite repeats, albeit 
the heterochromatinisation of the locus (Enukashvily & Ponomartsev, 2013; Eymery, 
Horard, et al., 2009; Hall, Mitchell, & O'Neill, 2012; Rosic et al., 2014). Compared to the total 
number of genomic pericentromeric repeats, only a small subset (2% to > 10%) is believed 
to be transcribed, suggesting that transcription occurs as a rare event (Saksouk et al., 2015). 
Furthermore, this transcription was shown to be mediated by RNAPII (Djupedal et al., 2005; 
Kato et al., 2005; J. Lu & Gilbert, 2007) and derived from both strands generating sense (in 
mice: T-rich; in humans: GGAAT) or antisense (in mice: A-rich; in humans: ATTCC) non-
coding transcripts (Bulut-Karslioglu et al., 2012; Jolly et al., 2004b; Rudert, Bronner, Garnier, 
& Dolle, 1995).  
Generally the transcription in cells is regulated by transcription factors that bind to the 
promoter regions of the target elements (Jolma et al., 2013; T. I. Lee & Young, 2013; Voss & 
Hager, 2014). Although the pericentromeric satellite repeats do not contain promoter 
elements, several transcription factors have been shown to bind to these repeats. In mice, 
the transcription factors Pax3 and Pax6 were discovered to repress the transcription from 
both strands by directly binding to the pericentromeric major satellite repeats (Bulut-
Karslioglu et al., 2012). The same study showed that simultaneous depletion of both 
transcription factors resulted in dramatic upregulation of major satellite repeats 
transcription accompanied by loss of repressive H3K9me3 and H4K20me3 marks from 
pericentromeric heterochromatin and impaired chromosome segregation (Bulut-Karslioglu 
et al., 2012). Furthermore, transcription factors HSF1 and TONEBP were shown to bind to 
human pericentromeric Satellite III repeats on chromosome 9 and subsequently upregulate 
the transcription upon heat and osmotic cellular stress respectively (Jolly et al., 2002; Jolly, 
Morimoto, Robert-Nicoud, & Vourc'h, 1997; Valgardsdottir et al., 2005; Valgardsdottir et al., 
2008). Additional transcription factors, including Snail1, (Millanes-Romero et al., 2013), 
SALL1 (Yamashita, Sato, Asashima, Wang, & Nishinakamura, 2007), KAP1 (also known as 
TIF1β or TRIM28) (Bartova, Pachernik, Kozubik, & Kozubek, 2007; Matsui et al., 2010) and 
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GFi1B were also detected to bind to mouse pericentromeric heterochromatin (Vassen, 
Fiolka, & Moroy, 2006).  
 
3.3.3  Pericentromeric transcription  
In mammalian systems low levels of pericentromeric satellite repeats transcription has been 
detected under various physiological conditions, including cell cycle, senescence, 
development and differentiation.  
A study in 2007 revealed that transcription of pericentromeric satellite repeat in mouse 
mammary gland cell line is regulated by the cell cycle (J. Lu & Gilbert, 2007). The author’s 
identified two distinct populations of major satellite repeat transcripts. The first population 
consisted of large ( > 1 kb), heterogeneous transcripts synthesized during the late G1 and 
early S phase of the cell cycle. This population was suggested to be involved in preparing 
heterochromatin for reassembly at the replication fork. On the other hand the second 
population was observed exclusively during mitosis consisting of transcripts smaller than 
200 nucleotides. This second population was suggested to function in heterochromatin 
formation by recruiting the HP1 back to pericentromeric heterochromatin followed mitosis 
(J. Lu & Gilbert, 2007).  This was concluded based on the facts that HP1 is (i) evicted from 
the pericentromeric heterochromatin during mitosis (Fischle et al., 2005; R. Wu, Singh, & 
Gilbert, 2006) and (ii) tethered to heterochromatin by an RNA molecule (Maison et al., 
2002).  
Other studies have also indicated a link between replicative senescence and transcriptional 
activation of pericentromeric satellite repeat which was accompanied by chromosome 
decondensation and reduced level of DNA methylation (Enukashvily, Donev, Waisertreiger, 
& Podgornaya, 2007; Gaubatz & Cutler, 1990).  
Furthermore, the transcription of the pericentromeric repeats was shown to be 
developmentally regulated in the mouse genome. For example in mouse embryos 
accumulation of pericentromeric transcripts were detected in the central nervous system 
whereas in adult mice the expression was restricted to liver and testis (Rudert et al., 1995). 
Moreover, in two cells stage embryos, a burst of pericentromeric repeats transcription was 
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found to be strand and parental specific leading to chromocentre formation (Probst et al., 
2010) which is a nuclear structure formed from the clustering of pericentromeric 
heterochromatin from multiple chromosomes (Guenatri et al., 2004) (Figure 1.8). 
Additionally, during the epithelial-to-mesenchymal transition step of embryonic 
development, major satellite repeat transcription was shown to be downregulated with 
transient release of HP1α from pericentromeric heterochromatin. The observed repression 
was attributed to binding of the Snail1 transcription factor to pericentromeric 
heterochromatin which in turn recruits the H3K4me3 specific deaminase LOXL2 corepressor, 
in order to oxidize H3 and repress major satellite transcription (Millanes-Romero et al., 
2013).  
 
Figure 1.8: A schematic representation of the chromocentre formation in an interphase cell 
nucleus by three individual chromosomes. Each chromosome contains pericentromeric 
satellite (large dots) and centromeric satellite (small dots) regions. Pericentromeric satellites 
from different chromosome associate in clusters forming chromocentre, whereas 
centromeric satellites surround the chromocentre as separated domains. Adapted from 
(Guenatri et al., 2004). 
 
Finally aberrant overexpression of pericentromeric satellite repeat has been detected in 
numerous pathological conditions, including cellular stress (Jolly et al., 2004a; Rizzi et al., 
2004; Valgardsdottir et al., 2008), cancer (Eymery, Horard, et al., 2009; Narayan et al., 1998; 
Qu, Dubeau, Narayan, Yu, & Ehrlich, 1999; Ting et al., 2011) and several genetic disorders 
(Hassan, Norwood, Gimelli, Gartler, & Hansen, 2001; Miniou et al., 1994; Shumaker et al., 
2006). 
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4. Cellular stress and transcription of pericentromeric repeats 
4.1 Cellular stress  
Cellular functions are required to be maintained in a fine balance for normal function and 
survival. This equilibrium is closely regulated with many factors that detect slight variation 
and induce homeostatic compensation (e.g temperature). However cells often become 
stressed when the ability to compensate is surpassed. Depending on the nature and the 
intensity of the stressor, that can be either environmental or a pathological factor, cells 
respond by various mechanisms to protect from stress induced damage. A main mechanism 
includes activation of heat shock transcription factors (HSFs) which in turn mediates drastic 
transcriptional upregulation of heat shock gene expression leading in synthesis of heat 
shock proteins (HSPs) (Morimoto, 1993; Welch, 1992). Notably, there are also several other 
mechanisms activated for specific stressors such as activation of p53 upon exposure to UV 
(Bruins et al., 2004; Kapoor & Lozano, 1998; Latonen, Taya, & Laiho, 2001). However, this 
thesis will focus only on the response mediated by the heat shock pathway. 
 
4.1.1 Heat shock proteins (HSPs) 
Heat shock proteins are a highly conserved family of proteins that function as molecular 
chaperones to maintain intracellular protein homeostasis by facilitating accurate folding of 
misfolded proteins and preventing protein aggregation. Additionally these proteins function 
as cellular lifeguards by blocking several steps of the apoptotic pathway (Schmitt, 
Gehrmann, Brunet, Multhoff, & Garrido, 2007). HSPs are divided into five groups based on 
their molecular weight: HSP100, HSP90, HSP70, HSP60 and the small HSPs (Liang & MacRae, 
1997; Waters, Lee, & Vierling, 1996). Each group contains highly conserved regulatory heat 
shock sequence elements (HSEs) on their proximal promoter regions which serve as binding 
sites for HSFs (Amin, Ananthan, & Voellmy, 1988; Amin, Fernandez, Ananthan, Lis, & 
Voellmy, 1994; Pelham, 1982; Perisic, Xiao, & Lis, 1989; H. Xiao & Lis, 1988).    
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4.1.2 Heat shock transcription factors (HSFs)  
Heat shock transcription factors are a family of transcription factors best known on 
regulating the expression of genes involved in the stress response. In mammals the HSF 
family consists of HSF1, HSF2, HSF3 and HSF4 (Fujimoto & Nakai, 2010; Pirkkala, Nykanen, & 
Sistonen, 2001) as well as more recently identified HSFY/HSFY2 and HSFX (Figure 1.9) 
(Bhowmick, Takahata, Watanabe, & Satta, 2006; Kichine et al., 2012; Kinoshita et al., 2006; 
Shinka et al., 2004; Tessari et al., 2004).  
Structurally, the HSF monomer contains a helix-loop-helix DNA binding domain (DBD) 
oligomerization domain (HR-A and HR-B) and a C-terminal heptad repeat C domain (HR-C) 
(Figure 1.9) (Akerfelt, Morimoto, & Sistonen, 2010; Littlefield & Nelson, 1999). The DBD is 
the most conserved domain within the HSF family and recognises HSEs throughout the 
genome (Harrison, Bohm, & Nelson, 1994; S. J. Kim, Tsukiyama, Lewis, & Wu, 1994; 
Littlefield & Nelson, 1999; Vuister et al., 1994). The oligomerization domain consists of an 
array of hydrophobic heptad repeats A and B and mediates HSF homo or 
heterotrimerization upon its activation (Peteranderl & Nelson, 1992; Rabindran, Haroun, 
Clos, Wisniewski, & Wu, 1993; Sorger & Nelson, 1989). Lastly, the HR-C domain suppresses 
spontaneous HSF trimerization in the absence of stimuli (Y. Chen, Barlev, Westergaard, & 
Jakobsen, 1993; Rabindran et al., 1993). Notably, while the DRB domain is found in all 
members of the HSF family, the HR-C domain is completely absent from HSF4 (Nakai et al., 
1997), a factor which is involved in differentiation and has no effect on the stress response 
(Fujimoto et al., 2004; Min, Zhang, Moskophidis, & Mivechi, 2004; X. H. Shi et al., 2009). 
Furthermore, HSFY/HSFY2 and HSFX with yet unknown cellular function lack both HR-C and 
oligomerization domains (Shinka et al., 2004).  
Among different members of the HSF family, HSF1 is believed to be the main stress 
response regulator by helping to preserve cellular integrity during stress conditions 
(McMillan, Xiao, Shao, Graves, & Benjamin, 1998; Vihervaara & Sistonen, 2014). HSF1 is a 
ubiquitously expressed phosphoprotein predominantly present in the nucleus (Jolly et al., 
1997; Khaleque et al., 2008; Mercier, Winegarden, & Westwood, 1999; Vujanac, Fenaroli, & 
Zimarino, 2005). The activity of this protein is regulated by various factors and post-
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translational modifications including phosphorylation, acetylation and sumoylation (Figure 
1.10A) (Y. M. Xu, Huang, Chiu, & Lau, 2012) 
 
 
 
Figure 1.9:  Members of human and mouse HFS family with schematic representation of the 
functional domains. (A) HSF family in human is comprised of HSF1, HSF2, HSF4 and recently 
identified HSFY and HSFX. (B) HSF family in mouse consists of HSF1, HSF2, HSF3, HSF4 and 
HSFY2. The functional domains of HSF1-4 members of the mammalian HSF family (exception 
of human HSF4) are a highly conserved DNA binding domain (DBD), oligomerization heptad 
repeat A and B (HR-A and HR-B) domain and C-terminal heptad repeat C domain (HR-C). 
Adapted from (Akerfelt et al., 2010).  
 
 
In the absence of cellular stress the HSF1 monomer, known to be constitutively 
phosphorylated on Ser303 and Ser307 residues (Chu, Zhong, Soncin, Stevenson, & 
Calderwood, 1998; Kline & Morimoto, 1997; Knauf, Newton, Kyriakis, & Kingston, 1996) 
forms an inactive complex by weakly interacting with heat shock proteins including HSP90 
(Ali, Bharadwaj, O'Carroll, & Ovsenek, 1998; Zou, Guo, Guettouche, Smith, & Voellmy, 
1998). 
A 
B 
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In response to stress HSF1 becomes activated by (i) dissociating from the repressed 
complex, (ii) forming a trimer and (iii) acquiring multiple PTMs including phosporylation on 
multiple serine residues (up to 12) such as Ser230, Ser326 and Ser419 (Akerfelt et al., 2010; 
Guettouche, Boellmann, Lane, & Voellmy, 2005; Holmberg et al., 2001). The activated trimer 
binds to the HSE of the stress-responsive gene, recruits coactivators and induces their 
transcription (Fujimoto et al., 2012; Petesch & Lis, 2012; S. T. Smith et al., 2004; Takii et al., 
2015b; D. M. Xu, Zalmas, & La Thangue, 2008; Zobeck, Buckley, Zipfel, & Lis, 2010) (Figure 
1.10B). 
However, this transcription is a transient process and upon synthesis of the target proteins 
the HSF1 is deactivated and released from DNA. The deactivation occurs through a negative 
feedback loop, where newly synthesized HSP70 and HSP40 bind and inhibit the activity of 
HSF1 (Abravaya, Myers, Murphy, & Morimoto, 1992; Baler, Welch, & Voellmy, 1992; Y. H. 
Shi, Mosser, & Morimoto, 1998; Sugito et al., 1995; Vjestica, Zhang, Liu, & Oliferenko, 2013). 
On the other hand the release of HSF1 from the DNA is triggered by acetylation of the Lys80 
residue in the DBD domain (Figure 1.10B) (Westerheide, Anckar, Stevens, Sistonen, & 
Morimoto, 2009). 
Despite the well–established role of HSF1 in regulation of heat shock response, growing 
evidence also suggests that HSF2 can greatly influence the expression of heat shock target 
genes in an HSF1 dependent manner (Bjork & Sistonen, 2010; Ostling, Bjork, Roos-Mattjus, 
Mezger, & Sistonen, 2007; Sandqvist et al., 2009).   
Finally it is noteworthy that in addition to cell stress, the functions of HSFs are implicated 
during immune response (Inouye et al., 2004; I. S. Singh, He, Hester, Fenton, & Hasday, 
2004; V. Singh & Aballay, 2006; M. Song, Pinsky, & Kellum, 2008; Y. Xie, Chen, Stevenson, 
Auron, & Calderwood, 2002) and development (eg. brain development, oogenesis, 
spermatogenesis) (Akerfelt et al., 2008; Y. H. Chang et al., 2006; Fujimoto et al., 2004; Kallio 
et al., 2002; Min, Han, Lee, Kim, & Park, 2000; Rallu et al., 1997; Takaki et al., 2006; G. H. 
Wang et al., 2004; G. H. Wang, Zhang, Moskophidis, & Mivechi, 2003).  
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Figure 1.10: Representative HSF1 post-translational modifications (PTMs) and HSF1 
activation cycle. (A) HSF1 is subject to multiple PTMs including phosphorylation (P), 
acetylation (A) and sumoylation (S). There modifications act as repressors or activators 
depending on the residue and the type of modification. Repressed HSF1 monomer is 
constitutively phosphorylated on Ser303 and Ser307 residues. In response to cellular stress, 
HSF1 becomes hypephosporylated. Among these sites phosphorylation of residues Ser230, 
Ser326 and Ser419 are the most studied. Acetylation of Lys80 releases the HSF1 complex 
from the DNA. (B) In the absence of cellular stress the HSF1 monomer forms an inactive 
complex by interacting with HSP90. Upon stress HSF1 dissociates from the complex, 
trimerizes, acquires multiple PTMs and binds to target regions inducing their transcriptional 
activation. The transcriptional activation is terminated by negative feedback loop from HSPs 
and HSF1 acetylation which releases the trimer from the DNA. Adapted and modified from 
(Akerfelt et al., 2010).  
A 
B 
 419 
Ser307 
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4.2 Transcription of pericentromeric satellite repeats upon cellular stress  
Numerous cellular stress conditions, including heat shock, hyperosmosis, exposure to 
ultraviolet light as well as to various hazardous chemicals and heavy metals were shown to 
cause transcriptional activation of pericentromeric satellite repeats (Eymery, Callanan, et al., 
2009; Eymery, Horard, et al., 2009; Jolly et al., 1997; Rizzi et al., 2004; Sengupta, Parihar, & 
Ganesh, 2009; Valgardsdottir et al., 2008). The level and the orientation of transcripts were 
dependent of the nature of the stressor, with the majority of examined stressor inducing 
transcription exclusively in the sense orientation. However, during the heat shock, which 
has been studied in more details, transcription has been reported to occur from both 
strands, with the sense orientation representing the main proportion of the transcripts 
(Valgardsdottir et al., 2008). A summary of the effect of all the examined stresses to date is 
shown in Figure 1.11.  
 
Figure 1.11: A summary of known stressors that were shown to induce pericentromeric 
repeat transcription in human cells.  Different stresses have been found to induce either a 
low (small pink arrow), medium (moderate pink arrow) or high (large pink arrow) 
derepression of pericentromeric satellite repeats. So far, only transcription factors HSF1 and 
TonEBP were shown to mediate the expression of pericentromeric repeats under heat shock 
and hyperosmotic stress respectively. The sense transcript orientation is indicated as a right 
pointing arrow, whereas the antisense is shown as a left pointing arrow. UVC=ultraviolet 
light C, MMS=methyl methanesulphonate.  Adapted and modified from (Eymery, Callanan, 
et al., 2009).  
 
Specifically for humans, the transcription of pericentromeric satellite repeats upon cell 
stress has been predominantly associated with formation of nuclear stress bodies (Biamonti, 
2004; Jolly et al., 2002).  
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4.2.1 Nuclear Stress Bodies  
The exposure of human cells to several different stresses (e.g heat shock, proteasome 
inhibitors and heavy metals) results in the formation of distinct nuclear structures termed 
nuclear stress bodies (NSBs) (Biamonti & Vourc'h, 2010; Cotto, Fox, & Morimoto, 1997; 
Mahl, Lutz, Puvion, & Fuchs, 1989). These are large structures ranging from 0.3–3 μm in 
diameter and are assembled on several human heterochromatic regions (chromosomes 9, 
12, 15) (Denegri et al., 2002). Each NSB consists of a cluster of multiple ribonucleoproteins 
complexes called Perichromatin Granules (PGs) whose function remains still unknown 
(Charlier, Lamaye, Thelen, & Thiry, 2009; Chiodi et al., 2000; Mahl et al., 1989). However 
some possible roles that have been proposed to date include: (i) control of transcription and 
splicing, (ii) establishment of the heterochromatin structure upon stress and (iii) activation 
of genes adjacent to the NSBs (Biamonti & Vourc'h, 2010). Additionally, while NSBs can form 
in any human cell type, so far no such structures have been detected in rodent cells 
(Denegri et al., 2002).  
 
4.2.2 Formation of NSBs 
The formation of NSBs has been mostly studied by exposure of cells to heat shock. Upon 
heat shock of human cells, HSF1 becomes activated and directly binds primarily to the 
pericentromeric heterochromatin q11-q12 region of human chromosome 9, which consist of 
an array of Satellite III repeats (Jolly et al., 2002; Jolly et al., 2004a; K. W. Jones, Prosser, 
Corneo, & Ginelli, 1973; Rizzi et al., 2004). Interestingly, in humans, the binding of HSF1 to 
Satellite III repeats occurs despite the absence of canonical HSE elements within its 
consensus sequence. Subsequently, the binding of HSF1 triggers a series of events leading to 
the assembly of PGs that form the NSBs. These events include: (i) Chromatin remodelling by 
directly recruiting HATs which induce histone acetylation thereby creating a more open 
chromatin structure (ii) recruitment of RNAPII, (iii) transcription of Satellite III repeats (Jolly 
et al., 2004a; Rizzi et al., 2004) and (iv) binding of several RNA-binding proteins such as 
splicing factors through direct interaction with Satellite III transcript (Figure 1.12) (Chiodi et 
al., 2004; Denegri et al., 2001; Metz, Soret, Vourc'h, Tazi, & Jolly, 2004). The Satellite III 
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transcripts are stable non-coding RNAs that remain associated with the transcription sites in 
the nucleus (Valgardsdottir et al., 2005; Valgardsdottir et al., 2008).   
There is a discrepancy regarding the size of these transcripts, with some studies indicating 
size larger than 10 Kb (Jolly et al., 2004a) whereas others suggest a heterogeneous length 
varying between 5 and 2 Kb (Rizzi et al., 2004). The transcription of these repeats is 
dependent on the activated HSF1 trimer, since deactivation and release of HSF1 results in 
dissociation of HAT and RNAPII leading to transcriptional inactivation. This is followed by 
disassembly of PGs and diffusion of RNA-binding proteins within the nucleus. Finally, 
satellite III transcripts get degraded and the locus re-establishes the high compact 
heterochromatin structure (Figure 1.12B) (Jolly et al., 2004a; Rizzi et al., 2004).  
It is noteworthy that HSF2 has also been shown to bind to Satellite III repeats in an HSF1 –
dependent manner (Alastalo et al., 2003; Sandqvist et al., 2009).  
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See next page for figure legend 
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Figure 1.12: Transcription of human Satellite III repeats and NSBs formation. (A) 
Transcription of Satellite III repeats. The HSF1 trimer binds to the Satellite III repeats leading 
to transcriptional activation and generation of Satellite III transcripts. These transcripts 
remain at the transcription site, recruit RNA-binding proteins and assemble into PGs 
complex. (B) Formation and dissociation of NSBs. In the absence of the stress, satellite III 
(blue arrow) is heterochromatinised (red nucleosome). a. In the presence of stress, the HSF1 
trimer binds to Satellite III repeats sequence and b recruits HAT inducing histone acetylation 
(green nucleosome). c. This is followed by RNAPII recruitment, transcription of Satellite III 
repeats and assembly of PGs by direct binding of RNA-binding proteins to the Satellite III 
transcript. Multiple PGs then cluster and form NSBs. d. The HSF1 trimer dissociate along 
with RNAPII and HAT resulting in transcriptional termination. This is followed by destruction 
of PGs and release of the RNA-bound proteins in the nucleus. e. Satellite III RNA gets 
degraded and a high order chromatin structure starts forming on the locus. f. Finally the 
region re-establishes its original structure. Adapted from (Biamonti, 2004). 
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5. Friedreich’s ataxia  
Importantly, a significant number of neurological disorders such as Huntington disease and 
Friedreich’s ataxia are caused by expansion of a specific class of microsatellite repeats (a 
category of repetitive DNA elements see figure 1.5) called trinucleotide repeats (Brouwer, 
Willemsen, & Oostra, 2009; Budworth & McMurray, 2013; Everett & Wood, 2004; 
McMurray, 2010). Such repeats, in common with pericentromeric satellite repeats have 
been reported to repress transcription, in a similar manner (Saveliev et al., 2003) (see 
below). This thesis is partly focused on Friedreich’s ataxia therefore the pathology and cause 
of the disease will be discussed in this section.  
Friedreich’s ataxia (FRDA) is the most common autosomal recessive neurodegenerative 
disorder occurring mainly in Caucasians with a frequency between 1:30 000 and 1:50 000 
(Koeppen, 2011, 2013; Vankan, 2013). Clinically, the disease is characterised by dysarthria, 
progressive limb and gait ataxia, lower limb areflexia, loss of vibratory and position sense, 
atrophy and weakness of the distal extremities, scoliosis, diabetes mellitus and hypertrophic 
cardiomyopathy, which is the frequent cause of fatality.  Neurologically, dorsal root ganglia 
(DRG), spinocerebellar tracts, cerebellum and medulla are predominantly affected tissues 
from the disease (Durr et al., 1996; Koeppen, 2013; Parkinson, Boesch, Nachbauer, Mariotti, 
& Giunti, 2013; A. H. Wood & Dubrey, 2013). At present there is no effective disease 
modifying therapy.  
The vast majority of FRDA cases (96%) are caused by pathological GAA repeat expansion in 
the first intron of the FXN gene on both alleles (Campuzano et al., 1996). Notably the age at 
onset and severity of the disease are proportional to the expansion of the GAA repeats; with 
patient onset during childhood usually have the longest expansion (Durr et al., 1996; Filla et 
al., 1996; Montermini, Andermann, et al., 1997; Montermini, Richter, et al., 1997; 
Nachbauer et al., 2014). The result of GAA repeat expansion is transcriptional repression of 
the FXN gene, leading to a partial deficiency in the mitochondrial protein frataxin 
(Campuzano et al., 1997; Campuzano et al., 1996; Koutnikova et al., 1997). The level of 
frataxin mRNA correlates well with the severity of the FRDA disease, with patients having 
~13-30% of frataxin mRNA relative to healthy individuals whereas heterozygous 
asymptomatic carriers generally expressing ~40% of frataxin mRNA relative to healthy 
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controls (Pianese et al., 2004). Additionally, it is worth mentioning that in 4% of cases, FRDA 
was reported to result from GAA-repeat expansion on one FXN allele and missense and 
nonsense mutation within the other allele of the FXN gene (Anheim et al., 2012; Bartolo, 
Mendell, & Prior, 1998; Bidichandani, Ashizawa, & Patel, 1997; Cossee et al., 1999; Sacca et 
al., 2013; Zuhlke et al., 2004).  
 
 
5.1 Frataxin protein  
Human frataxin is a highly conserved and ubiquitously expressed protein (Adinolfi, Trifuoggi, 
Politou, Martin, & Pastore, 2002; Gibson, Koonin, Musco, Pastore, & Bork, 1996). Initially, it 
is translated as a 210aa precursor in the cytoplasm followed by translocation into the 
mitochondria, where it undergoes functional maturation mediated by peptidase cleavage 
(Condo et al., 2007; Koutnikova et al., 1997; Koutnikova, Campuzano, & Koenig, 1998; 
Schmucker, Argentini, Carelle-Calmels, Martelli, & Puccio, 2008).  
The mature protein (14kD) is associated with the inner mitochondrial membrane and its 
main functions are reported to be (i) iron-sulfur (Fe-S) cluster biogenesis (Stehling, Elsasser, 
Bruckel, Muhlenhoff, & Lill, 2004), (ii) iron chaperoning (Bulteau et al., 2004), (iii) iron 
storage (Cavadini, O'Neill, Benada, & Isaya, 2002), (iv) heme biosynthesis (Yoon & Cowan, 
2004) and (v) control of iron mediated oxidative tissue damage (Jiralerspong, Ge, Hudson, & 
Pandolfo, 2001; Park, Gakh, Mooney, & Isaya, 2002; A. Wong et al., 1999). Therefore, 
deficiency of frataxin severely disrupts mitochondrial function through iron accumulation 
(Babcock et al., 1997; Bradley et al., 2000; Foury & Cazzalini, 1997; Gonzalez-Cabo & Palau, 
2013) and increases the sensitivity to oxidative stress through deregulation of intracellular 
antioxidant defences (Chantrel-Groussard et al., 2001; Gomes & Santos, 2013; Jiralerspong 
et al., 2001; Schulz et al., 2000; Shan et al., 2013). Furthermore, frataxin has also been 
implicated in regulation of apoptosis (Loria & Diaz-Nido, 2015; Mincheva-Tasheva, Obis, 
Tamarit, & Ros, 2014; Palomo, Cerrato, Gargini, & Diaz-Nido, 2011; Santos, Ohshima, & 
Pandolfo, 2001). For example depletion of frataxin was shown to cause (i) apoptosis of 
primary rat DRG neurons associated with an increase in intracellular Ca2+ levels and 
alteration of Ca2+ mediated signalling pathway (Mincheva-Tasheva et al., 2014) and (ii) 
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upregulation of several pro-apoptotic factors including p53 and BAX as well as activation of 
the caspase-3 pathway, leading to cell death in differentiated neuron like cells (Palomo et 
al., 2011).   
 
5.2 Transcriptional regulation of the FXN gene 
As illustrated in Figure 1.13A, the human FXN gene is located on the positive strand on 
chromosome 9 (9q21.11) and consists of 4 introns and 5 exons. The gene contains 3 
putative CpG islands with the first of them residing in exon 1 and part of intron 1 (Yandim et 
al., 2013).  Importantly, polymorphic (GAA)n repeats are located within the first intron of 
the FXN gene, in the centre of an Alu element (Campuzano et al., 1996; Clark et al., 2004; 
Montermini, Andermann, et al., 1997) followed by  a mononucleotide tract of adenines 
(poly A) (Monticelli et al., 2004). In unaffected individuals expansions of the GAA repeats 
may exist up to 30 triplets, whereas in disease causing mutations the expansion ranges from 
70 to more than 1700 repeats (Vankan, 2013). Furthermore, few repetitive elements 
including L2 (LINE) are also present along the FXN gene, with as yet unknown function 
(Greene, Entezam, Kumari, & Usdin, 2005) .  
The FXN gene is known to contain two main TSSs; TSS1 and TSS2 which are found 221 bp 
and 62 bp upstream of the ATG translation start site respectively (Campuzano et al., 1996; 
Kumari, Biacsi, & Usdin, 2011). Interestingly, the promoter regions were reported to contain 
instead of a TATA box, Inr/downstream promoter-like (Inr/DPE) elements starting 24bp 
downstream of TSS1, whose deletion was shown to significantly impair FXN expression 
(Figure 1.13B) (Greene et al., 2005).  
So far, only limited data is available regarding the regulation and identity of the 
transcription factors that orchestrate FXN transcription, which is considered to be expressed 
in all cells at low levels, with relatively higher levels reported in DRG, cerebellum and tissues 
with high metabolic rate including heart and liver (Campuzano et al., 1996; Koutnikova et 
al., 1997). Nevertheless, a few of the factors that were shown to be recruited to the regions 
flanking the TSS and ATG include CCCCTC-binding factor (CTCF) (Al-Mahdawi, Sandi, Mouro 
Pinto, & Pook, 2013; De Biase, Chutake, Rindler, & Bidichandani, 2009) as well as Serum 
Responsive Factor (SRF) and Transcription Factor AP2 (TFAP2) (K. Y. Li et al., 2010), factors 
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important for neural and neural crest development respectively (Figure 1.13B) (Alberti et al., 
2005; Eckert, Buhl, Weber, Jager, & Schorle, 2005; Knoll et al., 2006; P. P. Y. Lu & Ramanan, 
2011; Ramanan et al., 2005). 
Finally, physiological regulation of FXN expression is believed to be dependent on the 
intracellular iron concentration, as iron depletion results in downregulation of FXN 
expression in both healthy and FRDA cells (K. Y. Li, Besse, Ha, Kovtunovych, & Rouault, 
2008).  
 
 
Figure 1.13: The human FXN gene and its known regulatory elements. (A) The human FXN 
gene is located on chromosome 9 and consists of five exons and contains three putative 
CpG islands. The first intron of the gene harbours a number of (GAA)n repeats whose 
expansion leads to FRDA disease.  (B) Regulatory elements at the 5’end of the FXN gene. 
FXN is known to be transcribed from two transcription sites, TSS1 and TSS2. The regions 
between TSS1 and ATG is known to contain Inr/DPE elements and to bind SRF, TFAP2 and 
CTCF factors.  There are also a number of repetitive elements found along the FXN gene.  
Adapted and modified from (Yandim et al., 2013) 
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5.3 Transcriptional repression of the FXN gene by expanded GAA repeats 
The silencing-triggers and the exact molecular mechanism by which GAA repeat expansion 
induces FXN gene repression is not clear; however two models have been proposed which 
may act in concert or individually (Figure 1.14) (Schulz & Pandolfo, 2013).  
The first model suggests that the expanded GAA repeat causes an unusual non-B DNA 
conformation, the so called “sticky DNA” structure (Sakamoto et al., 1999; Vetcher et al., 
2002), as well as RNA:DNA hybrids, the so called R-loops (Grabczyk, Mancuso, & Sammarco, 
2007; Groh, Lufino, Wade-Martins, & Gromak, 2014; Reddy et al., 2011). These unusual 
conformations form physical blockage, therefore stalling the RNAPII and preventing the 
transcriptional elongation process (Figure 1.14A) (Groh et al., 2014; McIvor, Polak, & 
Napierala, 2010; Sakamoto, Ohshima, Montermini, Pandolfo, & Wells, 2001). 
The second model suggests that GAA repeat expansions induces heterochromatin 
formation, thereby epigenetically silencing the FXN gene (Figure 1.14B, 1.14C). This 
hypothesis was derived from a study where expression of a heterochromatin-sensitive 
human cell surface reporter gene (hCD2) was shown to be repressed in the presence of 
pathologically expanded GAA repeats in a manner reminiscent of position-effect variegated 
gene silencing (PEV) mechanism in transgenic mice (Saveliev, Everett, Sharpe, Webster, & 
Festenstein, 2003). The same study also correlated the repression of the reporter gene with 
a decrease in promoter accessibility as well as enhanced silencing through overexpression of 
heterochromatin protein 1 (HP1) (see section 2.2.2), a well-known PEV modifier (Saveliev et 
al., 2003). Consistently, heterochromatin associated histone modifications H3K9me3, 
H3K9me2, H4K20me3 and H3K27me3 were shown to be increased upstream of the 
expanded GAA on the FXN locus whereas the histone acetylation levels including H3K9ac, 
H3K14ac, H4K5ac, H4K8ac, H4K12ac and H4K16ac were revealed to be decreased at both 
the promoter and gene body of the FXN gene in variety of FRDA model systems such as 
lymphoblastoid cell lines, fibroblast cell lines, primary human and mouse tissues (P. K. Chan 
et al., 2013; Chutake, Costello, Lam, & Bidichandani, 2014; Y. Li et al., 2015; Yandim et al., 
2013). Lastly, various studies have also reported hypermethylation and hypomethylation of 
CpG islands upstream and downstream of pathologically expanded GAA repeats respectively 
(Al-Mahdawi et al., 2013; Yandim et al., 2013), which further supports the 
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heterochromatinisation of the FXN gene in FRDA. However the factors that initiate the 
heterochromatin formation on the locus are still unknown.   
 
 
 
 
Figure 1.14: A hypothetical model for the heterochromatin formation of the FXN gene with 
pathologically expanded GAA repeats. (A) The expansion of GAA repeats (shown in red) 
triggers non-B DNA conformations (e.g triple, hairpin) and RNA:DNA hybrids (R-loop) 
formation. These structures form physical blockage and potentially stall on–going 
transcription. (B) Recruitment of heterochromatin factors to the FXN locus. Although there 
is no evidence yet, the repetitive nature of the region and the unusual conformations may 
recruit chromatin modifying factors including SUV39H, HP1 and DNMTs. (C) The region 
proximal to the GAA repeats contain classic heterochromatin marks including DNA 
methylation, histone deacetylation, H3K9me3 and H3K27me3. Adapted and modified from 
(Yandim et al., 2013) 
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5.4 HDAC inhibitors and FRDA  
Since FRDA is a disease associated with heterochromatinisation of the FXN gene, targeting 
of factors that prevent heterochromatin formation could potential prove to be a good 
approach to find candidates for FRDA therapeutics. One group of these factors are HDACs 
whose inhibition would shift the equilibrium towards acetylation and hence a more open 
chromatin state.  
As mentioned in a previous section (see section 2.2.1.1) HDACs catalyse the removal of 
acetyl groups from ε-N-acetyl-lysine amino acid of histones which increases the attraction 
between DNA and positively charged histones (Haberland, Montgomery, & Olson, 2009; X. J. 
Yang & Seto, 2007). This in turn would permit other histone modifications associated with a 
higher order chromatin structure, including methylation, to be established on the locus 
(Alper et al., 2013; Buscaino et al., 2013; Nakayama, Rice, Strahl, Allis, & Grewal, 2001; 
Yamada, Fischle, Sugiyama, Allis, & Grewal, 2005). Furthermore histone deacetylation is 
required for the repression, mediated by DNA methylation and methyl-CpG-binding protein 
MeCP2 (P. L. Jones et al., 1998a; Nan et al., 1998). Therefore HDACs are generally 
considered as transcriptional repressors. Based on sequence similarity and function, HDACs 
are classified into four major groups, HDAC class I, II, and IV that require Zn2+ for deacetylase 
activity and class III (also known as Sirtuin or silent information regulator, SIRT1–7) that 
require nicotinamide adenine dinucleotide (NAD+) as a cofactor (Glozak & Seto, 2007).  
To date, various molecules have been developed to inhibit HDAC activity. The classical HDAC 
inhibitors, including Trichostatin (TSA) and suberoylanilide hydroxamic acid (SAHA also 
known as vorinostat) target solely class I, II and IV HDACs through binding to the zinc-
containing catalytic domain of HDAC (Codd, Braich, Liu, Soe, & Pakchung, 2009; Richon et 
al., 1996; M. Yoshida, Kijima, Akita, & Beppu, 1990). On the other hand class III HDAC 
inhibitors including nicotinamide and sirtinol function as NAD+ analogues or specific sirtuin 
structural inhibitors (Alcain & Villalba, 2009; Cen, 2010).  
In recent years, numerous HDAC inhibitors have been developed as potential candidates for 
treatment of numerous neurodegenerative diseases, including Friedreich’s ataxia (Chuang, 
Leng, Marinova, Kim, & Chiu, 2009; Didonna & Opal, 2015; Dietz & Casaccia, 2010; 
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Falkenberg & Johnstone, 2014; Marek et al., 2013; S. Sharma & Taliyan, 2015; Simoes-Pires 
et al., 2013; Soragni et al., 2011; K. Xu, Dai, Huang, & Jiang, 2011).   
Previous studies using classical HDAC inhibitors targeting mainly class I and II HDACs 
including TSA, SAHA (Herman et al., 2006), sodium valproate (Gottlicher et al., 2001) and 
suberoyl bishydroxamic acid (Rai et al., 2008) did not shown any significant effect on the 
FXN expression in FRDA patient cells lines neither in transgenic mouse models. However N1-
[2-aminophenyl]-N8-phenyloctanediamide (BML-210), a class I HDAC inhibitor was first 
shown to significantly upregulate FXN mRNA expression in FRDA primary lymphocytes and 
cell lines by increasing histone acetylation marks (H3K14, H4K5 and H4K12) (Herman et al., 
2006). Furthermore, synthesis of BML-210 derivatives revealed a number of pimelic 
diphenylamide molecules that specifically inhibit class I HDACs and increase FXN expression 
in various FRDA models. Some of these molecules (compound 106, 109, 136) were shown to 
significantly upregulate FXN mRNA and protein levels in the heart and the nerve tissue of 
KIKI (GAA230) and YG8 FRDA mouse models accompanied by an increase of the acetylation 
(H3K14, H4K5, H4K8 and H4K16) levels and no change of H3K9me3 levels (Rai et al., 2010; 
Rai et al., 2008; Sandi et al., 2011). Importantly, the reversal of silencing of the FXN gene is 
not restricted to class I HDAC inhibitors, as the class III HDAC inhibitor nicotinamide was also 
shown to restore the FXN expression in several FRDA models, including FRDA primary cells, 
cell lines and mouse models associated with reversal of the condensed chromatin structure 
formed by GAA repeats expansion (P. K. Chan et al., 2013).    
Nicotinamide is the amide of nicotinic acid (also known as Vitamin B3) and a non-
competitive end product inhibitor of SIRT1 HDAC (Avalos, Bever, & Wolberger, 2005; 
Bitterman, Anderson, Cohen, Latorre-Esteves, & Sinclair, 2002). 
SIRT1 is a member of the class III HDACs that localises in the nucleus (Byles et al., 2010; 
Michishita, Park, Burneskis, Barrett, & Horikawa, 2005; Vaquero et al., 2004) and is 
implicated in heterochromatin formation. The mechanism of chromatin compaction by 
SIRT1 includes deacetylation of the targets H4K16 and H3K9 histones (Imai, Armstrong, 
Kaeberlein, & Guarente, 2000; Vaquero et al., 2004) followed by recruitment and 
deacetylation of linker histone H1, loss of transcriptionally active chromatin mark 
H3K79me2 (Vaquero et al., 2004) and recruitment of SUV39H1 which in turn methylates 
H3K9 generating repressed chromatin H3K9me3 mark (Vaquero et al., 2007).  
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Notably SIRT1 can also target other substrates beside histones such as the cell cycle 
regulator P53 (Atkins et al., 2014; Gonfloni et al., 2014; Vaziri et al., 2001), DNA replication 
regulator TopBP1 (R. H. Wang et al., 2014) and various transcription factors (e.g NFκB, 
FOXOs, RORγt,) (Brunet et al., 2004; H. N. Kim et al., 2015; Lim et al., 2015; Yeung et al., 
2004).  
Biochemically, the deacetylaton process of SIRT1 consists of the transfer of an acetyl group 
from acetyl-lysine substrate to the ADP-ribose of NAD+ molecule causing the hydrolysis with 
subsequent release of O-acetyl ribose (OAADPr) and nicotinamide (Denu & Gottesfeld, 
2012; Sauve et al., 2001; Sauve, Wolberger, Schramm, & Boeke, 2006). However, an excess 
of free nicotinamide blocks the release of nicotinamide and therefore prevents hydrolysis of 
NAD+ (Figure 1.15) (Avalos et al., 2005; Bitterman et al., 2002).               
 
. 
 
            
 
 
Figure 1.15: Inhibition of SIRT by nicotinamide. SIRT1 transfers the Acetyl group from the 
acetyl-lysine substrate to NAD+ leading to the release of OAADPr and nicotinamide as well as 
deacetylation of the substrate.  The free nicotinamide blocks the SIRT1 activity. K represents 
the Lysine residue and Ac the acetyl group. 
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6. The proteasome  
Protein turnover is a vital cellular function predominantly controlled by the ubiquitin 
proteasome system (UPS). At its centre is the highly conserved (found in all three biological 
super-kingdoms) protease complex, the proteasome, which recognises, unfolds and 
degrades the poly-ubiquitin tagged (some exceptional cases is ubiquitin-independent) aged, 
misfolded or damaged proteins. Therefore it is an essential component of the cell that 
regulates protein quality maintenance both in cytoplasm and nucleus (Wojcik & DeMartino, 
2003). Moreover proteasome function is further linked with other cellular processes 
including DNA damage repair, transcription, signal transduction, cell division, cell 
differentiation, apoptosis and adaptation to environmental signals through (i) regulation of 
proteolytic processing and maturation of various polypeptides and (ii) degradation of many 
key cell regulators (Jariel-Encontre, Bossis, & Piechaczyk, 2008; Stadtmueller & Hill, 2011).  
Importantly, impairment of the proteasome function has been associated with cellular aging 
(Carrard, Bulteau, Petropoulos, & Friguet, 2002) and various pathological conditions such as 
cancer and neurodegenerative diseases (Adams, 2003a; Adams et al., 1999b; Catalgol & 
Grune, 2012; Dantuma & Bott, 2014; Q. Huang & Figueiredo-Pereira, 2010; Pajonk & 
McBride, 2001; Rajkumar, Richardson, Hideshima, & Anderson, 2005). 
 
6.1 Structure of the proteasome  
The most common eukaryotic proteasome is found as a 26S holoenzyme complex with a 
molecular mass of 2.5 MDa. It is comprised of the catalytic 20S core particle (CP) capped at 
one or both ends by the regulatory 19S particle (RP) (Figure 1.16) (T. Jung & Grune, 2013; 
Lasker et al., 2012; Nickell et al., 2009).  
The 20S particle is a barrel-like structure of four stacked rings, with two outer heptameric α 
subunits (α1-7) and two inner heptameric β subunits (β1-7) structured in a α7- β7- β7- α7 
manner (Groll et al., 1997; Heinemeyer, Trondle, Albrecht, & Wolf, 1994; Unno et al., 2002). 
The proteolytic activity of the CP is restricted to β1 (caspase-like), β2 (trypsin-like) and β5 
(chymotrypsin-like) subunits which face the inner chamber of the cylinder and function 
synergistically to cleave the substrate proteins into small peptides (Groll et al., 1999; 
Heinemeyer, Fischer, Krimmer, Stachon, & Wolf, 1997; Kunjappu & Hochstrasser, 2014). In 
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contrast, α subunits functions as a “gate”, preventing the access of incorrect substrate to 
the catalytic chamber (Groll et al., 2000).  
Importantly the 20S CP is an intrinsically enzymatically repressed complex that requires a 
19S regulatory particle (also known as PA700) in order for the substrate to enter the 
catalytic chamber (Stadtmueller & Hill, 2011). Therefore proteolysis is a highly regulated 
process dependent on the 19S particle which main function is recognition of the  
polyubiquitinated substrate, deubiquitination, protein unfolding and translocation into the 
20S particle (C. W. Liu & Jacobson, 2013).  It is further divided into the base and the lid (G. C. 
Lander et al., 2012).  
The 19S base contains six ATPases (Rpt1-6) forming a hetero-hexamer ring and four 
regulatory proteins (non – ATPase, Rpn 1, 2, 10, 13) (G. C. Lander et al., 2012; Tomko, 
Funakoshi, Schneider, Wang, & Hochstrasser, 2010). The ATPases serve to unfold the 
substrate, and then facilitate opening of the “gate” to allow entry of the substrate into the 
channel of the CP (Bar-Nun & Glickman, 2012; Beckwith, Estrin, Worden, & Martin, 2013; 
Rabl et al., 2008; Sledz et al., 2013). On the other hand, Rpn1/Rpn2 are scaffolding proteins 
providing a docking site for substrate recruitment (Elsasser et al., 2002; Rosenzweig, 
Bronner, Zhang, Fushman, & Glickman, 2012) whereas Rpn10/Rpn13 act as the ubiquitin 
receptors (Hamazaki, Hirayama, & Murata, 2015; Husnjak et al., 2008).  
The 19S lid contains 9 non-enzymatic regulatory proteins (Rpn3, Rpn5-9, Rpn11-12 and 
Rpn15) and is directly involved in substrate recognition and protein deubiquitination 
(Glickman et al., 1998; G. C. Lander et al., 2012; Pathare et al., 2014; Verma et al., 2002).  
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Figure 1.16: Structure of the 26S proteasome. The 26S proteasome consists of a 20S core 
particle and two 19S regulatory particles. The 20S consists of two heptameric α rings (α1-7) 
and two heptameric β rings (β1-7). The 19S particle is further divided into the base and the 
lid. The base consists of an ATPase (RPT1-6) ring and non-ATPase regulatory proteins (RPN1, 
2, 13, 10) whereas the lid contains 9 regulatory proteins (RPN 3, 5-9, 11, 12, and 15).  
Adapted from (Murata, Yashiroda, & Tanaka, 2009). 
 
 
6.2 Protein ubiquitination and degradation  
A poly-ubiquitin chain, linked to target proteins is considered to be the main recognition 
signal for the proteasome–dependent degradation pathway (Pickart, 1997).  Notably, some 
studies have also reported ubiquitin-independent proteasome degradation (Asher, Lotem, 
Sachs, Kahana, & Shaul, 2002; Asher, Tsvetkov, Kahana, & Shaul, 2005; Bercovich, 
Rosenberghasson, Ciechanover, & Kahana, 1989; Erales & Coffino, 2014; Kong et al., 2006; 
Shringarpure, Grune, Mehlhase, & Davies, 2003). The mechanism behind ubiquitin-
independent proteasome degradation remains poorly understood. Generally it is believed 
that this pathway could be a remnant of the pre-ubiquitin wold, as the proteasome has a 
longer evolutionary history compared to ubiquitin or could provide an alternative regulatory 
level of protein degradation (Erales & Coffino, 2014).  
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Ubiquitin is a highly conserved 76 amino acid peptide that can be covalently attached 
through formation of a bond between the terminal glycine of the ubiquitin and the lysine-48 
residue in the target protein. This attachment takes place in 3 steps:  firstly, the ubiquitin is 
activated in an ATP-dependent manner by the ubiquitin-activating enzyme (E1), creating a 
high energy thioester intermediate (E1- S~ubiquitin). Secondly, the activated ubiquitin is 
transferred from E1 to one of the many (over 40) ubiquitin-conjugating enzymes (E2), 
generating a second high-energy thioester intermediate (E2-S~ubiquitin). Finally, the 
ubiquitin is transferred directly or indirectly from the E2-S~ubiquitin to the target protein 
that it is specifically bound to by ubiquitin-ligase (E3) (Figure 1.17) (Berndsen & Wolberger, 
2014; Pickart & Eddins, 2004).  In humans, over 600 E3 ligases have been identified to date 
(W. Li et al., 2008). The mechanism of target protein recognition by the E3 ligases is poorly 
understood but it is believed that some protein conformation changes might play a role.  
Importantly, monoubiquitination by itself can modulate protein function, without triggering 
them for degradation (Gupta-Rossi et al., 2004; Haglund et al., 2003; Kodadek, 2010; 
Sigismund, Polo, & Di Fiore, 2004; Terrell, Shih, Dunn, & Hicke, 1998). Only further 
attachment of ubiquitin via intermolecular ubiquitin glycine-lysine bonds can act as a 
marker for proteasomal recognition and degradation (Sadowski & Sarcevic, 2010).  
Finally, it is worth mentioning that ubiquitination is a dynamic process and deubiquitination 
can also occur, mediated by various deubiquitinating enzymes (DUB) (Amerik & 
Hochstrasser, 2004; Ventii & Wilkinson, 2008).  
One substrate for ubiquitination and further degradation is a permanently or temporarily 
stalled/arrested RNAPII (Gillette, Gonzalez, Delahodde, Johnston, & Kodadek, 2004a; Malik, 
Bagla, Chaurasia, Duan, & Bhaumik, 2008; Wilson, Harreman, & Svejstrup, 2013).   
   
 
77 
 
 
Figure 1.17: Protein ubiquitination and proteasome mediated degradation. Initially the 
ubiquitin is activated in an ATP-dependent manner by E1 creating high-energy thioester 
intermediate (E1- S~ubiquitin). The ubiquitin is then transferred from E1 to E2 generating a 
second high-energy trioester intermediate (E2-S~ubiquitin). Finally the ubiquitin is 
transferred to substrate mediated by substrate bound E3. Polyubiquitinated substrates get 
degraded by the proteasome. Adapted from (Maupin-Furlow, 2012).  
 
 
6.3 Chromatin regulated function of proteasome 
Although the function of the proteasome was believed to be restricted to the cytoplasm, 
numerous studies revealed a proteolytic and non-proteolytic role of the proteasome in the 
nucleus of eukaryotic cells (Adori et al., 2006; Enenkel, 2014; Mengual, Arizti, Rodrigo, 
GimenezAmaya, & Castano, 1996; Reits, Benham, Plougastel, Neefjes, & Trowsdale, 1997). 
Growing evidence now suggests that proteasome is associated with chromatin (Geng, 
Wenzel, & Tansey, 2012; McCann & Tansey, 2014; A. Palmer et al., 1996), with some studies 
reporting identical or overlapping binding patterns for both proteasome particles (19S and 
20S) (Auld, Brown, Casolari, Komili, & Silver, 2006; Geng & Tansey, 2012; Krogan et al., 
2004b; Sikder, Johnston, & Kodadek, 2006; Szutorisz, Georgiou, Tora, & Dillon, 2006) whilst 
others have specifically focused on 19S RP (Ferry et al., 2009; Kitagawa, Ishii, Takeda, & 
Matsumoto, 2014b; Malik, Shukla, Sen, & Bhaumik, 2009; Satoh et al., 2009; Schwarz, Sohn, 
Kaiser, Jensen, & Mansky, 2010; Uprety, Lahudkar, Malik, & Bhaumik, 2012). Notably, there 
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are also some reports claiming that 19S and 20S particles associate with the chromatin in an 
independent and different manner (Gillette et al., 2004a; F. Gonzalez, Delahodde, Kodadek, 
& Johnston, 2002). Therefore the discrepancy of the findings makes it difficult to 
discriminate if the proteasome holoenzyme or its individual components are recruited on 
the chromatin.   
 
 
 
6.4 Proteasome recruitment to the chromatin  
Overall, interaction studies between proteasome subunits and chromatin by chromatin 
immunoprecipitation (ChIP) suggest a broad association of the proteasome with chromatin. 
Specifically, in yeast, proteasome particles, both 19S and 20S, were shown to be rapidly 
recruited to the RNAPII transcribed GAL10 gene upon its activation. Once activated, the 
proteasome was found to be associated with the entire transcribed portion of the GAL10 
gene and rapidly dissociated from chromatin upon transcriptional termination, mirroring the 
RNAPII kinetics (Geng & Tansey, 2012; Sikder et al., 2006). On the contrary, previous studies 
have reported that only 19S associates with the RNAPII transcribed GAL1 promoter upon its 
induction, while 20S is recruited later mainly accumulating at the 3’end of the gene (Gillette, 
Gonzalez, Delahodde, Johnston, & Kodadek, 2004b; F. Gonzalez et al., 2002). Furthermore, 
the  proteasome was also found to be recruited to regions transcribed by RNAPIII including 
noncoding RNA and tRNA genes in a transcriptionally–dependent manner (Geng & Tansey, 
2012). The association of the proteasome with transcriptionally active genomic regions is 
further strengthened by genome wide studies, where one or more proteasome subunits 
were revealed to be bound with the majority of transcriptionally active regions in the yeast 
genome (Auld et al., 2006; Sikder et al., 2006). Interestingly, the recruitment of the 
proteasome is not restricted to transcription sites, as budding yeast 
subtelomeres/telomeres (Geng & Tansey, 2012) and fission yeast centromeres (Kitagawa, 
Ishii, Takeda, & Matsumoto, 2014a) were also found to be associated with both proteasome 
particles and 19S RP respectively. Moreover, a study in mouse embryonic stem (ES) cells 
reported binding of the 19S and 20S proteasome at the cryptic (intergenic) gene promoters 
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(Szutorisz et al., 2006). Likewise the 19S RP was shown to be recruited to the promoter-
proximal and coding regions on the reporter gene in HeLa cells, whereas 20S was found to 
be associated weakly with the promoter-proximal regions and absent from coding regions 
(Lassot et al., 2007). Finally, the proteasome is also identified by a number of independent 
studies to get recruited to double-stranded DNA break sites where it degrades the stalled 
RNAPII (T. T. Huang & D'Andrea, 2006; Krogan et al., 2004a; K. B. Lee, Wang, Lippard, & 
Sharp, 2002; Malik et al., 2008). The presence of the proteasome on different 
compartments of chromatin suggests that its function is not restricted to regulating a 
specific process but rather a variety of chromatin functions.  
So far, three different models have been proposed to explain the mechanism of the 
recruitment of the proteasome holoenzyme or its individual components to chromatin 
(McCann & Tansey, 2014). The first model suggests that the proteasome is directly 
interacting with chromatin bound factors such as the Gal4 activator (C. Chang et al., 2001; F. 
Gonzalez et al., 2002) and nucleosomal histones (Chaves, Baskerville, Yu, & Reed, 2010; Qian 
et al., 2013). In the second model proteasome recruitment to chromatin is occurring 
through interaction with intermediate (adaptor) proteins such as Cks1 and Cdk1 bound to 
histone tails (Morris et al., 2003). Lastly, the third model, which can also explain the wide 
association of the proteasome with different chromatin regions, suggests that proteasome 
is simply recruited to chromatin through recognition of ubiquitinated proteins. This model 
comes in agreement with a recent study where 20S proteasome and ubiquitin were shown 
by ChIP-seq analysis to have similar pattern of genomic distribution, with significant 
rearrangement occurring upon proteasome inhibition (Catic et al., 2013). Furthermore, the 
same study revealed an increase in ubiquitin conjugated substrates bound to highly 
expressed genes with proteasome inhibition, indicating that the proteasome might be 
recruited to chromatin in order to degrade the ubiquitinated proteins.   
 
 
 
 
80 
 
6.5 Function of the Proteasome in transcription 
Increasing evidence suggests that one of the chromatin related functions of the proteasome 
is regulation of transcription (Geng et al., 2012). Since the proteasome is known to affect a 
large number of cellular pathways, it is often difficult to discriminate the direct from its 
indirect effect on transcription. Still, a number of genome-wide studies have identified the 
effect of the proteasome in transcriptional regulation, as chemical or genetic proteasome 
inhibition was shown to significantly disturb the expression patterns of a large proportion of 
the genome in yeast, mouse and human cells (Dembla-Rajpal, Seipelt, Wang, & Rymond, 
2004; Fleming et al., 2002; Z. Y. Tang, Wu, Gao, & Shen, 2008; Zimmermann et al., 2000).  
Transcription is a highly regulated process that can be categorised in 3 main phases: 
initiation, elongation and termination. Each phase is regulated by multiple factors that 
directly or indirectly associate with RNA polymerase and facilitate RNA synthesis.  
Importantly, the proteasome holoenzyme or its individual components are implicated in all 
3 phases.   
Firstly, the proteasome regulates the levels and binding of activators as well as recruitment 
of co-activators at 5’ regulatory regions, therefore controlling transcriptional initiation 
(Durairaj & Kaiser, 2014). For example, in yeast, the ATPase activity of 19S RP was shown to 
affect the stability and binding of the Gal4 transcriptional activator to promoters (Ferdous et 
al., 2007; F. Gonzalez et al., 2002; Nalley, Johnston, & Kodadek, 2006). Furthermore, the 
same particle was shown to act as a chaperone to recruit the co-activator complex SAGA to 
DNA bound activators including Gal4 (D. Y. Lee, Ezhkova, et al., 2005; Malik et al., 2009) 
Secondly, the proteasome is thought to promote transcription elongation. For instance, 19S 
was shown to physically interact with the yeast transcription elongation factor CDC68 
(Ferdous, Gonzalez, Sun, Kodadek, & Johnston, 2001). The same study also revealed 
elongation defects caused by mutations in 19S particle both in vivo and in vitro. Another 
study found recruitment of the 19S RP to the yeast transcription elongation complex PAF1, 
that was shown to be mediated though adaptor protein Cks1. This interaction was 
demonstrated to be essential for efficient transcriptional elongation by providing energy for 
nucleosome eviction (Pan, Sun, Wohlschlegel, & Reed, 2013). This was further strengthened 
by a previous finding where a 19S mutant was seen to display high nucleosome density 
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along the GAL1 locus upon transcriptional induction, indicating impairment in the process of 
nucleosome eviction (Chaves et al., 2010).  
Finally, the proteasome is thought to enable release of the RNAPII form the 3’end of the 
coding sequences leading to termination of transcription (Gillette et al., 2004a).  
So far, the majority of studies were performed in yeast and they indicate a role of the 
proteasome in regulation of transcriptional activation (Auld et al., 2006; Fatyol & Grummt, 
2008; Ferdous et al., 2001; F. Gonzalez et al., 2002; Kang, Pirskanen, Janne, & Palvimo, 2002; 
D. Y. Lee, Ezhkova, et al., 2005; Sulahian, Johnston, & Kodadek, 2006). However few studies, 
mostly in mammalian cells, suggest that the proteasome regulates not only transcriptional 
activation but also repression. A recent study in human cells revealed that inhibition of the 
20S proteasome results in increased levels of RNAPII and the active chromatin mark 
H3K4me3 at the glucocorticoid responsive gene promoter, where proteasome binding was 
identified (Kinyamu & Archer, 2007). Another study on mouse embryonic stem (ES) cells 
proposed that the proteasome blocks nonspecific transcription initiation by preventing 
preinitiation complex formation at cryptic gene promoters (Szutorisz et al., 2006). The same 
study showed that the 19S and 20S particles are assembled into a functional 26S 
proteasome at cryptic promoter sites and degrade RNAPII or a member of the pre-initiation 
complex that drives the transcription at these ectopic sites, thereby suppressing permissive 
transcription. This is an agreement with the effect of proteasome inhibition, which resulted 
in a significant increase in the transcription of intergenic and intragenic regions (Szutorisz et 
al., 2006). Moreover, a study performed in the liver of rats revealed that proteasome 
inhibition led to global hypomethylation (especially at H3K9 and H3K27 residues) and 
hyperacetylation (Oliva, Dedes, Li, French, & Bardag-Gorce, 2009). Finally another example 
comes from the HIV promoter, where the 26S proteasome was reported to repress its 
transcription during the latent viral stage (Lassot et al., 2007).  
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7. Hypotheses, Objectives and Aims  
Preliminary observations indicated that the proteasome was associated with 
heterochromatin both in pericentromeric and the pathological GAA triplet-repeat 
expansion. Therefore, the main hypothesis examined in this PhD thesis was that 
heterochromatin-mediated transcriptional repression might be dependent on proteasomal 
function. Additionally, this thesis also addressed the hypothesis that it might be possible to 
inhibit pathologically heterochromatinisation of the FXN gene in the incurable 
neurodegenerative disease as a potential radical therapy. 
The general objectives of this Ph.D were thus to investigate the transcriptional silencing of 
several DNA repetitive elements in mammalian cells and the factors that regulate their 
repression. The factors examined included an HDAC inhibitor (nicotinamide), the 
proteasome, cell cycle and HSF1. The DNA regions studied were: (i) the pathologically 
heterochromatinised FXN gene, (ii) pericentromeric repeats, (iii) centromeric repeats and 
(iv) LINE L1 and SINE B1 retrotransposons.  
 
The main aims of this Ph.D were therefore:  
 To assess the effect of HDAC inhibitor nicotinamide on the chromatin structure and 
expression of the FXN gene in FRDA patients (clinical trial) (chapter 2).  
 To investigate the heterochromatinisation of the FXN gene and the effect of 
proteasome inhibition on the expression of the FXN gene (chapter 3).   
 To determine the effect of proteasome inhibition on transcription of 
heterochromatic repeats (chapter 4).   
 To understand the role of the proteasome in maintenance of constitutive 
heterochromatin (chapter 4 and chapter 5). 
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 CHAPTER 2: The effect of high dose nicotinamide in patients with 
Friedreich’s ataxia 
 
2.1 Introduction  
It has previously been shown from our lab that treatment with the HDAC inhibitor 
nicotinamide can significantly upregulate FXN expression in primary human cells, cell lines 
and disease-affected tissues derived from a mouse model for Friedreich’s ataxia by apparent 
remodelling of the pathologically heterochromatinised FXN locus (P. K. Chan et al., 2013). 
More specifically, this FXN upregulation was accompanied by (i) a reduction in H3K9me3 
and H3K27me3 and (ii) an increase in H3 and H4 acetylation marks on the FXN locus. These 
findings lead to a clinical study to assess whether nicotinamide could be safely used to 
reactivate the epigenetically silenced FXN gene in FRDA patients. The study was conducted 
in three phases. Phase 1 was a single-dose, dose escalating phase undertaken over five 
visits. In phase 2 patients were administered escalating daily doses for five days and in 
phase 3 they were given their maximum tolerated dose daily for 8 weeks. It should be noted 
that this study was a collaborative effort and has been published in the Lancet my main 
contribution was the analysis of chromatin by ChIP.  
 
 
2.2 Results   
2.2.1 Phase 1 clinical trial  
The first phase of the clinical trial was performed to investigate the minimum dose at which 
nicotinamide could be safely used to upregulate FXN expression in ten FRDA patients.  This 
was achieved by orally given escalating doses of 0, 2, 4, 6, 7 and 8 g of nicotinamide at five 
different visits, with at least one week washout period between each visit. The treatment of 
all doses was well tolerated with the main side effect of nausea. Blood samples were 
collected before treatment and at 2, 4, 8 and 24h after dosing to analyse the 
pharmacokinetics and pharmacodynamics of nicotinamide, by measuring the plasma level of 
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nicotinamide as well as FXN mRNA and frataxin protein in peripheral blood mononuclear 
cells (PBMCs). In addition, the blood samples were collected at 8h at the last visit where 8 g 
of nicotinamide were given to patients, to analyse any possible changes in the chromatin 
structure of the FXN gene.    
Analysis of the effect of single, escalating doses of nicotinamide on frataxin protein 
concentration in patients with Friedreich’s ataxia over 24h revealed a statistically significant 
increase at 8h after administration of single dose of 2-8 g nicotinamide, with highest level at 
7 and 8 g. Moreover, no change of the frataxin protein level was observed at 2h after being 
given a single dose of 2-8 g of nicotinamide, with non-significant increase at 4h. Noticeably 
frataxin protein concentration was returned to baseline by 24h (Figure 2.1).  
 
 
Figure 2.1: The effect of single, escalating doses of nicotinamide on frataxin protein 
concentration in patients with Friedreich’s ataxia over 24 h. Data are mean values for the 
proportional change in concentration of frataxin protein in peripheral blood mononuclear 
cells (simple ratio relative to baseline). Error bars show SEs. For 0 g, n=10; 2 g, n=10; 3·5 g, 
n=1; 4 g, n=10; 6 g, n=9; 7 g, n=4; 8 g, n=1. The proportional change from baseline to 8 h 
showed a significant increase with increasing dose (p=0·0004). Adapted from (Libri et al., 
2014). 
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Further analysis of plasma nictonamide, FXN mRNA and frataxin protein in peripheral blood 
mononuclear cells showed that treatment with a single dose of 4g (Figure 2.2B) and 6g 
(Figure 2.2C) of oral nicotinamide, results in an initial dose-dependent upregulation of 
plasma nicotinamide which peaked at 2h after treatment, followed by FXN mRNA 
expression peaking at 4h and then frataxin protein concentration that peaked at 8h (Figure 
2.2B, 2.2C). No change of the FXN mRNA and frataxin protein was observed in the control 
group (Figure 2.2A). This finding agrees with the hypothesis that nicotinamide acts at the 
transcriptional level. 
The plasma nicotinamide levels after reaching their peak at 2h of treatment decreased 
gradually, in line with previously reported studies of the nicotinamide half-life (Horsman, 
Hoyer, Honess, Dennis, & Overgaard, 1993; Stratford & Dennis, 1994; Stratford et al., 1996).  
Noticeably the reduction of the FXN mRNA levels was faster than the frataxin protein 
concentration, consistent with the fact that the half-life of the mRNA is shorter than the 
half-life of the frataxin protein (Rufini et al., 2011). 
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Figure 2.2: Plasma nicotinamide, FXN mRNA and frataxin protein analysis of single-doses of 
nicotinamide over 24h in PBMCs for (A) no nicotinamide n=10, (B) a single 4 g dose, n=10 
and (C) a single 6 g dose n=9. Each measurement is shown as a simple ratio relative to each 
individual’s baseline; the mean for all subjects of this proportional change is shown. Green 
arrow indicates the dose timing. Error bars show SEs. Adapted from (Libri et al., 2014).  
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Moreover chromatin immunoprecipitation was performed to investigate the mechanism of 
FXN mRNA expression upregulation. Heterochromatic H3K9me3 and euchromatic H3Ac 
histone modification marks were examined on the regions flanking the GAA repeats in the 
first intron of the FXN gene. The results showed a reduction of the H3K9me3 in patients 
treated with nicotinamide after the dose compared to pre-dose although this was not 
statistically significant. No statistically significant change of the H3ac mark was observed on 
the regions examined (Figure 2.3B).   
 
Figure 2.3: Chromatin immunoprecipitation analysis of heterochromatic (H3K9me3) and 
euchromatic (H3ac) histone marks on the regions flanking the GAA repeats of the FXN locus. 
Patients were given a single dose of 8g nicotinamide followed 8 hours later by ChIP–qPCR 
using H3K9me3 and H3ac antibodies in PBMCs. (A) The location of the primers used to 
analyse the regions flanking the GAA repeats in intron 1 of the FXN gene. (B) Changes in the 
levels of H3K9me3 and H3ac between pre-dose (baseline) and 8 hours post-dose. Data were 
normalised against H3 followed by background subtraction (no antibody) and are shown as 
enrichment relative to baseline.  As an internal control the data were also normalised to 
average of housekeeping genes for H3ac and α-satellite repeats for H3K9me3 (see material 
and methods). Error bars show SEs, n=8.  
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2.2.2 Phase 2 Clinical trial  
The second phase of the clinical trial was performed to investigate the pharmacokinetics 
and pharmacodynamics of nicotinamide in relation to upregulation of FXN mRNA expression 
after dosing with nicotinamide for 5 consecutive days. In total 8 FRDA patients were 
administrated 3.5 g of nicotinamide on the first day, 4 g on the second day, 5 g on the third 
day and 6 g on fourth and fifth day. Two FRDA patients were used as a control group to 
identify any changes in FXN expression that was not due to treatment with nicotinamide. 
Blood samples were collected before dosing and 2, 4 and 8 h after dosing to check, as in 
Phase 1, the plasma nicotinamide levels, FXN mRNA expression and frataxin protein 
concentration levels. Additionally on the fifth day of treatment blood samples were taken 
8h post-dose to analyse the chromatin structure on the FXN gene.  
The results from the plasma and peripheral blood mononuclear cells showed an initial 
increase in nicotinamide levels that peaked at 2h irrespective of dose upon, followed by an 
increase in FXN mRNA expression and then the frataxin protein concentration (Figure 2.4B), 
while there was no change in the control group (Figure 2.4A). A similar pattern was 
observed in phase 1 of this study (Figure 2.2). However in Phase 2, after decay of 
nicotinamide, FXN mRNA expression fell to the initial levels, whereas frataxin protein 
concentration was maintained constantly at higher levels than the pre-dose (Figure 2.4). 
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Figure 2.4:  Plasma nicotinamide, FXN mRNA and frataxin protein analysis after daily doses 
of nicotinamide over 5 days. Data are mean values for nicotinamide plasma concentration 
and proportional changes in FXN mRNA expression and frataxin protein concentration in 
PBMCs (simple ration relative to baseline) for (A) no nicotinamide n=2 and (B) escalating 
doses of 3.5 – 6 g per day over 5 days. Error bars SEs, n=8. Green arrows indicate the time of 
dosing. Adapted from (Libri et al., 2014).  
 
 
Moreover chromatin immunoprecipitation was performed using antibodies against 
H3K9me3 and H3ac marks and DNA was amplified by qPCR using primers flanking the GAA 
repeats in intron 1 of FXN gene, as previously described in Phase 1. The H3K9me3 showed 
highly statistically significant down regulation, whereas the H3ac showed an increase, 
although this was not statistically significant, at both examined regions in treated patients 
before and after dose (Figure 2.5B). 
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Figure 2.5: Chromatin immunoprecipitation analysis of heterochromatic (H3K9me3) and 
euchromatic (H3ac) histone marks on the regions flanking the GAA repeats of the FXN locus. 
Patients were given a daily dose of nicotinamide over 5 consecutive days followed by ChIP-
qPCR using H3K9me3 and H3ac antibodies in PBMCs. (A) The location of the primers used to 
analyse the regions flanking the GAA repeats in intron 1 of the FXN gene. (B) Changes in the 
levels of H3K9me3 and H3ac between pre-dose (baseline) and post-dose of nicotinamide. 
Data were normalised against H3 followed by background subtraction (no antibody) and are 
shown as enrichment relative to baseline.  As an internal control the data were also 
normalised to average of housekeeping genes for H3ac and α-satellite repeats for H3K9me3 
(see material and methods). Error bars show SEs, n=8. Students t test: **p < 0.01, *p < 0.05. 
Adapted from (Libri et al., 2014).  
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2.3 Discussion  
The results shown in this chapter demonstrate that nicotinamide can restore FXN 
transcription at the pathologically silenced FXN gene in patients with FRDA. More 
specifically both phases of this study revealed that nicotinamide is effective in upregulating 
the FXN mRNA transcription thereby increasing the frataxin protein concentration in PBMCs, 
this correlated with a significant reduction in the heterochromatic modification H3K9me3 
and a non-significant increase in the H3ac marks on the regions flanking the GAA repeats in 
intron 1 of the FXN gene. This is perhaps not surprising since nicotinamide was previously 
shown not only to inhibit class III HDACs but also to inhibit SUV39H methyltransferase 
activity (Vaquero et al., 2007). A hypothetical mechanism through which nicotinamide may 
antagonise the pathological FXN gene silencing is shown in the Figure 2.6.  
 
 
Figure 2.6: Hypothetical mechanism by which nicotinamide might antagonise the 
pathological FXN gene silencing that causes Friedreich’s ataxia. Adapted from (Libri et al., 
2014) 
 
As mentioned in the general introduction (section 5.4), many studies have previously shown 
the effect of HDAC inhibition on the upregulation of FXN mRNA expression in patient 
lympoblastoid cell lines and PBMCs. In recent years, some HDAC inhibitors have been tested 
as potential drugs for cancer treatment in various clinical trials (Bolden, Peart, & Johnstone, 
2006; Gui, Ngo, Xu, Richon, & Marks, 2004; Mottamal, Zheng, Huang, & Wang, 2015; 
* 
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Walkinshaw & Yang, 2008). The study shown in this chapter is the first known clinical trial of 
the potential use of an HDAC inhibitior nicotinamide as a treatment for Friedreich’s ataxia.  
Another HDAC inhibitor (RG2833) was recently shown to reverse the FXN gene silencing in 
FRDA neurons derived from patient iPSCs to a similar degree as nicotinamide (Soragni et al., 
2014). The RG2833 compound was demonstrated to upregulate the FXN mRNA expression 
and frataxin protein concentration, with concomitant change of the epigenetic state of the 
FXN gene in these neuronal cells. Furthermore, the investigators identified a significant 
increase in H3K9 acetylation, accompanied by increased FXN mRNA in blood from patients 
treated with RG2833 (Soragni et al., 2014).  However, the major drawback is that this 
compound does not pass across the blood-brain barrier easily and converts from active to 
potential inactive toxic metabolic products (benzamidazole and products of amidolysis), 
which have a long elimination period in vivo (Soragni et al., 2014). On the other hand 
nicotinamide has good bioavailability, good safety profile, is rapidly absorbed after oral 
administration and rapidly penetrates all tissues, including easily passing through the blood-
brain barrier (Hoane, Kaplan, & Ellis, 2006; Knip et al., 2000; Spector & Kelley, 1979; 
Stratford & Dennis, 1994).   
Beside the ability to upregulate the expression of the FXN gene in FRDA, nicotinamide is also 
known to play a role in reducing effects of the oxidative stress, a major factor contributing 
to the pathology of FRDA (Crowley, Payne, Bernstein, Bernstein, & Roe, 2000; F. Li, Chong, & 
Maiese, 2006). Therefore this ability further strengthens the use of nicotinamide as a 
potential therapeutic agent.  
 
In summary the results in this chapter suggest that:  
 Treatment of FRDA patients with nicotinamide upregulates the FXN expression in 
PBMCs which is accompanied by reduction of H3K9me3 levels. This suggests that 
HDAC inhibition can overcome pathological silencing in humans providing a potential 
therapeutic avenue for this currently incurable disease. 
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2.4 Contributions 
FXN RNA and protein analysis was performed by Dr C.Yandim. The plasma nicotinamide 
levels were analysed by Dr Sophie Piper. Theona Natisvili performed the majority of ChIP 
experiments, with some help from Ms. Pui Pik Law. 
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CHAPTER 3: Binding of the proteasome to the FXN gene and the effect of 
proteasome inhibition on the FXN expression.   
 
3.1  Introduction: 
Recently, the Gene Control Mechanisms and Disease Group at the CSC carried out a study to 
investigate a possible mechanism for transcriptional repression of the FXN gene with 
expanded GAA repeats. Specifically, during the study, the distribution of RNAPII with 
different phosphorylation residues (Serine5 or Serine2) on its carboxy-terminal domain 
(CTD) was analysed via chromatin immunoprecipitation along the FXN locus using (i) healthy 
and FRDA patient lymphoblastoid cell lines (Healthy, FRDA_1 and FRDA_2) and (ii) primary 
cells. Serine5 phosphorylated RNAPII (S5P-RNAPII) has been shown by ChIP to be enriched 
at the promoter regions of active genes and so-called ‘paused genes’ where RNAPII has 
stalled near the promoter whereas Serine2 phosphorylated RNAPII (S2P-RNAPII) is 
associated with transcriptional elongation (Brookes & Pombo, 2009) (Figure 3.1). The results 
revealed an unusual binding distribution along the FXN gene, in both patient and healthy 
cells (manuscript under revision, PhD thesis Yandim 2012). The enrichment for S5P-RNAPII 
was found by ChIP to peak at exon 1 and rapidly decreased while moving downstream into 
the intron 1 to a similar extent in cells from both healthy and FRDA patients. Surprisingly, 
the S2P-RNAPII which typically increases steadily though the coding regions of active genes, 
had a similar distribution to S5P-RNAPII with a prominent peak found at exon 1 and with 
overall a relatively higher signal in FRDA cell lines compared to the healthy cell line. The 
unusual stalling of S2P-RNAPII was further supported by RNA Immunoprecipitation (RIP) 
using an anti-S2P-RNAPII antibody in the healthy cell line where 6-fold enrichment was 
detected for RNA transcripts from exon 1 relative with a region ~600bp downstream within 
the first intron (PhD thesis (Yandim, 2012). These results suggest that RNAPII is stalled at 
exon 1 in both healthy and FRDA derived cells and is consistent with a previous study (E. 
Kim, Napierala, & Dent, 2011) where more primary transcript was detected upstream rather 
than downstream of the identified RNAPII stalling site. These results are also consistent with 
several additional reports showing defects in the transcription elongation process at the FXN 
gene (E. Kim et al., 2011; Y. Li et al., 2015; Punga & Buhler, 2010). However it is noteworthy 
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that some studies have also attributed the reduction of the FXN transcription due to defects 
in the transcription initiation (Chutake et al., 2014; Chutake et al., 2015) or even both 
transcriptional initiation and elongation process (Kumari et al., 2011). 
 
 
                    
 
      
                                                                                        
 
Figure 3.1: RNAPII CTD phosphorylation patterns at (A) paused gene and (B) actively 
transcribed gene. Hypophosphorylated (nonP-RNAPII) is recruited to the promoter region 
and becomes phosphorylated at Ser5 CTD residue. S5P-RNAPII progresses toward the 
pausing site (promoter proximal region) where phosphorylation of Ser2 CTD residue permits 
the transcriptional elongation to take place. TSS, transcription start site; TES, transcription 
end site. Based on (Brookes & Pombo, 2009, 2012; Phatnani & Greenleaf, 2006).  
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Furthermore, in order to investigate the dynamics of RNAPII at exon 1 in more detail α-
amanitin and 6-dichloro-1β-ribofuranosylbenzimidazol (DRB) were used to inhibit the 
RNAPII and assess by ChIP the effect of the inhibition on the distribution of S2P and S5P-
RNAPII across the FXN gene. α-amanitin completely freezes RNAPII by blocking the 
translocation step of the transcript polymerization reaction (Brueckner & Cramer, 2008; 
Bushnell, Cramer, & Kornberg, 2002; Chafin, Guo, & Price, 1995; X. Q. Gong, Nedialkov, & 
Burton, 2004)  whereas DRB prevents elongation by inhibiting CDK9 which is required for S2 
phosphorylation of the RNAPII CTD (Bensaude, 2011; Chodosh, Fire, Samuels, & Sharp, 
1989; Dubois, Nguyen, Bellier, & Bensaude, 1994; S. Q. Xie, Martin, Guillot, Bentley, & 
Pombo, 2006). Thus, the DRB will prevent RNAPII which initiated from proceeding to 
elongation leaving only the already S2P-RNAPII to continue elongating (Figure 3.2A).  
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Figure 3.2: Investigation of RNAPII dynamics at exon 1 of the FXN gene. (A) Principle behind 
examining the dynamics of RNAPII on the FXN gene. RNAPII was inhibited with α-amanitin 
which inhibits both initiating and elongating forms of RNAPII or DRB which inhibits only the 
elongating form of RNAPII. The distribution of RNAPII (S5P- and S2P-RNAPII) after its 
inhibition was assessed using ChIP, as shown in (B). (B) S2P-RNAPII remained stalled at exon 
1 of the FXN gene in healthy cells but it was reduced following transcriptional inhibition in 
FRDA cell lines. S5P-RNAPII remained unaffected. X axis shows regions of the FXN gene 
identified by PCR and below is shown a schematic of the FXN gene indicating the site of GAA 
repeat expansion. B adapted and modified with permission from (PhD thesis (Yandim, 
2012)).  
  
 
 
In the healthy cell line, both inhibitors induced a small increase of the S5P-RNAPII and only a 
minor decrease of S2P-RNAPII enrichment at exon 1 (Figure 3.2B). These results are 
consistent with stalling of RNAPII at exon 1 of the FXN gene as the inhibition by DRB did not 
result in a decrease in the peak for RNAPII seen at exon 1.  Furthermore, the resistance of a 
S2P-RNAPII peak to both inhibitors indicates that in the healthy cell line the elongating 
RNAPII is surprisingly protected against proteasome mediated degradation as persistently 
stalled S2P-RNAPII (e.g during DNA damage) is normally degraded by the ubiquitin-
proteasome system (Daulny & Tansey, 2009; K. B. Lee et al., 2002; Somesh et al., 2005; 
Somesh et al., 2007; L. Y. Yang, Jiang, & Rangel, 2003). Thus, in the healthy FXN gene the 
RNAPII is not only stalled but is also unusually refractory to S2P-dependent degradation by 
the proteasome. In contrast to the healthy cell lines, treatment of patient cells lines with 
both transcriptional inhibitors induced a reduction of S2P-RNAPII levels at exon 1, whereas 
S5P-RNAPII remained unaffected (Figure 3.2B). These results together with the recruitment 
of the 19S proteasome on the patient FXN gene, analysed by ChIP, suggested that the 
proteasome might degrade the stalled S2P-RNAPII in the patient cell lines thereby 
preventing the transcription of the gene. Therefore, to investigate this possibility, the 
proteasome was inhibited at the same time as transcriptional inhibition and the level of S2P-
RNAPII on the FXN gene was assessed. The inhibition of the proteasome was achieved by 
using the well-known proteasome inhibitor PS-341 (Pyz-Phe-boroLeu, Bortezomib, 
Velcade®). PS341 is a dipeptide molecule targeting primarily proteasomal β5 (chymotrypsin-
like) site and secondarily the β1 (caspase-like) site (Berkers et al., 2005). It has high cell 
permeability, prolonged chemical stability and is the first approved proteasome inhibitor 
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used in patients to treat acute myeloid leukaemia (Chauhan, Hideshima, Mitsiades, 
Richardson, & Anderson, 2005; Field-Smith, Morgan, & Davies, 2006; Meenaghan et al., 
2010b; Richardson, Mitsiades, Hideshima, & Anderson, 2006; Sonneveld et al., 2012).  
As illustrated in Figure 3.3, treatment of patient cells with PS341 prevented the α-amanitin 
induced reduction of S2P-RNAPII in exon 1, supporting the hypothesis of proteasome 
dependent regulation of RNAPII at the FXN gene with pathologically expanded GAA repeats 
in FRDA. In contrast, simultaneous treatment of healthy cells with PS341 and α-amanitin 
had no effect on the level of RNAPII on the normal FXN gene (Figure 3.3), confirming the 
refractory nature of S2P-RNAPII to proteasome degradation in healthy individuals. 
Unpublished data from (Ph.D thesis  (Yandim, 2012).  
 
 
 
 
 
Figure 3.3: Proteasome inhibition by PS341 restores the S2P-RNAPII levels upon 
transcriptional inhibition by α-amanitin in FRDA (FRDA_1 and FRDA_2) cell lines and has no 
effect in a healthy cell line (Healthy_01). Graphs represent the binding of S2P-RNAPII 
measured by ChIP across the FXN gene after α-amanitin, PS341 and PS341 plus α-amanitin 
treatments. X axis shows regions of the FXN gene identified by PCR and below is shown a 
schematic of the FXN gene indicating the site of GAA repeat expansion. B adapted and 
modified with permission from Adapted and modified with permission from (Ph.D thesis  
(Yandim, 2012). 
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The main goal of this chapter was to further understand the role of the proteasome in 
regulation of FXN gene expression in FRDA and more specifically:  
 To investigate the heterochromatinisation of the FXN gene with pathologically 
expanded GAA repeats by measuring the repressive H3K9me3 and activating H3ac 
marks across the FXN gene in healthy and patient cell lines.   
  To assess the possible binding of the 20S CP of the proteasome which is required for 
proteasomal degradation along the FXN gene in healthy and patient cell lines, as 
previously only the binding of 19S RP was studied (Yandim, 2012). 
 To assess the global changes of the RNAPII levels upon proteasome and 
transcriptional inhibition, as previously the dynamics of RNAPII was studied 
specifically on the FXN gene.  
  To re-analyse the effect of the proteasome inhibition on the levels of mRNA and 
primary FXN transcripts in FRDA, both in vitro and in vivo using RNA spike to obviate 
the need for endogenous loading controls, as previously results suggested that 
proteasome inhibition might restore S2P-RNAPII levels at exon 1 in the FXN gene by 
increasing the reservoir of RNAPII available for transcription. (PhD thesis (Yandim, 
2012).   
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3.2  Results  
3.2.1 Expression of FXN is significantly reduced in FRDA disease cell lines 
In order to confirm the FXN repression in FRDA, FXN primary transcript RNA and mRNA 
levels were measured by q-RT-PCR in healthy (GM14926) and patient (GM15850, GM15851) 
EBV-transformed lymphoblastoid cell lines (Figure 3.4). Noticeably, both patient cell lines 
have similar levels of GAA repeat expansion (GM15850: 650/1030 repeats; GM16234: 
580/1030 repeats) but different levels of FXN expression. More specifically, the FXN mRNA 
expression was revealed to be 11 % and 28 % in GM15850 (hereinafter called FRDA_1) and 
GM16234 (hereinafter called FRDA_2) respectively, relative to the GM14926 (hereinafter 
called Healthy) cell line. Similarly, the expression of primary transcript was reduced to 12 % 
and 28 % in FRDA_1 and FRDA_2 respectively, compared to the healthy control (Figure 
3.4B).  
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Figure 3.4: Expression of FXN is significantly reduced in FRDA cell lines. (A) EBV-transformed 
human lymphoblastoid cell lines derived from healthy individual and two FRDA patients 
showing the length of GAA repeat within intron 1 of FXN gene. Exons are indicated by black 
boxes. The red box/arrow shows the GAA repeat. (B) FXN primary transcript and mRNA 
expression levels in the cell lines were detected by q-RT-PCR. The relative expression was 
normalised against GAPDH and are shown as fold change relative to Healthy cell line. Error 
bar = SEM of at least 3 biological replicates. *p < 0.05 (Student’s ‘t’ test) 
 
 
 
 
* 
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3.2.2 Decreased levels of histone acetylation and increased level of H3K9me3 histone 
modifications on the FXN gene in FRDA cell lines 
Considering that (i) previous studies have revealed that GAA repeats can stimulate 
heterochromatin mediated silencing by recruiting heterochromatin-related proteins (such 
as histone methyltransferases) (Yandim et al., 2013) and (ii) FXN is significantly repressed in 
the patient cell lines, we set out to investigate the chromatin status along the FXN gene in 
patient and healthy controls.  For this, chromatin immunoprecipitation was performed with 
antibodies against the normally repressive histone modification mark H3K9me3 and histone 
modification mark H3ac which is associated with an open chromatin structure (see general 
introduction section 2.2.1.2.4 and 2.2.1.1). Immunoprecipitated material was quantified 
using qPCR with primers covering the FXN gene locus from ~4500bp upstream of 
transcription start site to ~5000bp downstream of GAA repeat in intron 1 (Figure 3.5A). 
Additionally, primers against beta-globin (β-globin) and alpha-satellite (ALRsat) were used as 
positive controls for repressed chromatin; a primer against the housekeeping gene 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as positive control for 
active chromatin (Figure 3.5).  
As expected, the levels of H3K9me3 were low throughout the examined FXN locus in the 
healthy cell line where the gene is actively transcribed. On the contrary, higher levels of 
H3K9me3 were observed in all investigated FXN regions in two FRDA cell lines relative to the 
healthy cell line, while both controls (β-globin and ALRsat) showed similar levels of 
modification among all three cell lines. Importantly, H3K9me3 was particularly enriched in 
exon 1 of the FXN gene, with a minor enrichment occurring in the regions flanking the GAA 
repeats (In1P3 and In1P4) (Figure 3.5B).  
On the other hand, the overall histone H3 acetylation (H3ac) levels were noted to peak in 
exon 1 for all three cell lines, with a gradual decrease upon moving towards the GAA repeats 
in intron 1 of the FXN gene. However, overall lower levels of enrichment were 
demonstrated to be present at these regions in two FRDA cell lines when compared to the 
healthy cell line. Both controls, GAPDH for positive control and ALRsat for negative control, 
had similar levels of H3ac enrichment in all the three cell lines (Figure 3.5C).  
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Figure 3.5: The H3K9me3 and H3ac profile along the FXN gene in health and FRDA cell lines. 
(A) Schematic representation of the position and name of primer sets used to study the FXN 
gene locus. (B) H3K9me3 and (C) H3ac was analysed by chromatin immunoprecipitation and 
qPCR. ChIP signals are shown as relative enrichment to H3 with background subtraction. β-
globin, ALRsat and GAPDH were used as controls. Error bar represent SEM, n=2-3 
A 
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Analysis of FRDA patient cell lines demonstrated (i) higher levels of H3K9me3 throughout 
the FXN gene and (ii) primarily lower levels of H3ac in exon 1 of the FXN gene, confirming its 
pathological heterochromatinisation and transcriptional repression in FRDA. Interestingly, 
while the H3K9me3 levels were found to be similar in the two patient cell lines, the H3ac 
levels were higher in FRDA_2 compared with FRDA_1 which is consistent with the 
expression levels of the FXN in these two patient cells lines (see Figure 3.4B).  
 
 
 
3.2.3 Increased binding of the proteasome at the pathologically silenced FXN gene 
As mentioned in the introduction of this chapter, data from the GCMD lab showed marked 
reduction of the stalled S2P-RNAPII within the first exon of the FXN gene upon 
transcriptional inhibition in FRDA disease cell lines but not in the healthy cell line. One 
possible explanation for the observed S2P-RNAPII sensitivity at the pathologically silenced 
FXN locus was degradation of the stalled RNAPII complex by the proteasome, as had 
previously been shown in transcription–coupled DNA repair (K. B. Lee et al., 2002; Somesh 
et al., 2005; Somesh et al., 2007; L. Y. Yang et al., 2003). To test this hypothesis, ChIP was 
performed using two different antibodies against catalytic subunits of the proteasome (20S) 
to investigate whether the proteasome was actively recruited to the FXN gene. 
Immunoprecipitated material was quantified using qPCR with primers covering the FXN 
gene locus from ~4500bp upstream of transcription start site to ~5000bp downstream of 
GAA repeat in intron 1, as in the previous experiment (Figure 3.6A). Additionally, primers 
against β-globin, ALRsat and GAPDH regions were used as controls for inactive, repetitive 
element and active regions of the genome respectively.  
The result revealed binding of proteasome throughout the FXN locus, with an overall higher 
enrichment in the FRDA disease cell line compared to healthy cell line (Figure 3.6B, 3.6C). 
More specifically, the binding of the proteasome peaked in exon 1, and the regions flanking 
the GAA repeats in all the examined cell lines (Int1P3 and Int1P4). However, a prominent 
peak was only observed in exon 1 in the FRDA cells. Notably, proteasome ChIP signal was 
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also detected in all the controls, with similar enrichment levels between healthy and disease 
cell lines (Figure 3.6B, 3.6C). This is not surprising, as many studies have shown the 
regulatory role of the proteasome at fully active genes (G. A. Collins & Tansey, 2006; 
Ferdous et al., 2001; Hegde & Upadhya, 2006; D. Y. Lee, Ezhkova, et al., 2005; Lipford, 
Smith, Chi, & Deshaies, 2005; Muratani, Kung, Shokat, & Tansey, 2005) and transcriptionally 
inactive regions of the genome (Szutorisz et al., 2006).  
The proteasome complex consists not only of the catalytic particle (20S) but also of the 
regulatory particle (19S) (Adams, 2003b). The result presented in this thesis builds on our 
previous finding that the 19S proteasome is also present on the FXN locus in FRDA (Yandim, 
2012) and adds weight to the hypothesis that the FXN associated proteasome may be 
competent to degrade chromatin associated proteins such as RNAPII.  
Interestingly, comparison of the proteasome binding profile with the repressive histone 
modification H3K9me3 mark throughout the FXN locus revealed similar distribution pattern 
(compare Figure 3.5B and 3.6C), with exon 1 and regions flanking the GAA repeats showing 
the highest enrichment. Both H3K9me3 and proteasome were enriched at exon 1 in the 
patient cell lines (Figure 3.5 and 3.6). Importantly, this is the same region where S2P-RNAPII 
was previously shown to be stalled in all the cell lines but only significantly reduced upon 
transcriptional inhibition in the FRDA cell line. Furthermore, as mentioned above (see Figure 
3.3) treatment of cells with proteasome inhibitor concomitant with transcriptional inhibitor 
restored the S2P-RNAPII level on the exon 1 in the patient cell lines, whereas no effect was 
shown in the healthy cell line.  However, whether this restoration of S2P-RNAPII level is 
specific to the FXN gene will be investigated in the following section.  
The results so far suggest that the proteasome may have an important regulatory role in 
FRDA pathology, by possibly rendering the stalled RNAPII on the FXN gene with expanded 
GAA repeat more susceptible to degradation. 
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Figure 3.6: The proteasome binding along the FXN gene in healthy and FRDA_1 cell lines. (A) 
Schematic representation of the position and name of primer sets used to study the FXN 
gene locus. (B, C) The proteasome binding was analysed by ChIP using two different 
antibodies and immunoprecipitated material was measured by qPCR. ChIP signals are shown 
as relative enrichment to H3 with background subtraction. β-globin, ALRsat and GAPDH 
were used as controls. Error bar represent SEM n=3.  
A 
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3.2.4 Restored total level of RNAPII upon proteasome and transcriptional inhibition in 
lymphoblastoid cell lines (Healthy and FRDA) 
What is the effect of the proteasome and transcriptional inhibition on the global RNAPII 
level? To answer this question, healthy and patient lymphoblastoid cell lines were treated 
with proteasome inhibitor MG132, simultaneously with the transcriptional inhibitor α-
amanitin. MG132 (Z-Leu-Leu-Leu-al) is a C-terminal peptide aldehyde that blocks the 
proteolytic activity of all 20S catalytic core subunits (β1, β2 and β5) of the proteasome 
(Berkers et al., 2005; Tsubuki et al., 1993). It is a widely used proteasome inhibitor as it 
performs in a highly selective manner and is highly cell permeable (Elliott, Zollner, & 
Boehncke, 2003; Kisselev & Goldberg, 2001). As mentioned in the introduction of this 
chapter α-amanitin is a potent and selective RNAPII inhibitor interfering with the 
translocation step of the transcript polymerization reaction.  
Here, initially the cells were treated with MG132 at a final concentration of 10μM and α-
amanitin (65 μg/ml) was added in a culture medium an hour later. This was performed in 
order to give a sufficient time frame for the proteasome inhibition to occur before 
transcriptional inhibition would take place.  After adding the α-amanitin, cells were treated 
for an additional 8h in the presence of both drugs. Subsequently, cells were collected and 
lysed using lysis buffer. Total RNAPII and S5P-RNAPII levels were measured by western blot. 
It is worth mentioning that multiple attempts were made to measure the S2P-RNAPII, but 
no antibody was found to be efficient for the western blot analysis.  
The level of RNAPII was shown to increase upon proteasome inhibition and decrease upon 
transcriptional inhibition in both healthy and FRDA cell lines. Considering that (i) α-amanitin 
induces stalling of RNAPII (Brueckner & Cramer, 2008; X. Q. Gong et al., 2004; M. D. Rudd & 
Luse, 1996) and (ii) stalled RNAPII is sensitive to proteasomal mediated degradation 
(Karakasili, Burkert-Kautzsch, Kieser, & Strasser, 2014; Nguyen et al., 1996; Svejstrup, 2007) 
it was therefore expected that concomitant treatment of cells with MG132 and α-amanitin 
restored the total RNAPII levels in all the examined cell lines (Figure 3.7A). Similar results 
were also obtained for S5P-RNAPII (Figure 3.7B). 
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Figure 3.7: The total RNAPII level is restored upon concomitant proteasome and 
transcriptional inhibition in Healthy and FRDA cell lines. Healthy and FRDA cell lines were 
treated with MG132 for 1h followed by α – amanitin and MG132 treatment for an additional 
8h. Total protein cell lysate was immunoblotted with antibodies against total RNAPII (A) and 
S5P-RNAPII (B). α-tubulin served as a loading control.  
 
  
These results are reminiscent of the RNAPII dynamics at the FXN gene in patient cell lines, 
where proteasome inhibition prevented the α-amanitin induced depletion of RNAPII in exon 
1. In contrast, no effect was seen in the healthy cell lines (Figure 3.3), indicating an unusual 
RNAPII dynamics at the normal FXN gene where, upon stalling, RNAPII is resistant to 
proteasomal degradation. Hence, the RNAPII at the FXN gene in the healthy cells lines 
appears protected against proteasome mediated degradation.  
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3.2.5 The effect of in vitro proteasome and/or transcriptional inhibition on the cell 
viability and the levels of FXN expression  
The recovery of RNAPII stalling at exon 1 in the FXN gene in FRDA raised the possibility that 
proteasome inhibition could influence the FXN expression in FRDA by restoring the reservoir 
of RNAPII available for transcription. In order to investigate this, healthy and patient 
lymphoblastoid cell lines were treated with the proteasome inhibitor MG132 alone or 
simultaneously with transcription inhibitors α-amanitin and Actinomycin D (ActD). As 
mentioned above, α-amanitin is a specific inhibitor of RNAPII, whereas ActD inhibits all 
three RNA polymerases by intercalating into DNA (Bensaude, 2011; Trask & Muller, 1988). 
Consistently with the previous experimental setup, cells were initially incubated with 10µM 
MG132 for an hour, before adding α-amanitin (65µg/ml) or ActD (20µg/ml) in the culture 
medium followed by an additional 8h of treatment in the presence of either MG132, α-
amanitin, ActD or both MG132 and α-amanitin/ActD. Cells were sampled to assess viability 
by measuring the cell number using Guava flow cytometry (Figure 3.8 shows absolute cell 
numbers); the remaining cells were used for RNA extraction followed by q-RT-PCR in order 
to determine the expression levels of FXN mRNA and FXN primary RNA transcripts.  
 
 
Analysis of cell viability upon proteasome and transcriptional inhibition 
As shown in Figure 3.8 and Table 2, incubation of cells with MG132 was found to decreased 
the cell survival reaching 70%, 82% and 78% in Healthy, FRDA_1 and FRDA_2 cell lines 
respectively. Moreover, cellular viability decreased to 73%, 81% and 88% upon treatment 
with ActD in Healthy, FRDA_1 and FRDA_2 cell lines respectively, whereas treatment with 
65µg/ml α-amanitin for this period had little or no effect on viability. In addition, the cellular 
viability was similarly affected upon concomitant treatment with MG132 and ActD/α-
amanitin as well as MG132 treatment alone in all the examined cell lines (Figure 3.8, Table 
2). 
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Figure 3.8: The effect of proteasome and transcriptional inhibition on the survival of 
Healthy, FRDA_1 and FRDA_2 cell lines. 3X10^6 cells were treated with MG132, α-amanitin 
and ActD for 8h and cells were counted by Guava flow cytometry. Data represent absolute 
number of cells. Baseline indicated the starting number of cells (dashed line). Error bars = 
SEM of at least 2 biological replicates.  
 
 
 
Treatment Healthy  (n=2-3) 
Viability (%) 
FRDA_1  (n=2-3) 
Viability (%) 
FRDA_2   (n=2-3) 
Viability (%) 
DMSO  100 100 100 
MG132 70 82 78 
ActD 73 81 88 
α-amanitin 96 98 100 
MG132+ActD 67 71 76 
MG132+α-amanitin 70 76 76 
 
Table 2: Cell viability of Healthy, FRDA_1 and FRDA_2 cell lines upon treatment with 
proteasome inhibitor MG132, transcriptional inhibitors ActDα/amanitin and concomitant 
treatment of MG132 with ActD or α-amanitin for 8h. Values represent the average 
percentage of cell viability of 2-3 biological replicates.  
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Analysis of FXN expression upon proteasome and transcriptional inhibition 
Consistent with effective transcriptional inhibition by both ActD and α-amanitin the short 
lived c-MYC transcript was completely lost after 8h of treatment with both transcription 
inhibitors. There was a significant reduction of the c-MYC mRNA upon MG132 treatment in 
all the cells lines (Figure 3.9A), consistent with previously published studies although the 
mechanism is unknown (Bhatt et al., 2013; J. Jung et al., 2012; Suk et al., 2015).  
Furthermore, treatment of cells with transcriptional inhibitors for 8h, resulted in 50% 
reduction of the FXN mRNA levels in both Healthy and FRDA cell lines (Figure 3.9B), broadly 
consistent with the formal measurement of half-life (Punga & Buhler, 2010).  
Following the proteasome inhibition, both FXN mRNA and primary FXN transcripts were 
significantly downregulated in all the examined EBV cell lines. Similar levels of FXN mRNA 
downregulation were also obtained with concomitant treatment of Healthy and FRDA cell 
lines with proteasome inhibitor and transcriptional inhibitors (Figure 3.9B, 3.9C). Moreover, 
simultaneous treatment of cells with MG132 and ActD/α-amanitin resulted in similar levels 
of primary FXN transcript reduction as MG132 treatment alone in FRDA cells lines, indicating 
the effect of M132 is likely to be transcriptional rather than affecting the stability of the FXN 
RNA (Figure 3.9C).   
Contrary to what might expected if the proteasome was degrading stalled RNAPII at the FXN 
locus (Figure 3.3) as previously hypothesised its inhibition resulted in repression rather than 
upregulation of the FXN levels. It is possible that the recruitment of the proteasome to the 
FXN locus (Figure 3.6) and the downregulation of FXN expression upon proteasome 
inhibition (Figure 3.9B, 3.9C) indicated an additional active role for the proteasome in the 
regulation of FXN gene transcription (see more details in the discussion) in addition to 
effects it might have in removing stalled RNAPII at the stalling site.  
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See next page for figure legend 
114 
 
Figure 3.9:  In vitro proteasome inhibition downregulates FXN expression in Healthy and 
FRDA cell lines. c-MYC mRNA (A), FXN mRNA (B) and primary FXN transcript (C) were 
analysed by q-RT-PCR after MG132, ActD, α – amanitin, MG132 plus ActD (MG132 + ActD) 
and MG132 plus α – amanitin (MG132 + α – amanitin) treatments. MG132 was added to the 
cell culture one hour before adding α – amanitin/ActD. Data are presented as the relative 
expression normalised against spike and shows fold change relative to DMSO (vehicle) 
treatment of healthy cell line. Error bars = SEM of 2-3 biological replicates. c-MYC expression 
served as a control for the RNAPII inhibition.  
 
 
 
 
3.2.6 The effect of in vivo proteasome inhibition on the FXN and heterochromatin repeat 
(major, minor) expression  
Although proteasome inhibition was previously shown to rescue the degradation of stalled 
RNAPII at the FXN gene in patient EBV derived cells it did not result in FXN upregulation (see 
above). In parallel an in vivo approach was also adopted to address whether proteasome 
inhibition could upregulate FXN at the transcriptional level. An additional rationale for the 
use of in vivo approach stems from the finding that FXN protein itself is subject to 
proteasomal degradation (Rufini et al., 2011) suggesting that proteasomal inhibition might 
be therapeutically useful. Considering that FRDA is a degenerative disease, affecting central 
and peripheral nerve tissue (e.g cerebellum) as well as heart (Koeppen, 2011; Payne, Pride, 
& Babbey, 2011), YG8 transgenic mice (see materials and methods) which provide a mouse 
model for FRDA (Al-Mahdawi et al., 2004) were used to assess the effect of the proteasome 
inhibition directly in some of the affected tissues. YG8 transgenic mice (C57BL/6J 
background) contain two copies of the human FXN transgene with 190+90 repeats (Al-
Mahdawi et al., 2004) and show reduced levels of Frataxin protein (42% cerebellum, 25% 
heart) compared to wild type animals (Al-Mahdawi et al., 2006). Moreover these mice 
exhibit increased sensitivity to oxidative stress leading to an FRDA-like phenotype 
characterised by progressive neuron and cardiac pathology (Al-Mahdawi et al., 2006).   
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Furthermore, previous studies have shown that the proteasome is widely associated with 
different compartments of chromatin, such as actively transcribed genes (Geng & Tansey, 
2012; Sikder et al., 2006), centromeres (Kitagawa et al., 2014b) telomeres (Geng & Tansey, 
2012) as well as intergenic (cryptic) transcription start sites (Szutorisz et al., 2006). In this 
chapter it was shown that the proteasome is recruited to the FXN gene (Figure 3.6), with an 
increase in binding occurring at the pathologically heterochromatinised FXN locus. 
Therefore, in order to investigate whether the proteasome has a role in regulation of 
heterochromatic regions, the expression of major and minor satellite repeats consisting of 
pericentromeric and centromeric regions respectively was also analysed upon in vivo 
proteasome inhibition. 
Although there are many examples of administrating the proteasome inhibitor MG132 in 
animals (Caron et al., 2011; B. Chen et al., 2010; Inoue et al., 2009; Jamart, Raymackers, An, 
Deldicque, & Francaux, 2011), some studies suggest that MG132 is only partially effective in 
vivo, due to its rapid metabolism (C. M. Lee, Kumar, Riley, & Morgan, 2010). Therefore an 
alternative, for in vivo studies is the proteasome inhibitor PS341 which is already licensed 
for use in humans.  
Here, 3 groups of female and male YG8 transgenic mice were intraperitoneally injected with 
0.075mg/kg (low dose - group 1), 0.375 mg/kg (medium dose - group 2) and 0.750mg/kg 
(high dose - group 3) PS341 once a day for 5 consecutive days, whereas the untreated 
control group (group 4) was given the same volume of physiological saline (vehicle). 
Cerebellum and heart tissues were collected from each group followed by RNA extraction 
and q-RT-PCR using specific primers against (i) human FXN transgene, (ii) major satellite 
repeat and (iii) minor satellite repeat.   
As shown in Figure 3.10A, no significant change was identified in the FXN transgene 
expression in cerebellum tissue both in female and male mice upon in vivo proteasome 
inhibition. However the heart tissue revealed a sexual dimorphism, where downregulation 
of the FXN transgene expression was observed in the male mice with low and high dose of 
PS341, consistent with in vitro proteasome inhibition in EBV cell lines (see Figure 3.9). On 
the other hand, no change was seen in female mice (Figure 3.10B).  
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Interestingly, in vivo treatment of male mice with high dose (0.750mg/kg) of PS341 
upregulated the expression of major and minor satellite repeats in both cerebellum and 
heart tissue, with greater effect occurring in the heart tissue (Figure 3.11A, 3.11C). On the 
contrary, in the female mice, a small upregulation of the major and minor satellite repeats 
was seen in cerebellum (Figure 3.11B), while expression of these repeats was either 
unchanged or downregulated in the heart tissue (Figure 3.11D).  
Overall these data suggest that in vivo proteasome inhibition results in no change or 
downregulation of FXN expression in cerebellum and heart tissue respectively. This 
observed downregulation was sex-dependent occurring exclusively in the male mice. 
Additionally, the upregulation of heterochromatic repeats upon in vivo proteasome 
inhibition in the male mice indicates a role of the proteasome in repression of these 
repeats.  
A possible explanation for the difference observed between cerebellum and heart tissue 
could be due to the availability of the drug, as PS341 was previously reported to cross the 
blood-brain barrier poorly (Hemeryck et al., 2007).  
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Figure 3.10: The effect of in vivo proteasome inhibition of the FXN trangene expression in 
Cerebellum (A) and Heart tissue (B) of YG8 transgenic mice. The mice were injected 
intraperitoneally with 0.075mg/kg, 0.375 mg/kg and 0.750mg/kg PS341 while untreated 
controls received only saline for 5 consecutive days. Analyses of mRNA levels were 
conducted by q-RT-PCR using specific primers against human FXN transgene. Data are 
presented as the relative expression normalised against GAPDH and shows fold change 
relative to untreated control group. Error bars = SEM of at least 2 biological replicates. *p < 
0.05 (Student’s ‘t’ test). 
* 
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See next page for figure legend 
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Figure 3.11: The effect of in vivo proteasome inhibition on the expression of the 
heterochromatic repeats in the cerebellum (A, C) and heart (B, D) tissues. YG8 transgenic 
mice were injected intraperitoneally with 0.075mg/kg, 0.375 mg/kg and 0.750mg/kg PS341 
while untreated controls received only saline for 5 consecutive days. RNA was extracted and 
major satellite (A, B) and minor satellite (C, D) repeats were analysed by q-RT-PCR. Data are 
presented as the relative expression normalised against GAPDH and shows fold change 
relative to untreated control group. Error bars = SEM of at least 2 biological replicates. *p < 
0.05 (Student’s ‘t’ test). 
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3.3 Discussion  
3.3.1 Heterochromatinisation of the FXN gene in FRDA  
As mentioned in the introduction, two models have been proposed to explain the 
transcriptional repression of the FXN gene with pathologically expanded GAA repeats.  
The first model suggests that GAA repeats physically block RNAPII elongation though 
formation of abnormal non-B DNA structural confirmations (eg. triplex, hairpin) and 
DNA:RNA hybrids (R-loops) (Yandim et al., 2013). So far, the existence of such structures has 
been mainly studied in nucleosome-free plasmids in vitro or in Escherichia coli (Grabczyk et 
al., 2007; Ohshima, Montermini, Wells, & Pandolfo, 1998; Reddy et al., 2011; Sakamoto et 
al., 1999). Notably the presence of R-loops has only been recently detected in vivo over the 
expanded GAA repeat region on the native FXN gene in patient cells (Groh et al., 2014). 
Further studies on the endogenous FXN gene are required to determine the presence and 
the role of these structural conformations in the pathology of FRDA.  
The second model proposes that GAA repeats induce heterochromatinisation of the locus 
that epigenetically silence the FXN gene (Yandim et al., 2013). In this chapter, the 
heterochromatin modification H3K9me3 was shown to be elevated throughout the FXN 
gene with pathologically expanded GAA repeats in FRDA EBV cell lines, relative to the 
healthy cell lines. This repressive mark was found to be particularly enriched in Ex1 and the 
regions flanking the GAA repeats. In contrast to the heterochromatin mark, the euchromatic 
H3ac was shown to be reduced in regions upstream of the abnormally expanded GAA 
repeats in patient EBV cell lines, compared to the healthy cell line. Interestingly, despite the 
difference in the mRNA and primary transcript FXN expression between the two examined 
FRDA cell lines, the level of H3K9me3 was found to be similar. However the difference in the 
expression between the patient cell lines was well correlated with the H3ac levels. More 
specifically, patient (FRDA_2) with lowest level of FXN expression, exhibited the lowest level 
of H3ac on the regions upstream of GAA repeats. Taken together, these results suggest 
high-order chromatin structure formation caused by GAA repeat expansion in FRDA and is 
consistent with previously published studies investigating post-translational histone 
modification profiles along the FXN locus (Al-Mahdawi et al., 2008; De Biase et al., 2009; 
Greene, Mahishi, Entezam, Kumari, & Usdin, 2007; Herman et al., 2006; E. Kim et al., 2011; 
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Y. Li et al., 2015; Punga & Buhler, 2010). A summary of these studies investigating the 
chromatin changes on the FXN gene in shown in supplementary table S1.  
Additionally, further evidence indicating heterochromatinisation of the FXN gene in FRDA 
include: 
(i) Increased DNA methylation of CpG sites upstream of GAA repeats in various models of 
FRDA (Al-Mahdawi et al., 2013).   
(ii) Decreased binding of the chromatin insulator protein CTCF at the 5’ UTR region of the 
FXN gene in FRDA fibroblast cell lines and cerebella tissues (Al-Mahdawi et al., 2013; De 
Biase et al., 2009). CTCF functions to prevent the spreading of heterochromatin (Ong & 
Corces, 2014), therefore reduced occupancy of this factor on the FXN gene would 
potentially permit the spreading of heterochromatin from the expanded GAA repeats 
towards the promoter and resultant gene silencing. However it is worth mentioning that the 
spreading was recently shown to be restricted to the FXN locus and did not affect the 
expression of the adjacent genes (Y. Li et al., 2015). 
(iii) Heterochromatin silenced genes have a tendency to localise close to the nuclear 
periphery, interacting with nuclear lamina proteins (Andrulis, Neiman, Zappulla, & 
Sternglanz, 1998; Bolzer et al., 2005; Dietzel, Zolghadr, Hepperger, & Belmont, 2004; Guelen 
et al., 2008; Van de Vosse, Wan, Wozniak, & Aitchison, 2011). Similarly, the FXN gene with 
pathologically expanded GAA repeats was recently found to reposition to the nuclear 
periphery (Silva, Brown, Buckle, Wade-Martins, & Lufino, 2015).  
To date, neither the mechanism behind heterochromatinisation induced by GAA repeat 
expansion, nor the factors regulating its formation is known. Heterochromatin formation is 
controlled by multiple chromatin modifiers, such as H3K9 methyltransferases G9a and 
SUV39H. A chemical inhibition of G9a HKMT reduced the levels of H3K9me2/3, however this 
reduction was not accompanied by significant upregulation of FXN expression (Groh et al., 
2014; Punga & Buhler, 2010). In future, it would be interesting to assess the effect of SUV39H 
as well as EZH2/PRC2 in the regulation of FXN silencing. Certainly, identifying the key 
chromatin modifiers responsible for the FXN heterochromatinisation in FRDA and hence it’s 
repression will open a new avenue in developing effective treatments.  
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3.3.2 Proteasome binding to the RNAPII stalling site on the FXN gene 
Data from the GCMD lab (see more details in the Introduction of this chapter) revealed that 
the initiating (S5P) and elongating (S2P) forms of RNAPII are stalled within Ex1 of the FXN 
gene at similar levels in both healthy and patient cell lines (PhD thesis (Yandim, 2012). 
Consistently, a recent study identified, using chromatin immunoprecipitation, a high 
accumulation of total RNAPII at Ex1 of the FXN gene in both healthy and patient cell lines. 
However, the overall level of RNAPII was found to be significantly reduced in patient cells 
relative to the healthy control, which correlated with the difference in the FXN expression 
levels. Furthermore, the same study further measured actively transcribing RNAPII using a 
nuclear run-on assay and revealed significant transcriptional reduction upstream of GAA 
repeats, consisted with the RNAPII ChIP results (Groh et al., 2014). Similarly, Kim et al., also 
showed an enrichment of total RNAPII in Ex1 of the FXN gene in healthy cell lines, which was 
significantly decreased in FRDA cells (E. Kim et al., 2011).  
The stalling of RNAPII at the promoter-proximal region is a widespread biological 
phenomenon occurring in multiple regions of the genome such as HSP70 (Gilmour & Lis, 
1986; H. Tang, Liu, Madabusi, & Gilmour, 2000), c-MYC (Eberhardy & Farnham, 2001; 
Krumm, Meulia, Brunvand, & Groudine, 1992), DHFR and γ-actin (C. Cheng & Sharp, 2003). 
The proposed functions of promoter-proximal RNAPII stalling include: (i) establishing a 
permissive chromatin structure by maintaining the nucleosome – free promoter region in 
order to allow transcription factors and co-activators to easily access the DNA template, (ii) 
activating several genes simultaneously and rapidly upon a given stimulus e.g during heat 
shock and (iii) serving as a checkpoint for an efficient capping of the nascent RNA (Adelman 
& Lis, 2012). Whereas in the promoter-proximal region, the initialling RNAPII is known to be 
the predominant form, on the FXN gene, both initiating and elongating forms of RNAPII 
were detected. Therefore, this stalling effect was more reminiscent of RNAPII stalling during 
transcriptional arrest. So far, numerous factors, including topological constrains (Brill & 
Sternglanz, 1988; Garcia-Rubio & Aguilera, 2012), chromatin structure (Izban & Luse, 1991; 
Kireeva et al., 2005), sequences that are difficult to transcribe (Hawley, Wiest, Holtz, & 
Wang, 1993; Kerppola & Kane, 1988) and bulky DNA adducts have been suggested to induce 
permanent or temporary RNAPII stalling/arresting (Wilson et al., 2013). In the case of the 
FXN gene, the stalling could potentially arise from the abnormal DNA conformations and 
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heterochromatin formation by GAA repeats. Indeed previous in vitro and in bacteria studies 
reported stalling of RNAPII induced by GAA repeats (Grabczyk et al., 2007; Grabczyk & 
Usdin, 2000).  
Importantly, the high affinity of RNAPII binding to its template prevents its dissociation from 
the stalled sites. Hence, the stalled RNAPII might not only cause transcriptional blocking of 
the gene, but also interfere with the transcription-coupled repair process. Interestingly, 
organisms may have evolved to solve this problem by utilizing the proteasome complex to 
degrade the stalled RNAPII (Wilson et al., 2013). The molecular mechanism of how RNAPII 
becomes a target for degradation by the proteasome is still not clear. However, an in vitro 
study found that the hyper-phosphorylated form of RNAPII is subject to degradation (Mitsui 
& Sharp, 1999) and studies in yeast revealed that only the elongating form of RNAPII can 
become ubiquitinated (Huibregtse, Yang, & Beaudenon, 1997; Somesh et al., 2005). 
Consistently, the proteasome was shown to degrade the stalled elongating form of RNAPII 
at Ex1 of the FXN gene in the presence of pathologically expanded GAA repeats, as 
elongating RNAPII levels were restored in the presence of both transcriptional and 
proteasome inhibitors (see more details in the introduction of this chapter). In contrast, no 
such effect was seen in the healthy controls, indicating that stalled RNAPII on the FXN gene 
is protected against degradation. In this chapter, the stalling effect of RNAPII induced by 
transcriptional inhibition and further degradation by the proteasome was investigated at 
the global level by western blot. Thus, use of the proteasome inhibitor either alone or in 
combination with the transcriptional inhibitor resulted in an increase in the overall level of 
RNAPII. This indicated that stalling induced by transcriptional inhibition leads to RNAPII 
degradation by the proteasome. The main novel finding presented in this chapter is the 
binding of the 20S proteasome along with the FXN gene, which was particularly high in Ex1 
of the FXN gene in FRDA cells compared to healthy control. This elevated level of 20S 
proteasome overlaps with the RNAPII stalling site which would be consistent with there 
being direct degradation of RNAPII by the proteasome in Ex1 of the FXN gene only in the 
presence of pathologically expanded GAA repeats. On the other hand, low levels of 20S 
proteasome on the FXN gene in the healthy cells comes in agreement with the insensitivity 
of the stalled RNAPII to proteasome-induced degradation. One possible explanation for the 
difference in the recruitment of the proteasome between healthy and FRDA patient cells 
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could be due to an unusual conformation of RNAPII in the healthy cells or the absence of 
either RNAPII ubiquitination or an unknown factor that is recognised by the proteasome. 
Furthermore, the stalling of RNAPII in the healthy cells could serve as an additional check 
point for the FXN gene transcription, as this gene is required under normal conditions to be 
transcribed at low levels and overexpression was previously shown to be toxic for the cell 
(Navarro et al., 2011). Interestingly, the pattern of proteasome enrichment was reminiscent 
of the H3K9me3, suggesting that proteasome recruitment might be an important factor for 
abnormal chromatin formation caused by the GAA repeat expansion. Also, it is worth 
mentioning that the binding of the proteasome was validated using two different antibodies 
and is consistent with 19S binding along the FXN gene (PhD thesis (Yandim, 2012), implying 
that 26S proteasome is recruited to the FXN gene. However, more subunits are required to 
be further analysed, in order to confirm the presence of proteasome holoenzyme rather 
than its individual particles on the FXN locus.  
How do the pathologically expanded GAA repeats recruit the proteasome to the FXN gene? 
One possible hypothesis could be through interacting with Mismatch repair proteins such as 
MSH2/MSH3, factors that were previously shown to bind to both GAA repeats (Bourn, 
Rindler, Pollard, & Bidichandani, 2009; J. T. Du et al., 2012; Ezzatizadeh et al., 2012; Halabi, 
Ditch, Wang, & Grabczyk, 2012) and the proteasome (Hernandez-Pigeon, Laurent, Humbert, 
Salles, & Lautier, 2004). Moreover, proteasome could be recruited to the site in response to 
the presence of ubiquitinated RNAPII. Even though RNAPII ubiquitination at the FXN gene 
was not analysed, it is possible that degradation occurs through the classical ubiquitin-
proteasome pathway.  The precise mechanism by which RNAPII becomes a target for 
ubiquitination and further degradation by the proteasome is still not clear. In yeast, a 
proposed model for stalled RNAPII degradation consists of three main steps: (i) 
monoubiquitination of the stalled elongating form of RNAPII by the E3 ubiquitin ligase Rsp5 
(NEDD4 is the closest mammalian homologue), (ii) recognition of the monoubiquitinated 
form of RNAPII and subsequent polyubiquitination catalysed by the Elongin E3 ligase 
complex (Elongin A/B/C-Cullin mammalian homologue) and (iii) recruitment of the 26S 
proteasome and degradation of the largest subunit of RNAPII (Rbp1) causing its disassembly 
(Harreman et al., 2009; Wilson et al., 2013). This mechanism of RNAPII degradation is 
thought to be conserved in mammals, although the factors that catalyze each step have yet 
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to be all confirmed. To date, even though many E3 ubiquitin ligases have been identified 
(e.g BRCA1-BARD1, NEDD4), only NEDD4 knock-down was shown to significantly reduce 
DNA damage induced RNAPII ubiquitination in mammalian cells (Anindya, Aygun, & 
Svejstrup, 2007).  However, the NEDD4 knockdown did not show any significant effect on 
the expression of the FXN gene in both healthy and FRDA patient EBV cell lines (data not 
shown). Besides NEDD4, the human cells contain 5 other Rsp5 homologues including AIP4, 
Smurf1, Smurf2, WWP1, and WWP2 (Anindya et al., 2007) which could potentially 
ubiquitinate RNAPII. Further analysis is required to directly determine the mechanisms 
underlying the recruitment and the degradation of RNAPII by the proteasome at the FXN 
gene in FRDA. 
 
 
 
3.3.3 Downregulation of FXN expression and upregulation of heterochromatic repeat 
expression with proteasome inhibition  
The proteasome was shown to bind and potentially degrade the stalled RNAPII at Ex1 of the 
FXN gene with pathologically expanded GAA repeats. Given these results it was surprising 
that in vitro and in vivo proteasome inhibition did not cause any upregulation of FXN 
expression but rather induced either a marked decrease or no change in the transcript 
levels. More specifically, in vitro treatment with proteasome inhibitor resulted in a clear 
reduction of the FXN gene transcription, in both healthy and FRDA EBV cell lines. On the 
other hand, in vivo proteasome inhibition had virtually no effect on the FXN expression in 
the cerebellum while the effect was downregulation and no change in the heart tissue 
derived from male and female FRDA-model mice respectively. There are number of 
explanations that could account for the difference observed between in vitro and in vivo 
proteasome inhibition including the concentration of the inhibitor as the dose used for in 
vivo treatment was 5 times less than in vitro, duration of the treatment, different systems to 
mention a few. Additionally the variation in the effect on FXN expression between heart and 
cerebellum tissue could be due to different accessibility of the inhibitor to the target tissues.  
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So far, the majority of studies correlate the proteasome with activation of gene 
transcription rather than repression. Therefore the downregulation of both FXN and c-MYC 
expression shown here (Figure 3.9) is consistent with the function of the proteasome in 
facilitating RNAPII mediated gene transcription (Geng et al., 2012). As discussed in the 
Introduction, the proteasome affects each step of the transcriptional process (initiation, 
elongation, termination). For example at the promoter region, the proteasome is known to 
be required for activator turnover and recruitment of the co-activators (F. Gonzalez et al., 
2002). Also, the proteasome is thought to promote transcriptional elongation through 
interacting with various elongation factors (e.g FACT) and RNAPII (Ferdous et al., 2001; 
Gillette et al., 2004a; Sun, Johnston, & Kodadek, 2002). Lastly, the proteasome function is 
needed for accurate transcriptional termination as inhibiting its activity was shown to 
increase read through of a transcriptional termination site (Gillette et al., 2004a). Therefore, 
recruitment of the proteasome to the FXN gene might degrade the stalled RNAPII, however 
inhibiting its function could also inhibit transcriptional processes by preventing 
transcriptional elongation and termination from taking place. In addition, a proportion of 
stalled RNAPII might escape the degradation which could be regulated by elongation factors 
and deubiquitinating enzymes leading to resumption of the RNAPII transcription. This 
RNAPII escape from the stalling site was recently shown to occur with a stalled RNAPII that 
arose independently of DNA-damage (Karakasili et al., 2014).  Recruitment of factors that 
would allow RNAPII to escape from the stalling site could be controlled by the activity of the 
proteasome; hence inhibiting the proteasome would downregulate transcription, as seen in 
this chapter. The proteasome at the FXN gene in FRDA might function in (i) degrading the 
RNAPII and (ii) promoting the escape of RNAPII from the stalling site and (iii) regulate both 
transcriptional elongation and termination. More studies are required to address the 
precise role of the proteasome on FXN gene regulation.  
Additionally, it is noteworthy that a previous study using proteasome inhibitor reported 
accumulation of the frataxin protein (Rufini et al., 2015). Also, it is unclear in the Rufini 
study whether there was any additional effect on FXN transcription at the doses used - 
either transcription was not affected or minimally leaving enough mRNA to be translated 
into FXN protein. In addition, the observed accumulation could be explained by a long half-
life of the frataxin protein (~50h) (K. Y. Li et al., 2008) compared to the FXN RNA transcript 
(~8h).  
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Another key finding in this chapter is upregulation of pericentromeric and centromeric 
satellite repeats expression with in vivo proteasome inhibition in both cerebellum and heart 
tissue in male mice. On the other hand, in female mice, the effect of the proteasome 
inhibition on the expression of pericentromeric and centromeric satellite repeats was found 
to be tissue-dependent, with a small upregulation and downregulation detected in 
cerebellum and heart tissues respectively. Although females and males contain nearly 
identical DNA sequences, a significant proportion of genes have been reported to be 
differentially expressed between sexes in various tissues such as liver, brain, adipose, 
muscle (Clodfelter et al., 2006; Dewing, Shi, Horvath, & Vilain, 2003; Gomez-Abellan et al., 
2012; Trabzuni et al., 2013; Welle, Tawil, & Thornton, 2008; X. Yang et al., 2006). Data from 
the GCMD lab has recently found that the expression not only of genes, but also of the basal 
level of the heterochromatin repeats differs between males and females (Unpublished data, 
MSc thesis Marta Mauri, MPhil thesis Raquel SIlva). This sexual dimorphism on (i) the basal 
level of the repeat expression and (ii) the response to proteasome inhibition could 
potentially indicate either difference in the mechanism or abundance of factors that 
regulate the transcriptional repression of heterochromatic repeats between genders as well 
as different tissues.  
The role of the proteasome in regulation of the heterochromatic repeats is analysed in the 
following chapters.  
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In summary the results in this chapter suggest that:  
 The proteasome was found by ChIP to bind along the FXN gene in a pattern that 
resembles H3K9me3 heterochromatin. This finding would be consistent with the 
hypothesis that in FRDA proteasomal degradation of a stalled RNAPII might 
contribute to FXN silencing.  However, proteasome inhibition in tissue culture 
instead of upregulating FXN was found to downregulate FXN transcription whereas 
the expression of the gene remains largely unaffected by in vivo proteasome 
inhibition. Thus the proteasome might have pleiotropic effects on FXN expression. 
Thus, RNAPII degradation might take place in patient cells due to higher levels of 
proteasome recruited to the locus which might also regulate escape of RNAPII from 
pausing and further elongation of transcription. 
 That the proteasome may also play a role in silencing of constitutive 
heterochromatin was investigated by proteasome inhibition in vivo where this was 
found to upregulates pericentromeric and centromeric satellite repeat expression. 
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3.4 Contributions 
Treatment of YG8 mice with PS341 was performed by Dr M. Pook at Brunel University. RNA 
extraction from YG8 mice tissues and further analysis was performed by Theona Natisvili. 
Everything else in this chapter was performed by Theona Natisvili.   
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CHAPTER 4: Effects of proteasome inhibition and the cell cycle on regulation 
of constitutive heterochromatin 
 
4.1  Introduction  
In the previous chapter, in vivo proteasome inhibition was shown to increase the levels of 
transcripts derived from pericentromeric major and centromeric minor satellite repeats in 
male mice (Figure 3.11), suggesting a potential role for the proteasome in repression of 
heterochromatic repeats. In order to investigate this further, the effects of proteasome 
inhibition was assessed in this chapter on several regions including pericentromeric major 
satellite, centromeric minor satellites and the two most common retrotransposons, LINE L1 
and SINE B1 in NIH3T3 cells, a well-studied mouse embryonic fibroblast cell line. This cell 
line was chosen as, in contrast to the primary cells or lymphoblastoid cell lines is easier to 
grow and transfect for knockdown experiments and is derived from a male mouse 
(supplementary figure S1).  
Several studies have shown that proteasome inhibition induces cell-cycle arrest in various 
cell types. The phase of this cell cycle arrest is dependent on the cell type as well as the 
properties of the proteasome inhibitor (Adams et al., 1999a; Bonvini, Zorzi, Basso, & 
Rosolen, 2007; Ling et al., 2003; Machiels et al., 1997). The mitotic cell cycle is a highly 
regulated process consisting of four consecutive phases that is Gap 1 (G1), Synthesis (S), Gap 
2 (G2) and Mitosis (M) (Darzynkiewicz, Bedner, & Smolewski, 2001). Regulation of cell cycle 
is important for proper cell growth and proliferation (Gerard & Goldbeter, 2014). Cell cycle 
is known to play an important role in regulating chromatin structure (Ma, Kanakousaki, & 
Buttitta, 2015), which could potentially impact on chromatin associated processes such as 
transcription of heterochromatin repeats. More specifically two events during cell cycle are 
known to cause major changes in chromatin structure (Ma et al., 2015). These events are:  
(i) Incorporation of new histones into newly synthesized DNA during S-phase and 
re-establishment of post-translational histone modifications 
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(ii) The transcriptional machinery and chromatin associated proteins disassociate 
from chromatin during mitosis. In addition the chromatin detaches from the 
nuclear lamina.  
 
Major features of chromatin changes during the different phase of the cell cycle are shown 
in Figure 4.1.  Therefore in this chapter, cell cycle dependent regulation of heterochromatic 
repeats was analysed in order to exclude any possible effect of the proteasome treatment 
due to cell cycle skewing.  
 
 
Figure 4.1: Proposed model for structural changes of chromatin during the different phases 
(G1, S, G2, M) of the cell cycle (Ma et al., 2015). Cells during G1 display interaction of some 
regions of chromatin (predominantly heterochromatin) with the nuclear envelope and 
assembly of pre-replication complexes (pre-RCs) at euchromatic regions. During S phase 
DNA is replicated and newly synthesized (light green) and recycled (dark green) histones 
bind to DNA forming nucleosomes which in turn form nascent chromatin. At this stage 
histone ‘writers’ and ‘readers’ (see Introduction) associate with nascent chromatin in order 
to re-establish the appropriate histone code. During G2 phase nucleosomes mature and 
histone biogenesis is inhibited. During mitosis transcription factors and chromatin binding 
proteins dissociate from the chromatin, which becomes highly condensed. The nuclear 
envelope disassembles and lamina-associated domains are disrupted. Adapted and modified 
from (Ma et al., 2015). 
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The aims for this chapter were: 
 To assess the effect of proteasome inhibition and the cell cycle on the transcription 
of major satellite, minor satellite, LINE L1 and SINE B1 elements.    
 To determine the effect of proteasome inhibition on the general structure of 
constitutive heterochromatin.  
 To investigate the effect of proteasome inhibition and the cell cycle on the 
distribution of the number of chromocentres per cell. 
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4.2  Results 
4.2.1 Proteasome inhibition results in the upregulation of major satellite repeat 
expression  
In order to investigate whether transcriptional activity of heterochromatic repeats is 
controlled by the proteasome, NIH3T3 cells were treated with an inhibitor that blocks the 
proteolytic activity of the 20S core subunit. The effect of proteasome inhibition on transcript 
level of pericentromeric major satellite, centromeric minor satellite, LINE L1 and SINE B1 
were analyzed in NIH3T3 cells. Cells were treated with different concentrations (5µM, 10µM 
and 20µM) of the proteasome inhibitor MG132, and changes in transcript levels were 
measured by quantitative real time PCR (Q-RT-PCR) during an 8h time course. 
 
 
Effect of the proteasome inhibition on cell survival and morphology.  
Propidium iodide (PI) staining followed by FACS analysis revealed that an 8h incubation in 
5µM, 10µM and 20µM MG132 did not substantially affect cell survival. The treatment 
showed a dose dependent minor increase in the proportion of cell death (Figure 4.2A). 
Furthermore only minor morphological changes were observed in the cultures during the 
treatments, with a small proportion of cells showing characteristic cell shrinkage (Figure 
4.2B). This observed cell shrinkage could be an indicator of early event of apoptosis, (J. Liu, 
Lee, Galbiati, Kitsis, & Lisanti, 2001), which was previously shown to be caused by 
proteasome inhibition in multiple cells lines (Wojcik, 2002). 
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Figure 4.2: Proteasome inhibition leads to only minor morphological changes during the 
time course of treatment. NIH3T3 cells were treated with 5µM, 10µM and 20µM MG132. 
(A) Proteasome inhibition results in only 4% increase in cell death as estimated by uptake of 
PI. PI staining was performed on DMSO (Untreated) and MG132 treated cells for 8h, 
followed by FACS analysis to measure the percentage of dead cells. The intensity of the PI 
signal is shown on the X axes and the percentages of PI–positive cells that provides an 
estimate of the proportion of dead cells are shown in red. (B) Representative phase contract 
images of NIH3T3 cell cultures after treatment with MG132 for 8h. Arrows indicate the cells 
exhibiting shrinkage.  
 
 
 
 
 
PI 
DMSO              5μM MG132 
10μM MG132       20μM MG132 
           DMSO                           5μM MG132                     10μM MG132                20μM MG132 
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4.2.2  Effect of the proteasome inhibition on transcription of heterochromatic repeats  
A significant increase in transcript level of major satellite repeat was observed upon MG132 
treatment. The increase was dose dependent reaching 3, 5 and 10 fold upregulation when 
compared to DMSO, when treated with 5µM, 10µM and 20µM MG132, respectively. 
Furthermore reduction of minor satellite repeat transcript level was identified with 5µM 
and 10µM MG132, with no change at 20µM of treatment. A 1.2-fold increase in transcript 
level of SINE B1 repeat was also observed with all MG132 treatments, reaching statistically 
significant upregulation only at 8h of treatment. No statistically significant changes were 
found in expression of LINE L1 (Figure 4.3).   
 
 
Figure 4.3: Proteasome inhibition results in increased transcript level of major satellite 
repeat. NIH3T3 cells were treated with 5µM, 10µM and 20µM MG132 and transcript levels 
of major satellite, minor satellite, LINE L1 and SINE B1 were measured by q-RT-PCR. The 
relative expression was normalised against spike and shows fold change relative DMSO. 
Error bars indicate SEs of six biological replicates. * p<0.05, ** p<0.001, *** p<0.0001 
(Student ‘t’ test) 
 
* * 
* 
** 
** 
*** 
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This result suggests a role for the proteasome in regulating the transcript levels of major 
satellite repeats, the major component of pericentromeric heterochromatin. Whether the 
observed upregulation is occurring at the transcriptional level or post-transcriptional level 
will be analysed in the following sections.  Firstly it was important to investigate whether 
the effect of the proteasome inhibition on the cell cycle might contribute to the 
upregulation of major satellite expression observed here.  
 
 
 
4.2.3  Cell cycle dependent transcription of heterochromatic repeats  
Previous studies have shown that proteasome inhibition induces cell-cycle arrest in various 
cell types. The phase of this cell cycle arrest is dependent on the cell type as well as the 
properties of the proteasome inhibitor (Adams et al., 1999a; Bonvini et al., 2007; Ling et al., 
2003; Machiels et al., 1997).  
Although it was shown in mouse C127 cells that expression of major satellite repeats is cell 
cycle dependent (J. Lu & Gilbert, 2007), there is a paucity of studies examining  such cell 
cycle dependent transcription. More specifically the authors identified one population of 
abundant, large, heterogeneous major satellite repeat transcripts late in G1 phase, with 
their synthesis decreasing during mid S phase. Also they showed another population of 
small major satellite repeat transcripts that were synthesized exclusively during mitosis and 
quickly reducing during mitotic exit (J. Lu & Gilbert, 2007). On the other hand the expression 
of minor satellite repeats was found to peak during G2/M phase of the cell cycle (Ferri et al., 
2009). There was no available data found for the LINE L1 and SINE B1 in mammalian system. 
More detailed analysis of the cell cycle dependent regulation of transcription of 
heterochromatic repeats was therefore needed in order to exclude any possible effect of 
the proteasome treatment due to changes in proportion of cells in different stages of cell 
cycle.  
In order to confirm the expression of the major and minor satellite repeats in G1/S and 
G2/M phases respectively and identify any cell cycle effects on the expression of LINE L1 and 
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SINE B1 in NIH3T3 cells, counterflow centrifugal elutriation was performed for cell 
synchronization (Banfalvi, 2008). This is a biophysical cell separation technique in which the 
living cells are separated based on differences in cell size and sedimentation density, as the 
cell size is generally correlating with the cell cycle stage. During the elutriation process 
unfractionated cells enter the elutriation chamber where centrifugal force and counterflow 
of elutriation fluids retain the cells within the chamber. Gradient increase of the flow rate 
elutes cells from the chamber starting from smaller cells and followed by larger ones 
(Banfalvi, 2008) The schematic view of the principal of cell synchronisation by centrifugal 
elutriation is shown in Figure 4.4. This cell separation technique was used primarily because 
it offers the advantage of selection of cells during the whole cell cycle and does not affect 
the metabolism of cells (Banfalvi, 2008). By contrast, the previous studies (Ferri et al., 2009; 
J. Lu & Gilbert, 2007) used either chemical inhibition or a combination of chemical inhibition 
and mechanical shake off to synchronize the cells. Chemical inhibition was shown to lead 
quite often to perturbation of the cell metabolism (Darzynkiewicz, Halicka, Zhao, & 
Podhorecka, 2011; J. Gong, Traganos, & Darzynkiewicz, 1995; Kung, Zetterberg, Sherwood, 
& Schimke, 1990; Pardee & Keyomarsi, 1992; Urbani, Sherwood, & Schimke, 1995). It is 
worth mentioning that the main drawback of the centrifugal elutriation method is moderate 
dispersion of synchrony from the fractions obtained in the mid-late S, G2 and M phases 
during the elutriation process, resulting in enrichment of cells in specific cell cycle stage 
rather than complete synchronization. Best synchrony with elutriation is achieved in the G1 
phase of the cell cycle (Banfalvi, 2008), the phase where major satellite repeats were 
previously found to be expressed.  
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Figure 4.4: A schematic view of the principal of cell synchronisation by centrifugal 
elutriation. (a) Whole unfractionated cell population enters in the elutriation chamber. (b) 
Centrifugal force and counterflow drag force of elutriation fluid retain the cells within the 
chamber. (c) Gradient increase of flow rate elutes the cells based on their size, starting from 
smaller cells first followed by larger ones. Adapted from (Banfalvi, 2008). 
 
 
Following cell elutriation part of the eluted material was stained with PI followed by FACS in 
order to check the efficiency of the elutriation process; the remaining part was used for RNA 
extraction followed by q-RT-PCR, in order to investigate the expression of the repeats in 
different phases of the cell cycle.  
FACS analysis showed five cell fractions obtained by elutriation, each exhibiting different cell 
cycle profiles (Figure 4.5). More details regarding the fractions obtained are shown in 
material and methods. Representative images of the cell cycle profile of each fraction 
including the non-elutriated (control) are shown in Figure 4.5A. Analysis of the cell cycle 
distribution of the control revealed that 60%, 20% and 18% were in G1/G0, S and G2/M 
phase of the cell cycle respectively. Elutriated fraction 1 showed good separation of G1/G0 
phase where 92% of the cells were in this stage of the cell cycle. Furthermore good 
separation was obtained for the G2/M phase in fraction 5 where 75% of the cells were 
within this phase.  Fraction 3 showed the best enrichment for cells in S phase which was 
33%. Fraction 2 gave a similar percentage of cells in G1 as in non-elutriated material, with a 
modest increase (7%) and decrease (5%) in S and G2/M phases respectively.  Lastly, fraction 
4 gave a threefold increase of cells in G2 phase reaching 53% relative to the control (Figure 
4.5B).  
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Figure 4.5: Cell fractions, enriched at specific phases of the cell cycle were obtained by 
centrifugal elutriation. (A) Representative images of the FACS profiles after PI staining 
showing non-elutriated and five different fractions of elutriated material. (B) Cell cycle 
distribution of each fraction is shown as percentage of cells acquired. Error bars =SEs 
obtained from at least 3 biological replicates.                
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The expression of the repeats analysed by q-RT-PCR revealed changes in the expression of 
the major and minor satellite repeats, whereas LINE L1 and SINE B1 expression remained 
constantly similar throughout the different cell fractions (Figure 4.6). 
More specifically the expression of the major satellite repeat showed a statistically 
significant increase in fraction 1, which represents the majority of cells in G1/G0 phase of 
the cell cycle. Furthermore a minor increase in the transcript levels was observed in fraction 
3 which has the highest enrichment of the cells in S phase of the cell cycle. Also a reduction 
of the expression of the major satellite was detected in fractions 4 and 5 which represent 
the fractions where the majority of cells are in the G2/M phase of the cell cycle (Figure 
4.6A). Thus, this result indicates cell cycle dependent regulation of the expression of the 
major satellite repeats in NIH3T3 cell lines, with the expression of the transcript occurring 
primarily in the G1 phase of the cell cycle. Similar observations were reported in the 
previous study in mouse C127 cells (J. Lu & Gilbert, 2007). 
In contrast, the expression of minor satellite repeat with respect to cell cycle was 
substantially different from that of major satellite repeat. There was a statistically significant 
reduction of the transcript levels in fractions 1 and 2, fractions which contain either greatly 
depleted or decreased amounts of cells in G2/M phase respectively. An increase of minor 
satellite repeat expression levels occurred in fractions 4 and 5, fractions enriched with cells 
in G2/M phase of the cell cycle (Figure 4.6B). This result demonstrates cell cycle dependent 
regulation of minor satellite transcript level in the examined cells, with the expression 
occurring in the G2/M phase of the cell cycle, consistent with a previously published study 
using murine erythroleukemic (MEL) and NIH3T3 cell lines (Ferri et al., 2009). The expression 
of LINE L1 and SINE B1 was also examined, with only minor changes of the transcript levels 
occurring in the different fractions (Figure 4.6C, 4.6D). The results suggest cell cycle 
independent transcription of these retrotransposons in NIH3T3 cell lines.   
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Figure 4.6: Cell cycle regulated expression of the major and minor satellite repeats. NIH3T3 
cells were separated with centrifugal elutriation into five fractions, each enriched with cells 
in different phases of the cell cycle and transcript levels of the major (A), minor (B), LINE L1 
(C) and SINE B1 (D) was measured by q-RT-PCR. The relative expression was normalised 
against endogenous control (GAPDH) and is shown relative to RNA levels obtained with non-
elutriated cells. Error bars indicate SEs of at least 3 biological replicates. *p<0.05 (Student’s 
‘t’ test) 
 
 
 
 
 
 
  
* * 
* 
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4.2.4 Cell cycle independent expression of major satellite repeat and SINE B1 upon 
proteasome inhibition.  
In order to assess whether the increase in major satellite transcripts was due to the 
proteasome inhibition rather than cell cycle dysregulation, the cell cycle profile following 
proteasome inhibition treatment was analysed, concomitant with the expression of the 
repeats. NIH3T3 cells were treated for 1h, 2h, 4h and 8h with MG132 (final concentration 
20µM) dissolved in DMSO and PI staining was performed followed by FACS to analyse the 
proportion of cells at different cell cycle stages. A minimum of 10 000 events were acquired. 
In parallel RNA was extracted and q-RT-PCR was performed to analyse the expression of the 
repeats.  
FACS analysis revealed alteration in the cell cycle profile upon proteasome inhibition, 
primarily after 8h of MG132 treatment, with only minor changes occurring in the control 
(DMSO) (Figure 4.7A). More specifically, MG132 treatment resulted in a decrease of the 
proportion of cells within G1/G0 phase of the cell cycle, compared to DMSO, reaching 
statistically significant reduction only after 8h of treatment (Figure 4.7B). Furthermore there 
was a gradual increase of cells within G2/M phase which was apparent after 1h of 
treatment, showing a 3% increase at 1h treatment, followed by 7% increase for both 2h and 
4h with a further 22% increase at 8h, compared to the untreated (Figure 4.7D). No change 
was observed for the cell population within S phase for 1h and 2h of treatment, while a 
minor increase (4%) was identified at 4h and 8h of treatment (Figure 4.7C).  
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Figure 4.7 : The effect of proteasome inhibion on the cell cycle of NIH3T3 cells. NIH3T3 cells 
were treated with DMSO or 20µM MG132 for 1h, 2h, 4h and 8h followed by PI staining and 
FACS analysis. Proportion (%) of acquired cells in G1/G0 phase (B), S phase (C) and G2/M 
phase (D) are shown for treated (MG132) and untreated (DMSO) cells.  **p<0.001, 
***p<0.0001 (Student’s ‘t’ test) 
  ** 
*** 
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The RNA expression analysis of a time course treatment with 20µM MG132 showed 8 and 
16 fold upregulation of the major satellite repeat expression at 4h and 8h of treatment 
respectively, with no change at 1h and 2h of treatment, compared to untreated (DMSO) 
(Figure 4.8A). Furthermore, only minor changes were observed in the expression of the 
minor satellite repeat throughout the treatment period, with the highest, 1.2 fold increase, 
occurring at 8h of treatment (Figure 4.8B). Relatively moderate levels of upregulation of 
SINE B1 were observed at all time points of treatment, reaching a statistically significant, 1.2 
and 1.7 fold increase, of the transcript level at 4h and 8h of treatment respectively, 
compared to untreated (Figure 4.8D). Additionally, only minor changes were displayed in 
the expression of the LINE L1 at all the time points examined (Figure 4.8C).  
 
Taken together these results suggest that upregulation of the expression of the major 
satellite transcripts and SINE B1 upon proteasome inhibition is not a consequence of cell 
cycle dysregulation. Major satellite repeat was shown to be expressed primarily in the G1 
phase of the cells cycle (Figure 4.6A), whereas the proteasome inhibition stalls the cells in 
G2/M phase (Figure 4.7A). Similarly SINE B1 expression was not shown here to be regulated 
by the cell cycle hence any stalling upon proteasome inhibition should not affect its 
expression. However, it is worth mentioning that the small upregulation of the minor 
satellite repeat at 8h of treatment could possibly be due to the cell-cycle stalling effect of 
proteasome inhibition, since the expression of minor satellite was higher in G2/M phase 
where proteasome inhibition cell-cycle stalling is taking place. 
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Figure 4.8: A time course of the effect of proteasome inhibition in the expression of major 
satellite (A), minor satellite (B), LINE L1 (C) and SINE B1 (D) repeats. NIH3T3 cells were 
treated with 20µM MG132 for 1h, 2h, 4h and 8h followed by RNA extraction and q-RT-PCR. 
The relative expression was normalised against spike and shows fold change relative DMSO. 
Error bars indicate SEs of at least 10 biological replicates. *p<0.05, **p<0.001 (Student’s ‘t’ 
test) 
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4.2.5 Transcription dependent increase of major satellite repeat expression upon 
proteasome inhibition 
So far the results presented in this chapter suggest that proteasome inhibition upregulates 
major satellite repeat expression in the cell. However, this upregulation could be due to an 
increase of the transcription or to an inhibition of major satellite transcript degradation. 
Either of these would result in accumulation of the RNA transcript in the cell. In order to 
analyse this further, transcriptional inhibition was performed concomitant with proteasome 
inhibition. Two RNA polymerase inhibitors were used to block the transcription, DRB and 
ActD. As mentioned in chapter 3, DRB is CDK9 kinase inhibitor which associates with the 
positive elongation factor b (P-TEFb) and prevents Ser2 phosphorylation of the RNAPII C-
terminal domain (Chodosh et al., 1989; Ip et al., 2011; Marshall, Peng, Xie, & Price, 1996). 
This leads to disruption of the transcriptional progress by inhibiting the transition from 
transcriptional initiation to elongation (Bensaude, 2011). On the other hand, ActD 
intercalates into DNA and stabilizes topoisomerase-I DNA covalent complexes thereby 
preventing the progression of all three RNA polymerases (Bensaude, 2011; Trask & Muller, 
1988).  
Initially, NIH3T3 cells were treated with either 20µM MG132, 100µM DRB or both 100µM 
DRB and 20µM MG132 for 1h, 2h, 4h and 8h. DRB treatment alone was used to assess the 
efficiency of RNAP II inhibition and its effect on the repeat transcription (control).  RNA was 
extracted followed by cDNA synthesis and transcript levels of the repeats were analysed by 
qPCR using the same primers as previous experiments.  
Ongoing transcription by RNAPII was found to be effectively inhibited as the short lived c-
myc transcript was strongly reduced after 1h of treatment with DRB (Figure 4.9A).  
Proteasome inhibition resulted in a 5 and 16 fold increase in the major satellite repeat 
expression at 4h and 8h of treated cells respectively compared to untreated cells, 
confirming previously obtained results.  This increase was no longer seen in cells treated 
concomitantly with MG132 and DRB (Figure 4.9B), suggesting that upregulation of the 
expression of the major satellite repeat is dependent upon transcription rather than 
stabilisation of the transcript. Notably, the DRB treatment alone led to an initial decrease in 
major satellite repeat transcripts at 1h and 2h of treatment as might be expected, 
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surprisingly this was followed by a 1.5 and 3.5 fold increase at 4h and 8h of treatment 
respectively (Figure 4.9b, 4.10). This result is unexpected since it is thought that the major 
satellite repeat is exclusively transcribed by RNAP II (J. Lu & Gilbert, 2007; Rudert et al., 
1995; Valgardsdottir et al., 2005) which has been inhibited by DRB and therefore suggests a 
possible role of other RNA polymerases. Clearly one way of testing this hypothesis would be 
to inhibit all RNA polymerases by ActD and observe its effect on the transcription levels (see 
below Figure 4.11).  
Consistent with the previously described results (Figure 4.3, 4.8), the minor satellite and 
LINE L1 transcripts were not significantly affected by proteasome inhibition. However, DRB 
treatment resulted in significant reduction of both minor satellite and LINE L1 transcripts at 
all time points examined (Figure 4.9C and 4.9D) consistent with their transcription being 
dependent on RNAPII. Furthermore, a moderate level (1.5 fold) of upregulation of SINE B1 
expression was observed after 8h of MG132 treatment compared to untreated cells. Similar 
levels of upregulation were also obtained with concomitant MG132 and DRB treatment 
whilst 50% reduction with only DRB treatment (Figure 4.9E). It is noteworthy that SINE B1 
are predominantly transcribed by RNAPIII (Dridi, 2012; Williams, Tamburic, & Astell, 2004), 
therefore the upregulation upon MG132 and DRB treatment may still be the result of an 
effect on transcription mediated by RNAPIII.  
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Figure 4.9: A time course showing the effect of proteasome and/or RNAPII inhibition on the 
expression of c-MYC (A), major satellite (B), minor satellite (C), LINE L1 (D) and SINE B1 (E) 
repeats. NIH3T3 cells were treated with either 20µM MG132, 100µM DRB or both 100µM 
DRB and 20µM MG132 for 1h, 2h, 4h and 8h followed by RNA extraction and q-RT-PCR. The 
relative expression was normalised against ‘spiked’ RNA (see methods) and is shown as fold 
change relative to DMSO. Error bars indicate SEs of at least 3 biological replicates. *p<0.05 
(Student’s ‘t’ test). 
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Figure 4.10: A time course showing the effect of RNAPII inhibition on the expression of c-
MYC (A) and major satellite repeat (B). NIH3T3 cells were treated with 100µM DRB for 1h, 
2h, 4h and 8h followed by RNA extraction and q-RT-PCR. The relative expression was 
normalised against spike and shows fold change relative to DMSO. Error bars indicate SEs of 
at least 3 biological replicates. 
 
 
In order to confirm the transcription-dependent upregulation of the major satellite 
transcripts and potentially uncover the pathway of SINE B1 transcript accumulation upon 
proteasome inhibition, NIH3T3 cells were treated with either 20µM MG132, 20µg/ml ActD 
or both 20µg/ml ActD and 20µM MG132 for 1h, 2h, 4h and 8h. ActD treatment alone was 
used to assess the efficiency of inhibition of all three RNA polymerases (RNAPI, II and III) and 
to determine the RNA half-life of the major satellite, minor satellite, LINE L1 and SINE B1 
transcripts using kinetic studies of RNA decay. In a similar approach as above, RNA was 
extracted followed by cDNA synthesis and transcript levels of the repeats were analysed by 
qPCR using the same primers as previous experiments.  
Consistent with effective inhibition of transcription there was an exponential decay of all 
analysed transcripts. As expected, the c-MYC mRNA was degraded rapidly with a half-life of 
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approximately 20min (Gondran, Amiot, Weil, & Dautry, 1999). Half-lifes of approximately 
150min, 70min, 60min and 80min was measured for major, minor, LINE L1 and SINE B1 
RNAs respectively (Figure 4.11A). To our knowledge this is the first formal measurement of 
these half-lifes and the half-life of the major satellite repeat is longer than we had 
anticipated based upon a previous estimate which was less than 1 hour although this was 
based upon RNA FISH (J. Lu & Gilbert, 2007). 
Consistent with the previous results, proteasome inhibition resulted in a 5 and 14 fold 
increase in major satellite repeat expression following 4h and 8h of MG132 treatment 
respectively compared to untreated. This increase was blocked in cells treated 
concomitantly with both MG132 and ActD (Figure 4.11B), indicating that their upregulation 
in response to MG132 was transcription dependent (compare in Figure 4.11A MG132 and 
MG132+ActD). Strikingly, the upregulation at 8h seen following treatment with the RNAPII-
specific inhibitor DRB (Figure 4.9B) did not occur when all forms of RNAP were inhibited 
with ActD treatment (Figure 4.11B). It is tempting to speculate that RNAPI or III might be 
able to substitute for RNAPII in transcribing major satellite after 8h of RNAPII inhibition 
(Figure 4.9B and 4.11B). Interestingly a similar result was obtained for the SINE B1 element, 
suggesting that MG132 induced upregulation at the level of transcription leading to the 
accumulation of these transcripts after 8h of treatment with proteasome inhibitor (Figure 
4.11E).  Inhibition of RNAPI, II and III by ActD had a profound effect (Figure 4.11E) whereas 
the selective RNAPII inhibitor DRB was ineffective (Figure 4.9E). This result is consistent with 
RNAPIII being the predominant polymerase transcribing the SINE B1 element as previously 
suggested (Dridi, 2012; Williams et al., 2004). 
Furthermore, proteasome inhibition resulted in only minor changes in minor satellite and 
LINE L1 expression, whilst ActD and concomitant MG132 and ActD significantly diminished 
the transcript levels (Figure 4.11C, 4.11D).  
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Figure 4.11: A time course showing the effect of proteasome and/or all RNA polymerases 
(RNAPI, II and III) inhibition on the expression of major satellite (B), minor satellite (C), LINE 
L1 (D) and SINE B1 (E) repeats. (A) Represents best fitted exponential decay curve obtained 
with nonlinear regression for half-life calculations of c-MYC, major, minor, LINE L1 and SINE 
B1 transcripts. NIH3T3 cells were treated with either 20µM MG132, 20µg/ml ActD or both 
20µg/ml ActD and 20µM MG132 for 1h, 2h, 4h and 8h followed by RNA extraction and q-RT-
PCR. The relative expression was normalised against spike and shows fold change relative to 
DMSO. Error bars indicate SEs of 3 biological replicates. *p<0.05 (Student’s ‘t’ test).  
 * * 
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4.2.6 RNA FISH analysis confirms the increase transcription of the major satellite repeat 
upon proteasome inhibition  
RNA fluorescent in situ hybridization (RNA FISH) was undertaken to validate at the single cell 
level, the upregulation of the major satellite repeat transcription upon proteasome 
inhibition.  This imaging technique has been a successful method to optically detect single 
RNA molecules in fixed but otherwise intact cells, determining both presence and spatial 
location of the transcript within the cell (Femino, Fay, Fogarty, & Singer, 1998). This is 
especially important due to the presence of the 42 intergenic major satellite repeat 
sequences interspersed in the mouse genome outside of pericentromeric heterochromatin 
(Bulut-Karslioglu et al., 2012), that cannot be easily discriminated by q-RT-PCR. Moreover, 
RNA FISH is able to display the location of the transcript hence providing evidence of their 
transcription site (Levsky, Shenoy, Pezo, & Singer, 2002; Osborne et al., 2004). 
Here NIH3T3 cells, seeded on polylysine coated coverslips, were treated for 2h, 4h and 8h 
with 20µM MG132 and processed by RNA FISH using a probe set that was complementary 
to the major satellite repeat sequence and stained with DAPI (4',6-diamidino-2-
phenylindole; which binds to the minor groove of DNA). The RNA binding specificity was 
determined by digesting the cells with RNAse prior to hybridization with the probe step.  
As shown in figure 4.12, proteasome inhibition resulted in a gradual and dramatic increase 
of the major satellite repeat signal from the MG132 treated cells at 4h and 8h, compared to 
DMSO only, whilst no significant change was observed at 2h of treatment. Furthermore, no 
signal was detected with RNAse digestion of both treated and untreated cells, indicating 
dependency on the presence of RNA. It is worth mentioning that the RNAse digestion was 
performed for each time point; however the data is shown only upon 8h of treatment with 
MG132 and DMSO.  
In order to investigate the origin of the major satellite repeat transcripts (intergenic or 
pericentromeric) upon proteasome inhibition, multiple mid-zone z-section images were 
taken with confocal microscopy (Figure 4.13) and 3D images were reconstructed using 
Velocity software (Figure 4.14). The overall analysis of multiple z-section images confirmed 
the upregulation of the major satellite repeat transcripts upon 4h of treatment with 
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proteasome inhibitor MG132, compared to untreated (Figure 4.13B, 4.14B), whereas only 
minor changes occurred at 2h (Figure 4.13A, 4.14A). 
 
 
 
 
Figure 4.12: RNA–FISH analysis of major satellite repeat transcription upon proteasome 
inhibition. NIH3T3 cells were treated with 20µM M132 for 2h, 4h and 8h and were subjected 
to RNA-FISH analysis with mouse major satellite probe. Representative single z-section 
images for DAPI (blue), major (red) and merge are shown for 2h, 4h and 8h with DMSO and 
MG132 treatment. Negative control of hybridization was conducted with RNAse treatment. 
Scale bar 2µm.  
 
 
 
154 
 
The number of transcription sites detected per cell upon proteasome inhibition was highly 
heterogeneous (compare MG132_1 and MG132_2 in figure 4.13B, 4.14B). A clear signal of 
probe hybridization to the major satellite was revealed surrounding or within a proportion 
of DAPI-dense heterochromatin regions with the morphology characteristic of so-called 
chromocentres (Guenatri et al., 2004) (see more in the general introduction, Figure 1.8). In 
addition, the signal was also identified coming from areas of nucleus lacking chromocentres 
(Figure 4.13B, 4.14B), suggesting either the partial transcription from intergenic major 
satellite DNA sequences or it might reflect the migration of the transcript from the 
chromocentres.  
Notably, there was a very small number of major satellite hybridization signals detected in 
most of  the untreated (DMSO) cells, primarily surrounding or within the chromocentres 
(Figure 4.12, 4.13A, 4.14A). This clearly suggests the presence of major satellite repeat 
transcripts within the cells and confirms the previous studies of the transcription of 
pericentromeric heterochromatic repeats (Eymery, Horard, et al., 2009; Hall et al., 2012).  
Overall the RNA-FISH analysis is consistent with the observation of upregulation of major 
satellite repeat transcription upon proteasome inhibition, confirming previously obtained 
results using q-RT-PCR (Figure 4.3, 4.8A). Thus, RNA-FISH analysis indicates that proteasome 
inhibition leads to upregulation of RNA transcripts originating from major satellite DNA 
within pericentromeric heterochromatin, although it does not exclude the intergenic origin 
or their combination.  
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Figure 4.13: RNA-FISH analysis of major satellite transcription sites in cells upon proteasome 
inhibition. NIH3T3 cells treated with 20µM MG132 and DMSO only for 2h and 4h were 
subjected to RNA-FISH analysis with mouse major satellite probe set. Representative mid-
zone confocal z-sections merged images for DAPI (blue) and major (red) are shown for 2h 
(A) and 4h (B) treatment with DMSO and MG132. Scale bar 2µm. 
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Figure 4.14: Representative 3D images obtained following RNA-FISH using Velocity software 
for NIH3T3 cells treated with DMSO (A) and MG132 (B) for 4h with probe against major 
satellite repeat transcript. DAPI is shown in blue and major satellite repeat transcript in red.  
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4.2.7 No change in the main heterochromatic/euchromatic histone modification marks on 
the major satellite repeat locus upon proteasome inhibition  
The above data demonstrates the upregulation of transcription from major satellite repeat 
upon proteasome inhibition. In order to assess whether this upregulation might also impair 
the chromatin signature of pericentromeric heterochromatin, histone posttranslational 
modifications were analysed by ChIP.  
ChIP was performed using antibodies against the repressive histone modification H3K9me3 
and activating marks H3K4me3, H3K36me3 and H3ac on NIH3T3 cells after 20µM MG132 
treatment for 4h. Immunoprecipitated material was quantified using qPCR with the same 
primers as those used in the previous experiment. Additionally primers against the 
promoter and gene body of the housekeeping gene GAPDH and the brain-specific gene 
MOG (myelin oligodendrocyte glycoprotein) were used as positive and negative control for 
the euchromatic regions respectively.  
According to the q-PCR analysis, the H3K9me3, which is primarily associated with 
pericentromeric heterochromatin was highly enriched on major satellite repeat, as 
previously shown (Martens et al., 2005) and was reduced in all the remaining regions 
examined (Figure 4.15A). The absence of H3K9me3 from the minor satellite repeat, which 
forms the centromere was expected since centromeres are characterised by the 
centromere-specific histone H3 variant CENP that is occasionally interrupted by nucleosome 
containing H3K4me2 (Masumoto, Masukata, Muro, Nozaki, & Okazaki, 1989; D. K. Palmer, 
O'Day, Trong, Charbonneau, & Margolis, 1991; Purgato et al., 2015; Stimpson & Sullivan, 
2011). Additionally, in somatic cells, silencing of the retro-elements including LINE L1 and 
SINE B1 is thought to be achieved predominantly by DNA methylation, whilst histone 
modification marks appear to play only a minor role (Bierhoff, Postepska-Igielska, et al., 
2014), explaining the relatively low level of the H3K9me3 at the examined retro-element 
regions. The treatment of cells with proteasome inhibitor did not result in significant 
changes in H3K9me3 enrichment on the major satellite repeat, compared to untreated; or 
any of the remaining examined regions (Figure 4.15A).  
Overall, a balance between repressive and activating histone modifications regulates the 
expression of many genes and non-coding RNAs. As the main repressive mark (H3K9me3) 
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was not altering upon proteasome inhibition on the major satellite repeat loci, accompanied 
by the upregulation of their expression, next the activating histone modification marks were 
analysed.  
As expected, the highly conserved H3K4me3, which is found on the promoters of actively 
transcribed genes (Santos-Rosa et al., 2002; X. D. Zhao et al., 2007) displayed high levels of 
enrichment on the promoter of the GAPDH gene. In contrast, both heterochromatic regions 
(major, minor, LINE L1 and SINE B1) and an inactive gene (MOG) showed much lower levels 
of H3K4me3 (Figure 4.15B). Interestingly, whilst previous studies have correlated the level 
of H3K4me3 at the gene promoter with their transcriptional activity (Gu & Lee, 2013), 
amongst the repeat regions examined, the major satellite repeats revealed the highest 
enrichment for H3K4me3. No significant change of the level of H3K4me3 was observed on 
the major satellite repeat locus upon proteasome inhibition. Similar levels of the mark were 
also obtained in all the remaining regions examined (Figure 4.15B).  
H3K36me3 is a well-known mark associated with elongating RNA polymerase II (Ser2P) and 
appears on the gene bodies of actively transcribed genes (Chae, Danko, & Kraus, 2015; M. A. 
Hahn, Wu, Li, Hahn, & Pfeifer, 2011). The analysis of immunoprecipitated chromatin by 
H3K36me3 antibody revealed high enrichment of this mark on the GAPDH gene bodies and 
low levels in the heterochromatic repeats as well as the inactive MOG gene (Figure 4.15C). 
The treatment of the cell with MG132 did not alter the relative enrichment status either on 
major satellite repeat, centromeric repeat, retrotransposons or the inactive gene (Figure 
4.15C).  
In addition, histone acetylation levels that correlate with a transcriptionally active status of 
chromatin (Hebbes et al., 1988; Roh, Cuddapah, & Zhao, 2005) were examined upon 
proteasome treatment.  Overall histone H3 acetylation (K9, K14, K18, K23 and K27) were 
demonstrated to be increased on the GAPDH gene body and reduced in heterochromatic 
and inactive regions, with no change on the level of this modification upon proteasome 
inhibition (Figure 4.15D)  
 
 
159 
 
 
 
Figure 4.15: The proteasome treatment does not affect the global chromatin histone 
modification marks on the repetitive elements. NIH3T3 cells were treated with 20µM 
MG132 for 4h and underwent ChIP – qPCR against repressive mark H3K9me3 (A) and 
activating marks H3K4me3 (B), H3K36me3 (C) and H3ac (D). ChIP signal is shown as relative 
enrichment to H3 with background (no antibody) subtraction. Error Bars represent SEM, 
n=3.  
 
In summary, results in this section showed that proteasome inhibition did not have any net 
effect on four histone modifications (1 repressive and 3 activating) marks investigated on 
the major satellite repeat locus. The lack of effect might seem surprising given that 
proteasome inhibition led to significantly increased transcription of the repeats. One 
possible explanation might relate to the proportion of repeat sequences that have been 
activated by inhibiting the proteasome. The RNA FISH experiment indicates that the number 
of repeats or heterochromatic clusters that are transcriptionally activated might be a very 
small proportion of the total and therefore any chromatin changes would be diluted by the 
majority of DNA sequences which are not expressing the transcript (see discussion).  
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4.2.8 No change of H3K9me3 distribution on the pericentromeric heterochromatin foci 
(chromocentres) upon proteasome inhibition  
Chromatin Immunoprecipitation showed no significant change on the heterochromatic mark 
H3K9me3 on the major satellite repeat locus upon treatment with proteasome inhibition. 
To further validate this result, NIH3T3 cells were treated for 4h with proteasome inhibitor 
MG132 (final concentration 20µM) followed by Immunofluorescence (IF) analysis. 
Paraformaldehyde fixed and permeabilised cells were stained with DAPI (blue) and 
H3K9me3 (red) antibody and analysed by confocal microscope. As expected the DAPI 
staining clearly visualised the pericentromeric heterochromatin foci (chromocentres) (Figure 
4.16) which is formed by the coalescence of the major satellites within the nucleus (see 
introduction Figure 1.8). The H3K9me3 signal overlapped well with these heterochromatic 
foci with no significant change occurring between treated and untreated samples (Figure 
4.16). 
This result suggests that proteasome inhibition does not change the repressive histone 
modification mark H3K9me3 on the chromocentres, confirming previously obtained results 
by ChIP (Figure 4.15A).  
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Figure 4.16: Proteasome inhibition does not affect H3K9me3. NIH3T3 cells were treated 
with 20µM MG132 for 4h and immunolabeled with H3K9me3 antibody (red) and stained 
with DAPI (blue). Scale bar 10µm.  
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4.2.9  Alteration of the HP1α in the cells upon proteasome inhibition 
Both the chromatin immunoprecipitation and immunofluorescence experiments upon 
treatment of NIH3T3 cells with MG132 revealed no change in the histone modification 
signature at the major satellite repeat locus which forms the pericentromeric 
heterochromatin.  However the histone modifications are not the only factors regulating the 
pericentromeric heterochromatin. According to previous studies structural proteins such as 
HP1, predominantly HP1α and HP1β, are essential factors too, involved in the chromatin 
condensation and maintenance of stable heterochromatin domains (Azzaz et al., 2014; 
Cheutin et al., 2003). HP1α was previously shown to play a role in transcriptional gene 
silencing by changing the nucleosome packaging and preventing the accessibility of 
transcription factors for their binding sites (Azzaz et al., 2014; Danzer & Wallrath, 2004; 
Hiragami & Festenstein, 2005; Nielsen et al., 2001). 
Therefore the effect of proteasome inhibition on the localisation and distribution of HP1α 
was evaluated by immunofluorescence microscopy. IF was performed on NIH3T3 cells after 
treatment with the proteasome inhibitor MG132 with a final concentration of 20µM for 4h 
and 8h. Paraformaldehyde fixed and permeabilised cells were stained with DAPI (blue) and 
HP1α (green) antibody and analysed by confocal microscope. As expected, for all the 
samples and time points, DAPI staining highlighted pericentromeric heterochromatin 
domains. In the untreated cells, the HP1α proteins were highly accumulated in the DAPI 
dense stained regions, confirming their localisation on the pericentromeric 
heterochromatin. Interestingly, the treatment of cells with MG132 for both time points 
showed a dispersed distribution of the HP1α protein throughout the nucleus, clearly 
reducing the accumulation within the DAPI dense regions (Figure 4.17, 4.18).  
Whilst the distribution of HP1α was clearly changing upon treatment of NIH3T3 cells with 
proteasome inhibitor, total HP1α levels remained similar between treated and untreated 
cells, as shown by western blot (Figure 4.19).  
The results in this section suggest that proteasome inhibition leads to displacement of HP1α 
from pericentromeric heterochromatin, without visible changes in the DAPI dense staining 
domains. This observation is consistent with previous studies where loss of HP1 proteins 
from pericentromeric heterochromatin was not sufficient to disrupt the DAPI dense stained 
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regions and H3K9me3 in such heterochromatin domains (Mateos-Langerak et al., 2007; 
Mosch et al., 2011).   
 
 
 
Figure 4.17: HP1α distibution change upon 4h of proteasome inhibition. NIH3T3 cells were 
treated with 20µM MG132 for 4h and immunolabeled with HP1α antibody (green) and 
stained with DAPI (blue). Scale bar 10µm.  
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Figure 4.18: HP1α distibution change upon 8h of proteasome inhibition. NIH3T3 cells were 
treated with 20µM MG132 for 8h and immunolabeled with HP1α antibody (green) and 
stained with DAPI (blue). Scale bar 10µm. 
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Figure 4.19: Total HP1α protein levels remain similar upon proteasome inhibition. NIH3T3 
cells were treated with 20µM MG132 for 2h, 4h an 8h. Total cell lysate was probed with 
antibody against HP1α (~22 kDa) and α-tubulin (~55kDa) that served as a loading control.  
 
 
Finally, it is also noteworthy that all HP1 proteins were previously shown to be regulated by 
cell cycle. Specifically it was revealed that HP1 proteins were released from chromatin 
during the M phase of the cell cycle, while H3K9me3 levels remained unaffected (Fischle et 
al., 2005). This is relevant because proteasome inhibition results in cell cycle dysregulation 
and stalling of the cells in G2/M phase (Figure 4.7A). However following 2h and 4h 
treatment with MG132, only minor effects on the cell cycle were observed (see Figure 4.7A), 
whereas HPIα shows a clear change in its distribution in the vast majority of cells visualised 
(Figure 4.17). Therefore the observed displacement of HP1α is unlikely to be a result of the 
cell cycle effect of the proteasome inhibitor treatment.  
As HP1α release from the DAPI dense stained regions precedes the upregulation of the 
major satellite repeat transcription, it is tempting to speculate this step might be necessary 
to permit access of the transcriptional machinery to the heterochromatin.  
 
 
 
2h                                     4h                       
DMSO MG132   DMSO MG132    DMSO MG132 
8h                                     
α-tubulin (55 kDa-) 
     HP1α (22 kDa-) 
             Arbitrary Units             1       0.97        1        0.9         1         0.9 
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4.2.10 Proteasome inhibition leads to an increased number of heterochromatic domains 
(chromocentres) in NIH3T3 cells  
The immunofluorescence imaging of the chromocentres (visualised by DAPI staining) from 
fixed cells treated with proteasome inhibitor did not reveal any visible structural changes.  
Considering that major satellite repeats are located at these regions and from a previous 
study where these clusters were affected with concomitant major satellite upregulation 
(Zhu et al., 2011), it was further investigated whether the treatment of NIH3T3 cells with 
proteasome inhibitor could also affect the number of chromocentres. In order to acquire 
cells in a high-throughput method, an imaging flow cytometer (ImageStream X) was used. 
The ImagestreamX allows acquisition of a single cell image of each individual live cell, which 
is further processed using the IDEAS analysis software. 
As before, NIH3T3 cells were treated for 2h, 4h and 8h with either DMSO or MG132 (final 
concentration 20µM). Cells were collected and stained with DRAQ5 (5µM). DRAQ5 is a far 
red fluorescent DNA dye that easily penetrates through the lipid bilayer of live cell 
membranes and can allow visualisation of the highly condensed regions of heterochromatin 
that correspond to the chromocentres, in a similar manner to DAPI, with the advantage that 
DRAQ5 is less toxic for living cells (Yuan et al., 2004). A minimum of 20 000 events were 
collected for each sample. The gating and analysis strategy that was applied aimed at gating 
live single cells, in focus and stained with DRAQ5. This strategy allowed exclusion of those 
cells that were morphologically entering cell death, visible by granularity and cell 
morphology on brightfield (further explained in supplementary figure S2) 
Figure 4.20A illustrates representative images from the time course treatment described, 
both in brightfield and DRAQ5 channels. Figures 4.20B, 4.21B and 4.21C present the effect 
of the proteasome inhibition on the distribution of the number of chromocentres per cell, 
which presents a normally distributed data. More specifically, the treatment of the cells 
with MG132 for 2h resulted in a shift of the distribution towards the right, compared to 
DMSO only. This indicates that there was an increased number of the intranuclear DRAQ5 
stained foci per cell (average frequency 18 to 20) (Figures 4.20B, 4.21C). A further gradual 
shift to the right was observed at 4h and 8h of MG132 treatment, compared to DMSO, 
which indicates an additional increase in the number of DRAQ5 stained foci per cell (average 
frequency 18 to 22 for both time points) (Figures 4.20B, 4.21D).  
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Figure 4.20: The distribution of the number of chromocentres per cell is increased by 
proteasome inhibition. NIH3T3 cells were treated with 20µM MG132 for 2h, 4h and 8h 
followed by DRAQ5 staining and imaging using ImageSteamX. (A) Representative images 
from brightfield and DRAQ5 channels for each time point of the treatment. (B) Analysis of 
the number of DRAQ5 stained foci using IDEAS software upon treatment with cells with 
MG132 for each time point. Error bars indicate SEs of 3 biological replicates.  
 
168 
 
While the treatment with only the vehicle (DMS0) over the studied time points did not alter 
the overall distribution of the chromocentres (Figure 4.21A), a shift in the distribution and 
an increase in the number of chromocentres per cell was already apparent after 2h of 
MG132 treatment (Figure 4.21B).  
 
 
 
 
Figure 4.21:  Comparison of the distribution of the number of chromocentres per cell upon 
proteasome inhibition. NIH3T3 cells were treated with 20µM MG132 or DMSO for 2h, 4h 
and 8h followed by DRAQ5 staining and analyses by ImageStreamX. (A) No change of the 
distribution of the chromocentres with DMSO treatment for 2h, 4h and 8h. (B) Increase in 
the number of chromocentres per cell upon treatment of cells with MG132. (C) Shift of the 
distribution of the number of chromocentres per cell to the right following treatment of 
cells for 2h and 4h with MG132, compared to DMSO. (D) Shift of the distribution of the 
number of chromocentres per cell to the right following treatment of cells for 2h and 8h 
with MG132, compared to DMSO. Error bars represent SEs of 3 biological replicates.  
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4.2.11 Cell cycle regulated changes of the number of chromocentres 
The previous results suggested that proteasome inhibition increases the number of 
heterochromatic foci per cell, potentially affecting the structural organisation of the 
chromocentres. Considering that treatment of cells with proteasome inhibitor caused cell 
cycle dysregulation, it was therefore important to investigate the effect of the cell cycle on 
the chromocentre distribution.   
In order to assess the cell cycle effect on the changes of the number of chromocentres, 
NIH3T3 cells were sorted using counterflow centrifugal elutriation. The process was 
conducted using constant centrifugal force and gradient increase of flow rate. A proportion 
of the eluted material was stained with PI followed by FACS to check the efficiency of the 
elutriation process; the remaining cells were stained with DRAQ5 and imaged with 
ImageStreamX, as previously described.   
Representative images of the cell cycle profile of each fraction including the non–elutriated 
(control) are shown in Figure 4.22A. As expected, the control revealed 60%, 20% and 20% 
cells in G1/G0, S and G2/M phase of the cell cycle respectively. Elutriated fraction 1 showed 
high separation of G1/G0 phase where 92% of the cells were at this stage of the cell cycle. 
Moreover competent separation was achieved for the G2/M phase in fraction 5 where 71% 
of the cells were within this phase. Both fraction 2 and cells that had not been elutriated 
had similar cell cycle profiles. Lastly, fraction 4 was enriched for cells within G2/M phase 
reaching 58% (Figure 4.22B).  
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Figure 4.22: Cell fractions, enriched at specific phases of the cell cycle were obtained by 
centrifugal elutriation. (A) Representative images of the FACS profiles after PI staining 
showing non-elutriated and five different fractions of elutriated material. (B) Cell cycle 
distribution of each fraction is shown as a percentage of cells acquired. Data represent SEs 
of at least 2 biological replicates.                                                                                                                                                                                                                                                                                                                             
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The ImageStreamX gating and analysis strategy was performed as previously with a 
minimum of 20 000 acquired events. Figure 4.23A illustrates representative images for the 
non-elutriated and all the fractions mentioned both in the brightfield and DRAQ5 channels. 
As shown in Figure 4.23B, the cell cycle affects the distribution of the chromocentres per 
cell. In more detail, fraction 1 which represents the cells in G1/G0 phase of the cell cycle 
presented a shift of the distribution towards the left, compared to the non-elutriated, 
meaning there was a decreased number of DRAQ5 stained foci per cell (average frequency 
18 to 16) (Figure 4.23B, 4.23C). On the contrary fractions 4 and 5 representing the fractions 
highly enriched with G2/M phase of the cell cycle showed a shift of the distribution towards 
the right, compared to non-elutriated cells, indicating an increase of the number of 
chromocentres per cell (average frequency 18 to 21) (Figure 4.23B, 4.23C 4.23D). As 
expected, fraction 2 had a similar cell cycle profile as non –elutriated cells and showed no 
change in the chromocentre distribution compared to the non -elutriated cells (Figure 
4.23D). 
These results indicate cell cycle mediated regulation of the chromocentre distribution within 
the cell, with reduced number in G1/G0 phase and increased in G2/M phase of the cell 
cycle. This might make sense from a biological perspective as during G2/M the 
chromosomes are condensed and the centromeres separating to enable attachment of 
mitotic spindles to the individual chromosomes at the centromere (Cleveland, Mao, & 
Sullivan, 2003; Guenatri et al., 2004). 
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See next page for figure legend 
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Figure 4.23: Chromocentre distribution is affected by cell cycle. Not elutriated and fractions 
with different cell cycle profile were stained with DRAQ5 and imaged using ImageSteeamX. 
(A) Representative images from brightfield and DRAQ5 channels for not elutriated and each 
fraction containing cells with different cell cycle profiles. (B) Analysis of heterochromatic foci 
in all the fractions and not elutriated cells. (C) Analysis of heterochromatic foci in not 
elutriated, fraction 1 and fraction 5. (D) Analysis of heterochromatic foci in fraction 4 and 
fraction 5. (E) Analysis of heterochromatic foci in not elutriated and fraction 2. Error bars 
indicate SEs of at least 2 biological replicates.  
 
 
 
4.2.12 Analysis of the effect of cell cycle perturbations due to proteasome inhibition on 
the number of chromocentres per cell. 
According to the presented results, the distribution of chromocentres was affected by cell 
cycle and proteasome inhibition. Considering that proteasome inhibition caused cell cycle 
partial arrest in G2/M, it was necessary to investigate whether the changes on the 
chromocentres observed were directly caused by the treatment or indirectly caused by cell 
cycle skewing, or potentially a combination of both. Treatment of cells for 4h with 
proteasome inhibitor dramatically increased the number of chromocentres per cell (Figures 
4.20, 4.21), with only a relatively minor effect on the cell cycle, (Figure 4.7) indicating that 
the increase in chromocentre number appears to be independent of skewing of the cell 
cycle towards G2/M. To formally analyse this in more depth, the similarity function between 
(i) cell cycle profile of different fractions obtained by elutriation and (ii) cell cycle profile 
upon proteasome inhibition after 4h and 8h was compared – these measurements were 
obtained from PI staining. The similarity function was defined as the Euclidian distance (Lele, 
1993) between average values for the percentage number of cells in each phase of the cell 
cycle (G1/G0, S, G2/M) in the examined groups (more details regarding the analysis is shown 
in material and methods). The distances obtained from this analysis are shown in Table 1, 
where the minimum distance indicates highest similarity.  
As expected, the cell cycle profile upon treatment with DMSO gave the highest degree of 
similarity between the samples that had not been elutriated (Figure 4.22, table 3). On the 
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contrary, treatment of cells with MG132 for 4h and 8h gave cell cycle profiles similar to 
those obtained with fraction 2 and fraction 3 respectively (table 3). Notably fraction 2 and 
the not-elutriated sample gave very similar cell cycle profiles and in turn similar numbers of 
chromocentres per cell (Figures 4.22, 4.23).  
 
 
 Not-
elutriated 
Fraction 1 Fraction 2 Fraction 3 Fraction 4 Fraction 5 
4h DMSO  6.2 45.8 11.5 31.9 49.2 62.8 
4h MG132 17.7 59.5 16.8 18.2 36.7 51.3 
8h DMSO  6.9 43.4 13.5 34.3 50.9 64.1 
8h MG132 38.1 78.0 37.1 10.1 16.2 31.2 
  
Table 3: Euclidian distances between cell cycle profile upon proteasome inhibition and 
different fractions of elutriated and not elutriated material obtained from PI staining. The 
lower the value the higher the similarity. The smallest values indicating the highest similarity 
are shown in bold.  
 
Next, the chromocentre distributions, previously analysed by ImageStreamX, were 
compared between cells treated with either DMSO or MG132 for 4h and 8h and the 
fractions from the elutriated or not-elutriated material with the highest degree of similarity 
in respect of their cell cycle profile (Figure 4.24).   
In all DMSO treated samples analysed, the number of chromocentres per cell was highly 
similar compared with not-elutriated samples (Figures 4.24A, 4.24B). This result was 
expected as DMSO treatment had no effect on cell cycle distribution (data not shown). 
As illustrated in Figures 4.24C and 4.24D, a clear difference in the distribution of the number 
of chromocentres per cell was observed after 4h and 8h of MG132 treatment, relative to 
fractions 2 and 3 respectively. Notably, the difference was more pronounced at 4h of 
treatment when compared with 8h of MG132 treatment (Figures 4.24C, 4.24D). These 
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results suggest an effect of the proteasome inhibition on the regulation of the 
heterochromatic foci within the nucleus, rather than solely an indirect effect secondary to 
skewing of the cell cycle. However, to investigate this further, cells could be treated with the 
proteasome inhibitor followed by elutriation and Imagestream analysis, in order to 
determine at what cell cycle stage/s the increase in the number of chromocentres per cell 
occurs.  
Overall the results presented in this section imply that the effect of proteasome inhibition 
on the distribution of the number of chromocentres per cell does not appear to be solely 
secondary to cell cycle skewing (Figure 4.21C, 4.21D) and correlated with transcriptional 
upregulation of the major satellite repeats which in itself might loosen the association of 
centromeres with each other during interphase.  
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Figure 4.24: Comparison of distributions of the number of chromocentres per cell. 
Elutriation samples were compared with samples treated with MG132 or DMSO for 4h and 
8h. Those with the most similar cell cycle profiles (Table 3) are compared. (A, B) Cells 
treated with vehicle only (DMSO) and not-elutriated cells, have very similar overlapping 
distributions of chromocentres per cell as well as cell cycle profiles (C, D). After 4h and 8h of 
proteasome inhibition there is an increase in chromocentres (the distribution shifts to the 
right) despite having similar cell cycle profiles obtained in fraction 2 and fraction 3 
respectively of the elutriation.  
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4.3  Discussion 
4.3.1  Cell cycle mediated regulation of heterochromatic repeats 
Chromatin in proliferating cells is highly dynamic and each phase of the cell cycle was shown 
to induce changes in chromatin structure and accessibility (Figure 4.1). These changes could 
impact numerous chromatin associated processes such as gene expression. The effect of cell 
cycle has previously been extensively studied in the context of DNA replication and cell 
division.  However, so far, only few studies investigated the effect of the cell cycle in the 
regulation of transcription of repetitive elements. In this chapter, pericentromeric major 
satellite repeats and centromeric minor satellite repeats were shown to be preferentially 
transcribed during G1 and G2/M phases of the cell cycle respectively, consistent with 
previous studies (Ferri et al., 2009; J. Lu & Gilbert, 2007). The expression of LINE L1 and SINE 
B1 retrotransposons was found to be unaffected by the cell cycle.  It is worth mentioning 
that in this thesis, the analysis of the expression levels of these repeat transcripts, in 
contrast to the previous studies was performed without use of any chemical inhibitor to 
arrest the cell cycle, which could potentially cause stress or alter the metabolism of cells and 
induce unintended expression of the repeats.  
The cell cycle regulated expression of pericentromeric satellite repeats prior to the DNA 
replication process which takes place during S phase might play a role in (i) reassembling the 
high order heterochromatin structure and/or (ii) regulating heterochromatin replication. 
Studies in fission yeast, where heterochromatin is known to be repressed by an RNA 
interference mechanism (see more information in the general introduction) have reported 
transcription of pericentromeric repeats to peak during early S phase of the cell cycle (E. S. 
Chen et al., 2008; Kloc, Zaratiegui, Nora, & Martienssen, 2008). Rapid processing of these 
transcripts into siRNA was shown to promote H3K9me2 and recruitment of Swi6 
(homologue to HP1) and hence re-establishment of heterochromatin regions after the 
replication process (Kloc et al., 2008). In mammalian cells, transcription of pericentromeric 
major satellite repeats was identified to gradually increase during the course of G1, reaching 
a peak in late G1 phase of the cell cycle (J. Lu & Gilbert, 2007). In contrast to S. Pombe, the 
synthesis of these transcripts was shown to decrease from early S phase and was found to 
be substantially reduced by mid S phase, which coincides with the timing of replication of 
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pericentromeric heterochromatin (J. Lu & Gilbert, 2007) . Consistently, in this thesis, the 
transcription of major satellite repeats was found to take place predominantly during the G1 
phase of the cell cycle. It is important to mention that here, the methodology that was used 
to synchronise cells (centrifugal elutriation) did not allow isolation of a highly enriched 
population of cells in S phase. Therefore the limitation of this technique to synchronize the 
entire population of cells in S phase could explain the only slight increase of major satellite 
repeat expression found relative to unsynchronized cells. In both yeast and mammalian 
cells, transcription of pericentromeric repeats was shown to precede heterochromatin 
replication (J. Lu & Gilbert, 2007; Zaratiegui et al., 2011). The induction of pericentromeric 
repeat transcription in different phases could be explained by differences between the 
mammalian and fission yeast cell cycle and the different times of heterochromatin 
replication. The cell cycle of yeast consists of a very short G1 phase (Gomez & Forsburg, 
2004; Knutsen et al., 2011), whereas in mammals the G1 is typically the longest phase of the 
cell cycle (Donjerkovic & Scott, 2000; Harper & Brooks, 2005). In fission yeast, 
heterochromatin replicates in early S phase (S. M. Kim, Dubey, & Huberman, 2003) whereas 
in mammals the replication takes place during late S phase of the cycle (N. Collins et al., 
2002; Fuss & Linn, 2002; Lima-de-Faria & Jaworska, 1968; Nakayasu & Berezney, 1989; 
O'Keefe, Henderson, & Spector, 1992). Additionally, it is noteworthy that there are clear 
differences in pericentromeric heterochromatin repression and pericentromeric 
transcription between the two systems. Firstly, while the classic siRNA (21-25nt) mediated 
pathway plays an important role in heterochromatin repression in fission yeast (T. Volpe & 
Martienssen, 2011; T. A. Volpe et al., 2002; Zofall & Grewal, 2006), there is still no or little 
evidence for the existence of such RNAs in mammalian cells (F. Wang et al., 2006). However, 
some studies suggest that the binding of HP1α to pericentromeric regions is dependent on 
non-siRNA-sized pericentromeric transcripts (Maison et al., 2011; Muchardt et al., 2002). 
Secondly while cell cycle regulated transcription of pericentromeric repeats was disrupted in 
fission yeast Clr4 (homologue to SUV39H1/2) mutants (E. S. Chen et al., 2008), in 
mammalian cells their transcription during G1 phase was shown to be independent of 
SUV39H1/2 activity (J. Lu & Gilbert, 2007).  
On the other hand, the presence of minor satellite transcripts during the G2/M phase of the 
cell cycle is most likely to be important for proper kinetochore formation during mitosis. 
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Indeed, α-satellite transcripts were shown to be an integral component of the kinetochore 
structure in human cells (L. H. Wong et al., 2007). Moreover, in mouse cells, minor satellite 
transcripts were found to recruit and tether the M-phase specific chromosomal passenger 
complex (CPC), consisting of Aurora Kinase B (AUKB), INCENP and Survivin, to centromeric 
chromatin (F. L. Chan & Wong, 2012). The same study also showed that minor satellite 
transcripts enhance the activity of AUKB, a protein important in the microtubule-
kinetochore attachment, spindle checkpoint, and cytokinesis (Fu, Bian, Jiang, & Zhang, 
2007). 
Further studies are required in order to elucidate whether the transcription derived from 
pericentromeric and centromeric regions is a regulated process or a consequence of a 
dynamic regulation of the heterochromatin structure mediated by the cell cycle in 
mammalian systems. As the highly condensed structure of heterochromatin can inhibit the 
transcription of repetitive elements by blocking the access of essential factors, the ‘leaky’ 
heterochromatin that could possible arise during late G1 (just prior the DNA replication) and 
G2/M (prior or during the cell division) phases of the cell cycle might provide a “window of 
opportunity” for RNAPII and the transcriptional machinery to access the underlying DNA 
sequences. However, it is not clear if the transcription of the major and minor satellite 
repeats at G1 and G2/M phases of the cell cycle is a direct regulatory process regulated by 
the cell cycle or an indirect process secondary to changes in heterochromatin structure. It 
would now be interesting to analyse which factors associate with repetitive DNA sequences 
to drive the transcription and further analyse the functional consequences of perturbing the 
transcription of these endogenous repeats on cell cycle progression.  
As mentioned in the introduction, pericentromeric major satellite repeats from different 
chromosomes are known to physically associate to form chromocentres (Figure 1.8). 
Previous studies have shown that the number of chromocentres differs during the different 
cytogenetic stages of cell division i.e interphase, prophase, anaphase and metaphase, with a 
significant increase occurring from prophase and reaching a maximum number during 
metaphase (Guenatri et al., 2004).  In this chapter, the number of chromocentres per cell 
was quantified in live cells within each phase of the cell cycle and was shown to reduce in 
G1 phase compared to S, G2/M phases. Similarly, Bartholdi in 1991 showed an increased 
number of dispersed chromocentres during S and G2/M phase relative to G1 phase, without 
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measuring the absolute difference (Bartholdi, 1991). Consistently another study reported an 
increased number of chromocentres per nucleus during S phase compared to G0 in multiple 
cells including fibroblast, ES cells and macrophages (Mayer et al., 2005). So far, studies have 
measured the number of chromocentres in fixed cells stained either with DAPI or anti-
centromere antibody, which could potentially induce alterations in chromocentre structure 
and number. Indeed, examining the distribution of the number of chromocentres per cell in 
an unsynchronised population of paraformaldehyde fixed and living cells revealed distinct 
differences, with fixed cells showing an overall decrease in the number of chromocentres 
per cell relative to living cells (data not shown). 
Why does the number of chromocentres per cell increase during S and G2/M phase of the 
cell cycle? The increased number of chromocentres suggests de-clustering of the 
chromocentres. Interestingly, a previous study (Ito et al., 2014) found a correlation between 
chromocentre de-clustering and disruption of association of heterochromatin with the 
nuclear lamina, an important structural change of chromatin observed during S and G2/M 
phases (see more in the introduction of this chapter, Figure 4.1). Hence, de-clustering of 
chromocentres could potentially facilitate: (i) the accessibility of the replication machinery 
to the underlying DNA sequence of the pericentromere during S phase of the cell cycle and 
(ii) the assembly of kinetochore and separation of sister chromatids during mitosis.  
A summary of the cell cycle regulated transcription of heterochromatin and distribution of 
the number of chromocentres per cell in mammals is shown in Figure 4.25.  
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Figure 4.25: Summary of cell cycle effects on the transcription of pericentromeric and 
centromeric repeats and distribution of the number of chromocentres per cell. Transcription 
of major satellite repeats was detected in G1 phase of the cell cycle, whereas transcription 
of minor satellite repeats was found in G2/M phase. The number of chromocentres per cell 
was lower in G1 phase of the cell cycle relative to S and G2/M phases.  
 
 
 
 
4.3.2 The effect of proteasome inhibition in regulation of transcription of heterochromatic 
repeats 
Mammalian cells have evolved multiple complex mechanisms to repress the transcription of 
repetitive elements. It is generally accepted that heterochromatinisation (see more in the 
general introduction) of repetitive regions is the main physical barrier for restricting the 
accessibility of the transcriptional machinery to repetitive DNA sequences. Over the last 
decade, progress in the analysis of the chromatin structure has uncovered many epigenetic 
properties of heterochromatin and the mechanisms that initiate and maintain 
heterochromatin formation is under intense investigation. Mis-regulation of 
heterochromatic repeat expression has been reported to have deleterious effects on 
chromosome segregation and genome stability. For example ectopic overexpression of 
satellite repeats was shown to cause impaired mitosis, centromere amplification, lack of 
sister-chromatid cohesion and increased DNA double-strand breaks (Bouzinba-Segard et al., 
2006; Zhu et al., 2011). Expression of interspersed repeats LINEs and SINES and their further 
insertion into new genomic loci was found to lead to insertional mutagenesis, increased 
            Growth  
             Transcription of major satellite repeats 
            Chromocentres per cell  
  
                               DNA replication  
                 Chromocentres per cell  
           Growth and preparation for mitosis 
Transcription of minor satellite repeats   
                    Chromocentres per cell  
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DNA double-strand breaks and genomic rearrangements such as deletions, duplication and 
inversions (Cordaux & Batzer, 2009; deHaro et al., 2014). Additionally, absence of the 
SUV39H gene was found to significantly reduce the levels of H3K9me3 from pericentromeric 
heterochromatin, downregulate the satellite repeats expression (Lehnertz et al., 2003; 
Muramatsu, Singh, Kimura, Tachibana, & Shinkai, 2013) and induce various chromosomal 
instabilities including aneuploidies, presence of so called “butterfly” chromosomes and 
aberrant chromosome segregation (A. H. Peters et al., 2001). To date multiple factors such 
as ubiquitin E3 ligase BRCA1 (Zhu et al., 2011), the histone demethylase KDM2A (Frescas et 
al., 2008), transcription factors Pax3 and Pax9 (Bulut-Karslioglu et al., 2012) were identified 
to silence satellite repeats in mammalian systems, indicating that a variety of functionally 
distinct cellular components might contribute to the regulation of heterochromatin. Data 
presented in this chapter suggests that the multisubunit enzymatic complex, the 
proteasome, might facilitate transcriptional silencing of pericentromeric repeats.  
In this chapter, proteasome inhibition was shown using two independent techniques (RNA-
FISH and q-RT-PCR) to cause dose-dependent, transcription-dependent and cell-cycle 
independent upregulation of major satellite repeat expression. This transcriptional 
upregulation clearly indicates a loss of repression in constitutive heterochromatin and 
suggests that the proteasome acts as a transcriptional repressor of pericentromeric repeats 
in mouse cells. However, at this point it is worth mentioning that the effect of proteasome 
inhibition could not be entirely restricted to the pericentromeric regions, as the effect might 
also take place at 42 intergenic major satellite repeats which were previously mapped and 
identified to be interspersed throughout the mouse genome (Bulut-Karslioglu et al., 2012). 
One way of confirming the origin of these transcripts would be by performing RNA 
sequencing after treatment of cells with proteasome inhibitor. Additionally, RNA 
interference-mediated depletion of each proteasomal subunit will elucidate which are 
required for transcriptional activation of major satellite repeats.  
Notably, while proteasome inhibition showed significant effects on the major satellite 
repeat expression, centromeric minor satellite repeats and retrotransposon LINE L1 were 
largely unaffected. On the other hand, a small albeit significant transcriptional activation of 
SINE B1 elements was shown to occur specifically at high-dose and prolonged treatment of 
the cells with proteasome inhibitor. This increase of SINE B1 expression could partly explain 
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the downregulation of housekeeping gene transcription with proteasome inhibition, as 
previous studies have shown that various SINE transcripts including SINE B2 and Alu 
(homologue to SINE B1) function as transacting transcriptional repressors which block 
mRNA synthesis by directly associating with RNAPII (Allen, Von Kaenel, Goodrich, & Kugel, 
2004; Espinoza, Allen, Hieb, Kugel, & Goodrich, 2004; Mariner et al., 2008).  
Why is it that proteasome inhibition specifically upregulates pericentromeric repeat 
transcription rather than centromeric repeats? As mentioned in the general introduction, 
the chromatin structure of centromeres differs significantly from pericentromeres and 
euchromatin by incorporating a highly specialised variant of histone H3 (B. E. Black & 
Bassett, 2008; Guse et al., 2011; Hori et al., 2013; Perpelescu & Fukagawa, 2011; Warburton 
et al., 1997). On the other hand LINE L1 and SINE B1 elements are thought to be 
predominantly repressed by DNA methylation including hypermethylation of their promoter 
regions (see general introduction section 3.1.3). Therefore these different categories of 
repetitive elements appear to be repressed in distinct ways and proteasome inhibition 
might compromise (via an direct or indirect manner) the overall heterochromatin 
organisation of pericentromeric regions leaving the centromeric repeats unaffected. Indeed, 
in this thesis, proteasome inhibition was shown to cause displacement of HP1α, a bona-fide 
pericentromeric heterochromatin associated protein (see general introduction section 
2.2.2), from chromocentres. In contrast, no obvious changes in the distribution and 
enrichment of H3K9me3, which serves as a platform for HP1 recruitment to chromatin, 
were identified. Interestingly, a previous study has shown global histone hyperacetylation 
and hypomethylation in the liver of rats following treatment with proteasome inhibitor 
(Oliva et al., 2009). Furthermore, treatment of multiple myeloma (MM) cells with 
proteasome inhibitor was found to downregulate HDACs expression accompanied by global 
histone hyperacetylation (Kikuchi et al., 2010). In this thesis the levels of histone 
modifications associated with open chromatin structure and active transcription including 
H3 panacetylation, H3K36me3 and H3K4me3 were also examined and found to be 
unaffected at satellite repeats after proteasome inhibition. A possible explanation for the 
observed stable levels of histone modifications could be due to transcriptional activation of 
a very small proportion of the total major satellite repeats, which are represented 
approximately 10 000 times in each chromosome (Garagna, Zuccotti, Capanna, & Redi, 
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2002). Hence chromatin immunoprecipitation that was used to examine these histone 
modifications might not be able to detect such small variations.  
Consistent with the findings presented here, various studies have attributed transcriptional 
activation of pericentromeric repeats to either partial or full dissociation of HP1 from 
pericentromeric regions without any changes in H3K9me3 levels. For example knockdown of 
the lysine-specific demethylase 2A (KDM2A) which specifically demethylates H3K36me2 in 
cell lines was shown to delocalise the HP1 from chromocentres and this was correlated with 
derepression of pericentromeric repeat expression but no change in H3K9me3 levels 
(Frescas et al., 2008). Another study has also reported that mutation of histone variant H3.3 
at an early stage of development resulted in increased accumulation of major satellite 
repeat transcripts which was accompanied by displacement of HP1 from chromocentres 
(Santenard et al., 2010). Moreover, another interesting example comes from BRCA1-
deficient cells, where a significant reduction in the number of HP1 positive foci and loss of 
ubiquitylation of histone H2A (H2Aub) apparently induced activation of major and minor 
satellite repeat transcription (Zhu et al., 2011). Finally HP1α/β double knockout MEF cells 
were shown to upregulate major satellite repeat expression, without affecting the 
localization of H3K9me3 (Mosch et al., 2011).  
As the release of HP1 from chromatin during M phase of the cell cycle was shown to be 
dependent on H3 serine 10 phosphorylation (H3S10ph) (Fischle et al., 2005; Hirota, Lipp, 
Toh, & Peters, 2005), it would be interesting to assess the level of this modification mark on 
the pericentromeric heterochromatin in the presence and absence of proteasome inhibitor. 
In addition, other histone modifications, such as H2Aub, mark associated with regulation of 
pericentromeric repeat expression and the heterochromatic H4K20me3 mark which was 
found to be increased at the distal estrogen receptor-α (ESR1) enhancer after proteasome 
inhibition (G. L. Powers, Rajbhandari, Solodin, Bickford, & Alarid, 2013) and therefore might 
be worth analysing at satellite repeats after treatment of cells with proteasome inhibitor.  
 A previous study has reported upregulation of major satellite repeat expression linked with 
a marked decrease of the number of chromocentres per cell upon deletion of BRCA1 gene in 
mice (Zhu et al., 2011). In contrast, in this thesis transcriptional activation of major satellite 
repeats upon treatment of cells with proteasome inhibitor was accompanied by an increase 
of the number of chromocentres per cell far beyond than that induced by skewing of the cell 
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cycle. Of note, Zhu and colleagues used confocal microscopic images to count the 
chromocentres and based on the cell morphology and increased intensity of apoptotic 
marker caspase 3, the authors likely included a high number of apoptotic cells in their 
analysis. As apoptotic cells contain less chromocentres per cell, with an average frequency 1 
spot per cell (data not shown); this could potentially have a major impact on the final 
calculation of the chromocentre number in a population of cells. On the other hand, we 
measured the chromocentres in each cell within a population of non-apoptotic cells (gating 
was used in order to exclude dead and apoptotic cells) using Imagestream. Therefore, 
differences in the technique and cell population used for the analysis could thus explain the 
discrepancy with our results. The increased number of chromocentres per cell suggests 
destabilisation of chromocentre structure, which in turn could reduce the compaction of 
heterochromatin and increase accessibility of the transcriptional machinery to the 
underlying DNA sequences. It would be very interesting to use the Imagestream analysis 
described here to analyse BRCA1 deficient mice and gate independently on the apoptotic 
versus non-apoptotic populations to analyse chromocentre numbers per cell.  
The potential molecular mechanisms behind the upregulation of major satellite repeat 
expression with proteasome inhibition will be analysed and discussed in the following 
chapter (chapter 5).  
Lastly it is important to mention that the proteasome inhibitor PS341 is currently used to 
treat patients with multiple myeloma (Bross et al., 2004; Field-Smith et al., 2006; 
Meenaghan et al., 2010a; Moreau et al., 2012; Richardson et al., 2005; San Miguel et al., 
2008). The anti-myeloma effects of the inhibitor were reported to mainly include inhibition 
of the nuclear factor kappa B (NFkB) activation though preventing the degradation of its 
inhibitor IkB, disruption of the cell cycle and induction of apoptosis (Hideshima et al., 2002; 
Hutter et al., 2012; Ling et al., 2002; Mitsiades et al., 2002; Pham, Tamayo, Yoshimura, Lo, & 
Ford, 2003). Another anti-myeloma effect of PS341 could be upregulation of 
pericentromeric repeat transcription. This accumulation of satellite repeat transcripts is 
likely to cause genome instability, making a cell more prone to apoptosis. Furthermore as 
the use of the drug has been reported to have significant side effects including 
gastrointestinal disturbances, peripheral neuropathy and thrombocytopenia (Field-Smith et 
al., 2006), it would be interesting to assess the levels of the pericentromeric repeat 
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transcripts in patients and correlate any side effects that might be due to the disruption of 
pericentromeric heterochromatin.  
 
 
 
4.3.3 Possible role of RNAPI and/or RNAPIII in transcription of major satellite repeats  
Transcription in eukaryotic cells is performed by three RNA polymerases, RNAPI, RNAPII and 
RNAPIII. RNAPI is known to transcribe ribosomal RNA genes (with an exception of 5S rRNA). 
RNAPII transcribes protein-coding genes (mRNA genes) and many noncoding RNA (ncRNA) 
such as microRNA (miRNA). RNAPIII transcribes tRNAs genes, 5S RNA, various small ncRNAs 
including U6 small nuclear RNA (U6 snRNA), 7SK RNA and H1 RNA (Dieci, Fiorino, 
Castelnuovo, Teichmann, & Pagano, 2007). There is evidence suggesting that different RNA 
polymerases can often work together to coordinate their target gene expression (Raha et 
al., 2010).   
Considering that pericentromeric satellite repeats (i) do not harbour detectable promoter 
elements and (ii) lack sequence conservation (Saksouk et al., 2015), it was difficult to predict 
which RNA polymerase mediated their transcription. Studies in yeast and mammalian cells 
have shown that transcription of pericentromeric repeats is driven by RNAPII (Djupedal et 
al., 2005; Kato et al., 2005; J. Lu & Gilbert, 2007; Oya et al., 2013). However, preliminary 
results in this thesis suggest a possible role of RNAPI and/or III in the transcription of major 
satellite repeats. It is worth mentioning that Lu and colleagues treated the cells with RNAPII 
inhibitor (DRB) for a short time course (1h) and observed a significant reduction of the levels 
of satellite repeat transcripts. Similarly, in this thesis, treatment of cells with RNAPII 
inhibitor for a short time course (<2h) strongly reduced the levels of major satellite repeat 
transcripts; only the prolonged treatment (>2h) caused accumulation of these transcripts in 
the cells. 
Further studies are required in order to elucidate the possible function of RNAPI and RNAPIII 
in pericentromeric repeat transcription. This could be achieved by examining the binding of 
RNAPI and/or III on pericentromeric repeats in the presence and absence of RNAPII. 
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Furthermore, it would be interesting to assess the effect of the combinatory inhibition of 
RNAPI with RNAPII and RNAPIII with RNAPII on the levels of pericentromeric repeat 
transcription.  
 
 
 
In summary the results in this chapter have further focused on the role of the proteasome in 
the regulation of pericentromeric repeat expression using proteasome inhibition which 
resulted in: 
 Cell-cycle independent and transcription dependent upregulation of pericentromeric 
satellite repeat expression 
 No change in the H3K9me3, H3K4me3, H3K36me3 and H3ac levels at major satellite 
repeats 
 Delocalisation of HP1α from chromocentres 
 Increased number of chromocentres per cell that would be unlikely to be simply 
accounted for by cell cycle skewing towards G2/M.  
 
These findings suggested that proteasome activity might be required for maintaining the 
stability of heterochromatin clusters within cells and the pericentromeric localisation of a 
key component of heterochromatin, HP1α, as well as silencing of the pericentromeric 
repeats. Based on the sequence of events following proteasome inhibition it appears that 
HP1α delocalises first followed by disaggregation of centromeric clusters and upregulation 
of transcription of pericentromeric repeats. Interestingly, there were no changes in the 
histone modifications examined (see discussion). 
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CHAPTER 5: Investigating the molecular mechanism of the major satellite 
repeat transcriptional upregulation upon proteasome inhibition 
 
5.1  Introduction 
In the previous chapter it was shown that proteasome inhibition upregulates the 
transcription of major satellite repeats. This is accompanied by release of HP1α from 
pericentromeric heterochromatin and an increase in the number of chromocentres per cell. 
As the proteasome participates in a large number of cellular pathways and controls the 
steady-state level of many proteins it is difficult to distinguish between direct involvement 
of the proteasome on the transcription of the pericentromeric repeat and indirect effects 
mediated by a protein whose level is controlled by the proteasome activity. Additionally, 
accumulation of misfolded proteins due to proteasome inhibition is known to trigger cell 
stress responses (Boyault et al., 2007; Bush, Goldberg, & Nigam, 1997; Goldberg, 2003; 
Johnston, Ward, & Kopito, 1998; Kawazoe, Nakai, Tanabe, & Nagata, 1998; Mathew, 
Mathur, & Morimoto, 1998; Obeng et al., 2006; Rao & Bredesen, 2004) therefore a 
component from the cell stress pathway could also be responsible for the de-repression of 
the major satellite repeat.  Therefore the main goal of this chapter was to investigate the 
molecular mechanism for transcriptional upregulation upon proteasome inhibition. More 
specifically the aims of this chapter were: 
 To analyse the possible proteasome recruitment to the repetitive elements and the 
effect upon proteasome inhibition  
 To examine the effect of the proteasome inhibition on RNAPII recruitment to the 
repeats 
 To investigate the activation of the cell stress pathway and the role of HSF1 in the 
transcriptional upregulation of major satellite repeats upon proteasome inhibition.  
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5.2 Results  
 5.2.1 Investigation of proteasome binding in heterochromatic repeats 
The first step to assess whether the proteasome is directly involved in the repression of 
major satellite repeats was to investigate the distribution of the proteasome in the nucleus 
and more specifically the possible binding of the proteasome to the pericentromeric 
regions.  
Numerous studies have shown the presence of the proteasome in the nucleus of eukaryotic 
cells (Mengual et al., 1996; A. Palmer, Mason, Paramio, Knecht, & Rivett, 1994; J. M. Peters, 
Franke, & Kleinschmidt, 1994; Rivett, Palmer, & Knecht, 1992; Wojcik, Paweletz, & 
Schroeter, 1995) and its recruitment to various regions of the chromatin including 
centromeres (Kitagawa et al., 2014a), yeast telomeres (Geng & Tansey, 2012) and  sites of 
cryptic transcriptional initiation (Szutorisz et al., 2006).  
To confirm the nuclear localisation of the proteasome in NIH3T3 cell lines and to investigate 
whether the proteasome is co-localized with heterochromatin antibodies against the β6 
subunit of the 20S proteasomal particle were employed. As expected the 
immunofluorescence analysis revealed a diffuse presence of the proteasome throughout 
the cells, with the signal coming from both, the cytoplasm and the nucleus. However, the 
20S proteasomal particle was found to be relatively excluded from heterochromatin 
domains represented by DAPI dense stained region (Figure 5.1).  
 
 
      
Figure 5.1: Proteasome distribution within the cell.  NIH3T3 cells were immunolabeled with 
20S Proteasomal particle antibody (red) and stained with DAPI (blue). Scale bar 10µm.  
 
         DAPI                                  20S (β6) proteasome                             Merge  
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To further validate these results, ChIP was performed with the same antibody used for the 
immunofluorescence experiment and immunoprecipitated material was quantified using 
qPCR with primers against major, minor, LINEL1 and SINEB1 heterochromatin regions. 
Additionally primers against GAPDH and MOG genes were used as controls, representing 
transcriptionally active and inactive regions respectively.  
As illustrated in Figure 5.2, the analysis of immunoprecipitated material by qPCR showed 
binding of the proteasome in all the examined regions to a similar extent, with the 
exception of minor satellite repeats, where significantly lower levels of enrichment were 
detected. 
 
Figure 5.2: Proteasome subunit β6 is recruited to heterochromatic regions, active gene 
(GAPDH) and inactive gene (MOG) in NIH3T3 cells measured by ChIP-qPCR. Enrichment level 
is presented relative to input. Error bars SEM, n=3 biological replicates. 
 
Chromatin immunoprecipitation revealed high levels of the 20S proteasome on the major 
satellite repeats sequences whereas the immunofluorescence showed exclusion from the 
DAPI-dense regions where this sequence is known to reside. This difference might be 
explained by how the techniques differ. For example in the case of immunofluorescence the 
proteasome appeared excluded from the DAPI –dense regions which could be due to the 
physical inaccessibility of the antibody to the proteasome epitope when it is packaged into 
highly compacted regions such as heterochromatin whereas chromatin 
immunoprecipitation is performed on sonicated chromatin.  
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5.2.2 Small overall increase of 20S proteasome binding on various chromatin regions upon 
proteasome inhibition 
Transcriptional activation of the major satellite repeats upon proteasome inhibition (shown 
in the previous chapter) and binding of the proteasome to the major satellite repeats in the 
absence of the proteasome inhibition raised the question as to what happens to the 
proteasome binding upon proteasome inhibition? To address this question, NIH3T3 cells 
were treated with DMSO or proteasome inhibitor MG132 at a final concentration of 20μM 
for 4h followed by ChIP. In a similar approach to that explained in the previous section, 
immunoprecipitated material was analysed by qPCR using primers against major, minor, 
LINE L1 and SINE B1 heterochromatin regions as well as GAPDH and MOG.  
According to the qPCR analysis, in the absence of proteasome inhibition, uniform binding of 
the β6 subunit of the 20S proteasome was observed on major satellite repeats, LINE L1, SINE 
B1 as well as active GAPDH and inactive MOG genes. A significantly smaller enrichment was 
also observed for the minor satellite repeats (Figure 5.3), consistent with the previous ChIP 
experiment (Figure 5.2). When NIH3T3 cells were treated with MG132 a slight increase of 
proteasome binding was identified for all the examined regions (Figure 5.3). This is in 
agreement with a previous study (Szutorisz et al., 2006) where proteasome inhibition was 
revealed to increase the proteasome binding at the intergenic regions in ES cells; this 
increase varied amongst the different proteasomal subunits with β6 20S and RPN12 19S 
proteasome showing the largest increase of binding while the α4 and β4 subunits were not 
affected by proteasome inhibition (Szutorisz et al., 2006).   
193 
 
 
Figure 5.3: Proteasome inhibition induces slight overall increase of proteasome binding on 
heterochromatin regions, active gene (GAPDH) and inactive gene (MOG).  NIH3T3 cells were 
treated with DMSO or MG132 at a final concertation of 20μM for 4h followed by ChIP-qPCR. 
Enrichment level is presented relative to input. Error bars SEM, n=3 biological replicates. 
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5.2.3 The effect of proteasome inhibition on distribution and binding of RNAPII in 
heterochromatin regions   
Despite the formation of highly condensed chromatin at repetitive elements, RNAPII might 
still access the underlying DNA sequences causing transcriptional activation of the repeats. 
However, it has been suggested that it is important that the level of transcription of 
endogenous repetitive sequences remains low, as high transcription derived from repetitive 
elements might lead to various diseases including cancer (Criscione, Zhang, Thompson, 
Sedivy, & Neretti, 2014; Eymery, Horard, et al., 2009; Ting et al., 2011). Given that the 
proteasome had been proposed to degrade RNAPII in the case of transcription-coupled 
repair (K. B. Lee et al., 2002; Somesh et al., 2005; Wilson et al., 2013) and to prevent cryptic 
transcription (Szutorisz et al., 2006), we hypothesised therefore that the proteasome might 
also contribute to the repression of the transcription of repetitive elements by actively 
degrading the RNAPII bound to the repeats. Hence inhibition of proteasome activity might 
be expected to increase the transcription of repeats, as seen in the previous chapter 
(chapter 3).  
In previous sections, the proteasome was shown by ChIP to bind to the major satellite 
repeats which is abundant in pericentromeric heterochromatin. One possible hypothesis for 
the recruitment of the proteasome to chromatin is through recognition of its ubiquitinated 
substrates. A number of chromatin associated substrates can become polyubiquitinated 
including histones, RNAPII, transcriptional factors and co-factors and ultimately become a 
target for proteasome dependent degradation (Beaudenon, Huacani, Wang, McDonnell, & 
Huibregtse, 1999; C. Chen et al., 2005; Fuchs & Ronai, 1999; Karakasili et al., 2014; Z. Liu, 
Oughtred, & Wing, 2005; Mitsui & Sharp, 1999; Ouni, Flick, & Kaiser, 2011; R. K. Singh, 
Kabbaj, Paik, & Gunjan, 2009; Vinas-Castells et al., 2010; S. P. Wang et al., 2009; Zenke-
Kawasaki et al., 2007). One example is polyubiquitination and degradation of stalled RNAPII 
during transcription coupled DNA repair by the ubiquitin-proteasome system (Anindya et 
al., 2007; Ghosh-Roy, Das, Chowdhury, Smerdon, & Chaudhuri, 2013; K. B. Lee et al., 2002; 
Somesh et al., 2005; Somesh et al., 2007; Wilson et al., 2013). A similar mechanism, of active 
removal of the RNAPII by the proteasome, could potentially take place in heterochromatin 
regions thereby reducing the chances for transcription to occur. In order to investigate this 
hypothesis, NIH3T3 cells were treated with DMSO or proteasome inhibitor MG132 at a final 
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concentration of 20μM for 4h and the levels of S5P-RNAPII and S2P-RNAPII were measured 
by ChIP-qPCR in various heterochromatic regions including major satellite, minor satellite, 
LINE L1 and SINE B1. Additionally primers against the promoter and gene body of the 
GAPDH gene were used as positive controls for S5P-RNAPII and S2P-RNAPII respectively and 
primers for MOG gene were used as a negative control for both forms of RNAPII.  
As expected, S5P-RNAPII and S2P-RNAPII were found to be enriched at the promoter and 
the gene body of GAPDH respectively with a small decrease upon proteasome inhibition 
(Figure 5.4) which is consistent with the downregulation of GAPDH expression albeit not 
statistically significant (data not shown). In contrast to GAPDH, the levels of both forms of 
RNAPII were lower at heterochromatic regions and the inactive MOG gene and virtually 
unaffected upon treatment of cells with proteasome inhibitor (Figure 5.4).  
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Figure 5.4: S2P-RNAPII and S5P-RNAPII binding on the heterochromatic repeats were 
unaffected by proteasome inhibition. NIH3T3 cells were treated with DMSO or MG132 at a 
final concentration of 20μM for 4h followed by ChIP-qPCR. Enrichment level is presented 
relative to input after background (no antibody) subtraction. Error bars SEM, n=4-7. 
 
 
To further validate these results, NIH3T3 cells were treated with DMSO or MG132 at a final 
concentration of 20µM for 4h followed by IF using DAPI and antibodies against S5P-RNAPII 
and S2P-RNAPII. The analysis of IF images showed that firstly the signals from S5P-RNAPII 
and S2P-RNAPII antibodies were largely excluded from heterochromatin domains identified 
by DAPI dense stained regions in both treated and untreated cells (Figure 5.5A, 5.6A). 
Secondly, while in the untreated cells the signal from S5P-RNAPII antibody was confined to 
the nucleus, the treatment of cells with proteasome inhibitor caused appearance of the 
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signal within the cytoplasm (Figure 5.5A). Lastly, the proteasome inhibition was found to 
increase the overall intensity for both phosphorylated forms of RNAPII within the nucleus 
(Figure 5.5B, 5.6B). This result is consistent with the western blot presented previously 
(Chapter 3, Figure 3.7) and a previous study (Kinyamu & Archer, 2007).  
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Figure 5.5: Immunofluorescence analysis for S5P-RNAPII upon proteasome inhibition. 
NIH3T3 cells were treated with MG132 at a final concentration of 20µM for 4h following by 
IF using DAPI and antibody against S5P-RNAPII. (A) Representative IF images. Scale bar 
10µM.  Arrows represent the signal coming from the cytoplasm. (B) Analysis of the mean 
nuclear intensity. Error bars SEM n = 332 and 508 cells for DMSO and MG132 respectively. 
AU represents Arbitrary Units. *p<0.05 (Student’s ‘t’ test) 
B 
* 
199 
 
   
            
 
Figure 5.6: Immunofluorescence analysis for S2P-RNAPII upon proteasome inhibition. 
NIH3T3 cells were treated with MG132 at a final concentration of 20µM for 4h following by 
IF using DAPI and antibody against S2P-RNAPII. (A) Representative IF images. Scale bar 
10µM (B) Analysis of the mean nuclear intensity. Error bars SEM n = 88 and 72 cells for 
DMSO and MG132 respectively. AU represents Arbitrary Units. *p<0.05 (Student’s ‘t’ test). 
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5.2.4 Proteasome inhibition induces activation of the cell stress response pathway in 
NIH3T3 cells  
Several studies have shown that proteasome inhibition induces cell stress and activates the 
heat shock pathway (Bush et al., 1997; Kawazoe et al., 1998; Stangl et al., 2002; Zaarur, 
Gabai, Porco, Calderwood, & Sherman, 2006). Considering that various cellular stresses 
were also shown in several human studies to activate the transcription of pericentromeric 
satellite repeats (Eymery, Horard, et al., 2009; Jolly et al., 1997; Rizzi et al., 2004; 
Valgardsdottir et al., 2008), it was hypothesized here that proteasome inhibition could 
potentially upregulate the transcription of murine major satellite repeats though activating 
the cell stress pathway.  In order to investigate this hypothesis, firstly it was essential to 
confirm the activation of the cell stress pathway with the concentration of the inhibitor and 
the duration of treatment used throughout this thesis in NIH3T3 cells. Therefore, NIH3T3 
cells were treated with proteasome inhibitor MG132 at a final concentration of 20µM for 
2h, 4h and 8h. Part of the sample was lysed and used to assess the activation of HSF1 by 
western blot; the remaining was used for RNA extraction followed by cDNA synthesis and 
qPCR with primers against mRNA transcript of heat shock protein HSP70 gene. Additionally 
NIH3T3 cells were treated with DMSO, 5μM, 10μM and 20μM of MG132 for 8h followed by 
RNA extraction, cDNA synthesis and qPCR with primers against mRNA transcripts of major 
heat shock proteins encoding genes HSP70 and HSP90.  
As illustrated in Figure 5.7A, activation of HSF1 indicated by an increase of the molecular 
size which is likely to occur due to the phosphorylation of HSF1, as previously shown 
(Metzler et al., 2003; Sarge, Murphy, & Morimoto, 1993) was already apparent from 2h of 
MG132 treatment and maintained at 4h and 8h of treatments. As HSF1 is a transcription 
factor required for transcriptional activation of heat shock protein genes (Kroeger, Sarge, & 
Morimoto, 1993; Morimoto, 1998; Sarge et al., 1993; Trinklein, Chen, Kingston, & Myers, 
2004), a dramatic time dependent increase of the expression of HSP70 was observed upon 
treatment of cells with proteasome inhibitor compared to the untreated control (DMSO) 
(Figure 5.7B). In addition, a highly significant dose-dependent upregulation of HSP70 and 
HSP90 expression were also detected upon treatment of cells with different concentrations 
of MG132 relative to untreated (Figure 5.7C).  
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These results confirm the activation of the cell stress pathway (also known as heat shock 
pathway) upon proteasome inhibition in NIH3T3 cells.  
 
 
Figure 5.7: Activation of the cell stress response pathway upon treatment of cells with 
proteasome inhibitor MG132. NIH3T3 cells were treated with 20μM MG132 for 2h, 4h and 
8h (A and B) as well as 5μM, 10μM and 20μM MG132 for 8h (C). (A) Activation of HSF1 
factor upon proteasome inhibition (see text): Total cell lysate was probed with antibody 
against HSF1 (~75kDa) and GAPDH (~38kDA) that was serving as a loading control. (B) Time-
dependent upregulation of HSP70 expression upon proteasome inhibition: Upon 4h and 8h 
of DMSO or 20μM MG132 treatment, RNA was extracted followed by q-RT-PCR with primers 
specific to HSP70 mRNA transcript. The relative expression was normalised against spike and 
fold change shown relative to DMSO. Error bars SEM, n=3. (C) Dose-dependent upregulation 
of HSP70 and HSP90 expression: Upon 5μM, 10μM and 20μM MG132 for 8h, RNA was 
extracted followed by q-RT-PCR with primer against HSP70 and HSP90 mRNA transcript. The 
relative expression was normalised against spike and fold change shown relative to DMSO. 
Error bars SEM, n=6. *p<0.05 (Student’s ‘t’ test).   
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5.2.5 Heat shock activates the transcription of major satellite repeats in NIH3T3 cells  
It was shown here that proteasome inhibition upregulated the expression of major satellite 
repeats (chapter 4) and could also activate the heat shock pathway (see above). Previous 
experiments by others had predominantly focused on the effect of the heat shock in 
upregulating the specific subset of pericentromeric satellite repeats in human cells. Here we 
examined, for the first time, whether heat shock itself could upregulate a range of repetitive 
elements in mice including the predominant pericentromeric major satellite repeats. 
Here NIH3T3 cells were heat shocked for 1h at 43oC or maintained at 37oC (control). The 
heat shocked cells were then returned to 37oC for 1h and 3h (recovery). From each time 
point (Control, Heat shocked, Recovery 1h, Recovery 3h) RNA was extracted followed by 
cDNA synthesis and qPCR with primers against heterochromatic regions of pericentromeric 
major satellite, centromeric minor satellite, retrotransposons LINE L1 and SINE B1. 
Furthermore the levels of HSF1, HSP70 and HSP90 mRNA transcripts were also examined by 
specific exon-exon junction primers.  
The results of the q-PCR analysis are illustrated in Figure 5.8. The expression of HSF1 was 
slightly increased (~1.3 fold) 1h immediately after the heat shock and was maintained at 
similar levels 1h after recovery before dropping to the initial levels at 3h of recovery (Figure 
5.8A). Furthermore, as expected, the expression of HSP70 was dramatically increased by ~80 
fold upon heat shock compared to the control and was subsequent reduced to ~30 fold 
after 1h of recovery and completely abolished by 3h of recovery (Figure 5.8B). Similarly to 
HSP70, HSP90 mRNA was significantly upregulated upon heat shock and sustained at similar 
levels 1h after recovery followed by some reduction at 3h of recovery. In contrast to HSP70, 
the levels of HSP90 transcripts were constantly maintained throughout the heat shock and 
the recovery time points were significantly higher relative to the control (Figure 5.8C). 
Interestingly, the heat shocked NIH3T3 cells specifically expressed the major satellite 
repeats ~ 2.7 fold higher compared to the control (Figure 5.8D) which is in agreement with 
previous studies of pericentromeric satellite repeat expression in human cells (Eymery, 
Horard, et al., 2009; Rizzi et al., 2004; Valgardsdottir et al., 2008).  Furthermore, the levels of 
major satellite transcripts were kept on average ~2 fold higher at 1h of recovery relatively to 
control and were reduced to the initial level only after 3h of recovery (Figure 5.8D). In 
contrast to the major satellite, the minor satellite and LINE L1 transcripts were reduced by 
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~10-20% during the heat shock and throughout the recovery periods compared to the 
control whereas SINE B1 remained unaffected (Figure 5.8D). In conclusion, of the repeats 
examined the upregulation in expression levels due heat shock was restricted to the major 
satellite repeat sequences. 
 
 
 
 See next page for figure legend 
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Figure 5.8: Effect of the heat shock on the expression of (A) HSF1, (B) HSP70, (C) HSP90 and 
(D) heterochromatic repeats including major, minor, LINE L1 and SINE B1. NIH3T3 cells were 
heat shocked for 1h at 43oC followed by 1h and 3h of recovery at 37oC. For each time point 
RNA was extracted and q-RT-PCR was performed. The relative expression was normalised 
against spike and is shown as fold change relative DMSO. HS indicates the Heat shock and 
RC represents the recovery. Error bars SEM, n=3 biological replicates. *p<0.05 (Student’s ‘t’ 
test).     
 
 
5.2.6 Suppression of the cell stress response abolishes the transcriptional activation of 
major satellite repeats upon proteasome inhibition   
Considering that the cell stress and more specifically activated HSF1 was shown to cause 
transcription of pericentromeric Satellite III repeats in the human cells (Jolly et al., 2004a; 
Valgardsdottir et al., 2008), investigation was needed to assess the potential role of the 
HSF1 transcription factor in transcriptional activation of the major satellite repeats upon 
proteasome inhibition in the mouse genome. Clearly, one way of investigating that would 
be to inhibit simultaneously HSF and the proteasome and observe its effect on transcription 
levels of major satellite repeats. So NIH3T3 cells were treated with either DMSO (vehicle) or 
proteasome inhibitor MG132 and HSF1 inhibitor Quercetin. Quercetin (3,3′,4′,5,7-
pentahydroxyflavone) is a flavonoid that suppresses the cell stress response in the presence 
of various stressors by affecting several steps of the HSF1 activation pathway, including 
hyperphosporylation, DNA binding and transcriptional activity (O. Gonzalez et al., 2009; M. 
V. Powers & Workman, 2007; Zanini et al., 2007).  
Initially Quercetin (100μM) was added to the culture medium of NIH3T3 cells and 4 hours 
later MG132 (20µM) was added. This was done in order to give some time for the HSF1 
inhibition to take place before the proteasome inhibition. After the addition of MG132, cells 
were treated for an additional 4 hours in the presence of both drugs. RNA was extracted 
followed by cDNA synthesis and transcript levels of the repeats were analysed by qPCR 
using the same primers for the DNA repeat sequences as in the previous experiments. 
Additionally, primers against mRNA transcripts of HSF1 and HSP70 were used as a control 
for the effect of the treatments.   
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The effects of both proteasome and HSF1 inhibition are shown in Figure 5.9A and 5.9B. The 
proteasome inhibition upregulated the expression of HSF1 by ~2.3 fold whereas Quercetin 
and concomitant treatment of cells with Quercetin and MG132 reduced the HSF1 transcript 
levels by 40% and 50% respectively relative to DMSO. Furthermore, the HSP70 mRNA 
transcript levels were found to be dramatically increased by ~530 fold with MG132 
treatment while simultaneous treatment of cells with Quercetin and MG132 showed only 
~44 fold increase compared to DMSO, resulting in 92% reduction in the expression of HSP70 
relative to MG132 treatment (Figure 5.9B).  
Importantly, while proteasome inhibition increased the major satellite transcripts level by 
~3.6 fold, concomitant treatment of cells with MG132 and Quercetin caused only ~1.5 fold 
increase relative to DMSO, which represents a similar level obtained by Quercetin treatment 
alone (Figure 5.9C). This result suggests that HSF1 is required for the transcriptional 
activation of major satellite repeats upon proteasome inhibition.  
Additionally a slight reduction of the level of minor satellite transcript was detected upon 
treatment of cells with Quercetin with further decrease with the combination of both 
proteasome and HSF1 inhibition. Lastly only minor changes were observed on the 
expression of LINE L1 and SINE B1 with all the treatments (Figure 5.9C). The results indicate 
that proteasome inhibition requires activation of HSF1 in order to specifically upregulate 
major satellite repeats expression.  
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Figure 5.9: The effect of HSF1 and proteasome inhibition on the expression of (A) HSF1, (B) 
HSP70 and (C) heterochromatic repeats. NIH3T3 cells were treated with proteasome 
inhibitor MG132 in the presence and absence of HSF1 inhibitor Quercetin (4h with 100μM 
Quercetin only followed by 4h with 20μM Mg132 + 100μM Quercetin). RNA was extracted 
followed by q-RT-PCR. The relative expression was normalised against spike and is shown as 
fold change relative DMSO. Error bars SEM, n=3 biological replicates. 
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5.2.7 HSF1 binds to major satellite repeats upon proteasome inhibition  
In order to investigate whether HSF1 transcription factor might operate directly at 
pericentromeric and centromeric heterochromatin regions, the canonical recognition 
sequence of the HSF1 was aligned to the major satellite and minor satellite consensus 
sequence respectively. Interestingly, the analysis of the alignment revealed a high homology 
of the HSF1 binding to a portion of major satellite repeat (Figure 5.10A, Supplementary 
figure S3), indicating that HSF1 transcription factor might directly associate with 
pericentromeric heterochromatin. In contrast, no apparent consensus HSF1 binding site was 
found within the minor satellite repeat expression of which is unaffected by proteasome 
inhibition (Supplementary figure S3).  
To further investigate the binding of HSF1 to major satellite repeats, NIH3T3 cells were 
treated with DMSO (control) or proteasome inhibitor MG132 at a final concentration of 
20μM for 4h followed by ChIP using antibody specific to HSF1. The immunoprecipitated 
material was analysed by qPCR with primers against major and minor satellite repeats as 
well as primer against the promoter regions of HSP70 which was used as a positive control 
for HSF1 binding as HSF1 has been shown previously to bind here (Abravaya, Phillips, & 
Morimoto, 1991; Fujimoto, Takii, Hayashida, & Nakai, 2015; Ostling et al., 2007; 
Westerheide et al., 2009). 
As expected, the treatment of cells with MG132 showed an enrichment of HSF1 on the 
promoter regions of HSP70 gene (Figure 5.10B). Importantly HSF1 enrichment was also 
found on the major satellite repeats upon proteasome inhibition whereas no signal was 
detected on the minor satellite repeats (Figure 5.10B). This result correlates well with the 
alignment analysis and indicates that HSF1 appeared to be recruited to pericentromeric 
heterochromatin through binding to the major satellite repeats upon proteasome inhibition.  
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Figure 5.10: Transcription factor HSF1 binds to major satellite repeats upon proteasome 
inhibition. (A) Alignment of a portion of the pericentromeric major satellite consensus 
sequence with the canonical binding sequence of the HSF1 transcription factor. (B) ChIP-
qPCR analysis of HSF1 binding on the major and minor satellite repeats upon treatment of 
NIH3T3 cells with DMSO or 20μM MG132 for 4h. The promoter region of HSP70 served as a 
control for HSF1 binding. ChIP signal is shown as enrichment relative to input after 
background (no antibody – see methods) subtraction. Error Bars represent SEM, n=3 
biological replicates.  
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5.2.8 Transduction of NIH3T3 cells enhance the activation of transcription of major 
satellite repeats upon proteasome inhibition   
So far, the results in this chapter suggest that transcriptional activation of major satellite 
repeats upon proteasome inhibition, are mediated by the transcription factor HSF1. The 
function of Quercetin was previously proposed to be cell-type specific as well as to depend 
on the type and the condition of stress applied (R. K. Hansen, Oesterreich, Lemieux, Sarge, & 
Fuqua, 1997). For example in HeLa, HepG2 and COLO 320DM cells, Quercetin was shown to 
(i) inhibit the DNA-binding of HSF1 to the HSE (ii) reduce the protein level of HSF1, 
predominantly of the phosphorylated form of HSF1 and (iii) reduce the expression of HSF1 
and HSF2 (Hosokawa et al., 1992; Nagai, Nakai, & Nagata, 1995; A. Sharma, Meena, & Bhat, 
2010). Quercetin has also been shown to inhibit several protein kinases (Levy, Teuerstein, 
Marbach, Radian, & Sharoni, 1984; Matter, Brown, & Vlahos, 1992). Therefore, in order to 
rule out potential non-specific effects of Quercetin, the effect of stable HSF1 knockdown, 
followed by treatment with proteasome inhibitor was examined in NIH3T3 cells.  
The stable HSF1 knockdown in NIH3T3 cells was performed by using 3 different lentiviral 
pGIPZ-HSF1 shRNA expression constructs. In parallel identical lentiviral vectors containing 
either a non-targeting ‘scrambled’-shRNA or an empty vector with no shRNA insertion were 
used as controls for the procedure. The shRNA expressing cells and the infection efficiency 
of lentivirus were monitored by fluorescence microscopy 48h after infection, as pGIPZ 
vectors contain TurboGFP and shRNA as part of a single transcript (Supplementary figures S4 
and S5). 
To assess the efficiency of the knockdown, HSF1 mRNA expression and protein levels were 
analysed in puromycin selected NIH3T3 cells. For the HSF1 mRNA expression analysis, RNA 
was extracted followed by cDNA synthesis and qPCR with primers against HSF1 mRNA 
transcript; the HSF1 protein levels were detected by western blot using antibody specific to 
HSF1. As illustrated in Figure 5.11A and 5.11B, q-RT-PCR and western blot data revealed that 
transduction with HSF1-shRNA 1, 2 and 3 resulted in similar decreases in HSF1 mRNA and 
protein levels by approximately 80%, 60% and 45% respectively compared to the uninfected 
control. On the other hand the levels of both HSF1 mRNA and proteins were largely 
unaffected by transduction with the scrambled shRNA and the empty vector (Figure 5.11A, 
5.11B).  
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Figure 5.11: HSF1 knockdown in NIH3T3 cells. (A) HSF1 mRNA expression levels in 
uninfected and in puromycin selected NIH3T3 cells analysed by q-RT-PCR after transduction 
with HSF1-specific shRNA (shRNA 1, 2, 3), scramble shRNA and empty vector. The relative 
HSF1 mRNA expression was normalised against spiked in RNA and is shown as fold change 
relative to uninfected control. Error bars represent SEM, n=3 biological replicates. (B) 
Representative image of HSF1 protein levels in uninfected and puromycin selected NIH3T3 
cells analysed by western blot after infection with HSF1-specific shRNA (shRNA 1, 2, 3), 
scrambled shRNA and empty vector. GAPDH served as a loading control.  
 
 
Having confirmed the HSF1 knockdown, uninfected NIH3T3 cells, HSF1 knockdown (HSF1 
shRNA 1, 2, 3) cells and controls with scrambled shRNA and empty vector were treated with 
DMSO or proteasome inhibitor MG132 at a final concentration of 20μM for 4h. RNA was 
extracted followed by cDNA synthesis and qPCR with primers against HSF1 and HSP70 mRNA 
transcript as well as major satellite repeat transcript.  Although the levels of HSF1 correlated 
well with the upregulation of HSP70 gene expression upon treatment of cells with MG132 
(Figure 5.12A, 5.12B), surprisingly no correlation was found between the extent of HSF1 
knockdown and the expression of major satellite repeats upon proteasome inhibition 
(Figure 5.12A, 5.12C). However, transduction and selection with puromycin for ~10 days of 
the control shRNA and empty vector both resulted in an increased response to MG132 
treatment relative to untransduced cells. So it is possible that in addition to the effect of 
HSF1 knockdown, the cells were already ‘primed’ by the stress of transduction for major 
satellite upregulation. Thus, the experiment is potentially confounded by this additional 
effect of transduction. Interestingly, similar but much less pronounced effects were seen 
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with HSP70 upregulation in the non-targeting controls. Thus the presence of MG132 
resulted in upregulation of major satellite repeat expression as shown in the previous 
chapter; however the levels were observed on average to be higher in all the lentivirus 
transduced cells, including HSF1 shRNA, Scramble shRNA and Empty Vector compared to 
uninfected cells (Figure 5.12C).  
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Figure 5.12: The effect of the HSF1 knockdown in the expression of major satellite repeats 
followed by treatment of NIH3T3 cells with proteasome inhibitor. NIH3T3 uninfected cells, 
HSF1 knockdown cells with HSF1 shRNA, scramble shRNA and empty vector were treated 
with DMSO or 20μM MG132 for 4h. The expression of (A) HSF1, (B) HSP70 and (C) major 
satellite were analysed by q-RT-PCT.  The levels of HSF1 and HSP70 served as a control for 
the knockdown and the function of HSF1. The relative expression was normalised against 
spike and is shown as fold change against uninfected with DMSO only treated, which was 
set as 1. Error bars represent SEM n=3 biological replicates. *p<0.05 (Student’s ‘t’ test).     
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5.2.9 The HSF1 knockout partially reduced the expression of major satellite repeats upon 
proteasome inhibition in immortalized mouse embryonic fibroblasts (iMEFs)  
Given that the knockdown experiment for HSF1 was partially confounded by non-targeting 
effects (see above) of the procedure is was decided to adopt a knockout approach. For this 
we collaborated with Professor A. Nakai (Japan) who kindly supplied us with immortalised 
MEF (iMEFs) derived from knockout and wildtype mice (see more in materials and 
methods). The absence of HSF1 in HSF1 null (-/-) iMEFs was confirmed by western blot 
(Figure 5.13A).  
RNA was extracted from the HSF1+/+ and HSF1-/- cells, followed by cDNA synthesis and 
qPCR with primers against various heterochromatin repeats including major satellite and 
minor satellite repeats, LINE L1 and SINE B1. No significant difference in the expression 
levels of major satellite repeat, LINE L1 and SINE B1 was revealed between wild type and 
HSF1 knockout cells (Figure 5.13B). However, on average a ~2 fold increase of the 
expression of minor satellite repeats was found in HSF1-/- compared to the wild type albeit 
not statistically significant (Figure 5.13B). Minor satellite upregulation was not seen with 
Quercetin treatment (see Figure 5.9C) or proteasome inhibition (see Figure 4.3, 4.8B) and 
was not investigated further.  
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Figure 5.13: The basal heterochromatic repeats expression levels in HSF1 wild type (+/+) and 
HSF1 null (-/-) iMEFs. (A) The HSF1 is absent in HSF1-/- iMEFs. Total cell lysate from HSF1+/+ 
and HSF1-/- was blotted with antibody against HSF1 and GAPDH that served as a loading 
control. (B) The expression levels of major satellite, minor satellite, LINE L1 and SINE B1 in 
HSF1+/+ and HSF1-/- cells analysed by RNA extraction followed by q-RT-PCR. The relative 
expression was normalised against GAPDH and is shown as fold change against HSF1+/+. 
Error bars represent SEM n=4 biological replicates. 
 
 
 
 
Next, the HSF1+/+ and HSF1-/- iMEFs were treated with DMSO (vehicle) or MG132 at a final 
concentration of 5μM, 10μM and 20μM for 4h. RNA was extracted, followed by cDNA 
synthesis and qPCR with primers against HSP70 and major satellite repeats. As expected, in 
the wild type cells, the expression of HSP70 was dramatically and dose-dependently 
increased upon treatment of cells with MG132, compared to the untreated control. On the 
contrary, in HSF1 knockout cells, the upregulation of HSP70 was completely abolished upon 
proteasome inhibition (Figure 5.14A). The transcriptional activation of major satellite 
repeats upon MG132 treatment was apparent in both wild type and HSF1 knockout cells as 
illustrated in Figure 5.14B. However, the level of this upregulation on average was 
approximately doubled in the wild type cells compared to the HSF1 knockout cells within 
each treatment concentration (Figure 5.14B), suggesting that HSF1 has a partial function on 
the regulation of the pericentromeric major satellite repeat transcription upon proteasome 
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inhibition.  Notably, in the wild type cells the major satellite repeat transcription was found 
to negatively correlate with the dose of the proteasome inhibitor, reaching ~19 -, 14 - and 
10 - fold increase with 5μM, 10μM and 20μM MG132 treatment respectively, relative to the 
untreated control (Figure 5.14B). On the contrary, in NIH3T3 cells the upregulation of the 
major satellite transcription upon proteasome treatment was shown to be dose–dependent 
(Figure 4.3). There is no clear explanation for this difference however it might reflect cell-
type specific differences. Nevertheless, deletion of HSF1 partially inhibited the upregulation 
of major satellite repeat expression upon proteasome inhibition. It is possible that other 
HSFs are responsible for the remaining upregulation seen, this is not the case for HSP70 (see 
discussion).     
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Figure 5.14:  The effect of the proteasome inhibition on the expression of (A) HSP70 and (B) 
major satellite repeats in wild type and HSF1 knockout cells. HSF1+/+ and HSF1-/- iMEFs 
were treated with DMSO or 5μM, 10μM and 20μM MG132 for 4h followed by RNA 
extraction and q-RT-PCR.  The relative expression was normalised against spike and is shown 
as fold change relative to DMSO. Error bars represent SEM n=2-3 biological replicates.  
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5.3 Discussion 
In this chapter, two hypotheses were proposed to explain the transcriptional activation of 
pericentromeric satellite repeats with proteasome inhibition. These hypotheses were: i) 
degradation of RNAPII by the proteasome and (ii) activation of heat shock pathway, which in 
turn facilitates expression of major satellite repeats. The next sections will discuss this in 
more detail.  
 
5.3.1 Does proteasome mediate the degradation of RNAPII at major satellite repeats 
leading to its transcriptional activation?  
As mentioned in chapter 3, the proteasome was shown to bind to the FXN gene and 
degrade the stalled S2P-RNAPII in the presence of expanded GAA repeats. In the chapter the 
total levels of S2P- and S5P RNAPII and their binding at heterochromatic repeats were 
analysed in the presence and absence of the proteasome inhibitor in order to assess 
whether a similar mechanism might operate to degrade RNAPII on repetitive DNA elements 
and thereby facilitate transcriptional silencing. Here, both S2P- and S5P-RNAPII were shown 
to accumulate by treating the cells with proteasome inhibitor, consistent with previous 
study (Kinyamu & Archer, 2007). This observed increase in the total levels of S2P and S5P-
RNAPII with proteasome inhibition could indicate prevention of degradation of both forms 
of RNAPII when inhibiting the catalytic proteasomal activity. Serine 5 phosphorylation of 
RNAPII was previously shown in vitro to inhibit polymerase ubiquitylation and further 
degradation (Somesh et al., 2005) suggesting that S2P-RNAPII is the target for proteasome-
dependent degradation at the RNAPII stalling site. This was consistent with the finding that 
S2P-RNAPII is apparently degraded by the proteasome at the RNAPII stalling site in the FXN 
gene (see chapter 4). Additional studies have also shown that RNAPII marked by S2P 
becomes a target for proteasome mediated degradation, which is an important process in 
transcription-coupled DNA repair (K. B. Lee et al., 2002; Somesh et al., 2007)..  In mammalian 
cells, ubiquitylation and degradation of hyperphosphorylated RNAPII was shown to be 
mediated by E3 ligases NEDD4 and Smurf1 (Anindya et al., 2007). Of note Anindya and 
colleagues analysed RNAPII with an antibody (4H8) which according to the authors 
recognises both phosphorylated and unphosphorylated RNAPII. However, some studies 
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argue against the specificity of this antibody, suggesting the monoclonal 4H8 antibody 
recognises only S5P-RNAPII (Alder et al., 2010; Stock et al., 2007). In addition, a fraction of 
ubiquitylated S5P-RNAPII mediated by BRCA1/BARD1 was shown to be degraded by the 
proteasome (Starita et al., 2005). Therefore, it is tempting to speculate that cells might have 
evolved different mechanisms to degrade stalled RNAPII, whether it is marked by S5P or 
S2P. At this point it is worth mentioning that not all the ubiquitylation pathways lead to 
RNAPII degradation (Daulny et al., 2008; K. B. Lee & Sharp, 2004; Mikhaylova et al., 2008). 
For example in yeast, RING finger ubiquitin-ligase Asr1 was shown to ubiquitylate S5P-
RNAPII resulting in ejection of Rpb4/7 subunits and inhibition of polymerase activity (Daulny 
et al., 2008). Alternatively, the accumulation of the hyperphosphorylated RNAPII could be 
attributed to inhibition/deactivation of the phosphatases that remove phosphate groups 
from RNAPII. Dephosphorylation of RNAPII CTD is catalysed mainly by (i) Ssu72 which 
targets specifically S5P and S7P- RNAPII (Hausmann, Koiwa, Krishnamurthy, Hampsey, & 
Shuman, 2005; Krishnamurthy, He, Reyes-Reyes, Moore, & Hampsey, 2004; Reyes-Reyes & 
Hampsey, 2007; D. W. Zhang et al., 2012) and (ii) Fcp1 which is specific for S2P-RNAPII (Cho, 
Kobor, Kim, Greenblatt, & Buratowski, 2001; Ghosh, Shuman, & Lima, 2008). In future 
experiments, to investigate whether the accumulation of S2P and S5P-RNAPII is due to 
effects of the proteasome inhibition on the stability and function of RNAPII CTD 
phosphatases, cells could be treated with phosphatase inhibitor concomitant with 
proteasome inhibitor followed by analysis of the levels of both forms of RNAPII within the 
nucleus.  
In contrast to an increase in total levels of S2P and S5P-RNAPII, the binding of both 
phosphorylated forms of RNAPII to pericentromeric major satellite repeats which was 
analysed by ChIP, were found to be unaffected by proteasome inhibition. Although this 
could be considered surprising, as upregulation these repeats was found to be dependent 
on RNAPII mediated transcription (chapter 4), one explanation for similar levels of RNAPII at 
pericentromeric repeats DNA would be that the proteasome inhibition resulted in increased 
kinetics of transcription which might not be detected by examining steady state levels. 
Another possible explanation could be due to the transcriptional activation of a relatively 
small fraction of the total amount of repeat units (~10 000 per each chromosome). Hence, 
detection of RNAPII by ChIP in such a small proportion of repeat units may not be possible 
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by ChIP. Furthermore the absence of S2P- and S5P-RNAPII from chromocentres which was 
analysed by IF after treatment of cells with proteasome inhibitor, would suggest that 
repeats are activated from the outer surface of the chromocentres. This is consistent with 
the RNA-FISH results shown in the previous chapter (chapter 4), where the majority of 
major satellite repeat transcripts were detected surrounding the chromocentres.  
The presence of the proteasome at major satellite repeats revealed by ChIP would support 
the hypothesis of RNAPII degradation. In contrast to the ChIP results presented here, 
proteomics of isolated chromatin segments (PICh), which is a protocol that directly detects 
the steady-state protein composition of the chromatin (Dejardin & Kingston, 2009), did not 
shown any specific enrichment of the proteasome subunits on the pericentromeric major 
satellite repeats in mouse ESCs (Saksouk et al., 2014). On the other hand, recruitment of the 
proteasome was previously shown at telomeres (Geng & Tansey, 2012), which is also 
predominantly repressed and consists of telomeric satellite repeats (Blackburn, 1991; 
Zakian, 2012). Furthermore, analysis by ChIP of proteasome binding in mouse thymocytes 
showed higher enrichment of the proteasome at heterochromatic repeats and inactive 
genes, compared to active genes (Yandim, 2012). Lastly, it is noteworthy that the absence of 
co-localisation of the proteasome with chromocentres determined by IF could indicate, 
similarly to RNAPII, that binding of the proteasome also occurs at the outer surface of the 
chromocentres. 
Based on the evidence presented in this chapter, it is not clear whether RNAPII is degraded 
by the proteasome at major satellite repeats and further studies are required in order to 
examine this hypothesis. As RNAPII needs to be ubiquitinated in order to be recognised and 
degraded by the proteasome (Anindya et al., 2007; Beaudenon et al., 1999; Harreman et al., 
2009; Ratner, Balasubramanian, Corden, Warren, & Bregman, 1998), one approach would 
be to knockdown the E3 ligases that were shown to add ubiquitin to RNAPII (eg. NEDD4, 
AIP4, Smurf1, Smurf2, WWP1, and WWP2) (Anindya et al., 2007; Ingham, Gish, & Pawson, 
2004) and analyse the transcript levels of major satellite repeats as well as ubiquitinated 
RNAPII. Furthermore, in yeast, disassembly and removal of ubiquitinated RNAPII from a DNA 
damage site which is followed by proteasome mediated degradation was shown to be 
facilitated by AAA ATPase Cdc48 and its adaptor proteins Ufd1, NP14, Ubx4/5 (Verma, 
Oania, Fang, Smith, & Deshaies, 2011). Considering that (i) degradation of RNAPII is 
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evolutionarily conserved and (ii) the process of removal of stalled RNAPII is similar between 
DNA–damage dependent and independent pathways (Karakasili et al., 2014), homologues of 
Cdc48 factors might also be present in mammalian cells and facilitate degradation of RNAPII 
at various regions of the genome. If such homologues are present in mammals, it would be 
interesting to investigate whether their activity is implicated in removal of ubiquitinated 
RNAPII from pericentromeric repeats. Finally recruitment of the proteasome to the 
pericentromeric chromatin and the effect on its inhibition could be further assessed by the 
Histone Association Assay (HAA) which is essentially western blot analysis of ChIP material 
which permits the quantification of the relative amount of cellular protein bound to 
chromatin (Ricke & Bielinsky, 2004).  
 
 
 
 
5.3.2 Proteasome inhibition partly upregulates major satellite repeat transcription by 
activating the heat shock stress pathway 
As mentioned in the introduction, various cellular stresses were previously shown to induce 
pericentromeric repeat transcription specifically in human cells (see Figure 1.11). Among 
them heat shock is the best studied and was shown in human cells to activate 
pericentromeric Satellite III transcription at 9q12 pericentromeric region of chromosome 9 
which in turn forms a central core for the formation of a nuclear stress body (see more in 
the general introduction). Notably Eymery and colleagues further demonstrated in 2010 
that secondary nuclear stress bodies could also arise from the transcription of 
pericentromeric Satellite II and Satellite III repeats at various chromosomes in heat shocked 
tumour cell lines (Eymery, Souchier, Vourc'h, & Jolly, 2010). Furthermore, heat-shocking 
both normal and cancer cell lines resulted in increased levels of pericentromeric satellite 
transcripts but no change in centromeric transcription was detected (Eymery, Horard, et al., 
2009). Consistently, in this thesis heat shock was shown to cause a marked increase of 
mouse pericentromeric major transcript levels whereas centromeric minor transcripts 
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remained largely unaffected or slightly decreased in mouse cells, indicating evolutionary 
conservation in the response to the heat shock. Similar to minor satellite repeats, 
retrotransposon LINE L1 elements were found to be unaffected. Furthermore, in contrast to 
previous studies (Allen et al., 2004; Fornace & Mitchell, 1986; T. H. Li, Spearow, Rubin, & 
Schmid, 1999; Mariner et al., 2008) where heat shock was shown to also upregulate both 
human Alu elements and mouse SINE B1 and SINE B2 transcription, no such effect was 
found in this thesis. One possible explanation for this discrepancy, at least in NIH3T3 cells 
could be due to the difference in the heat shock temperature, as a previous study (Allen et 
al., 2004) used a higher temperature (~3oC difference) to induce stress.  
Considering that the stress response is evolutionarily highly conserved among different 
species (Kultz, 2003, 2005), proteasome inhibition which is known to induce accumulation of 
misfolded proteins and activate the stress pathway (Boyault et al., 2007; Bush et al., 1997; 
Goldberg, 2003; Johnston et al., 1998; Kawazoe et al., 1998; Mathew et al., 1998; Obeng et 
al., 2006; Rao & Bredesen, 2004), which was also confirmed in this thesis, was analysed and 
shown to be largely responsible for transcriptional activation of major satellite repeats. 
Based on the data that (i) HSF1 binds to major satellite repeats, (ii) treatment of cells with 
both HSF and proteasome inhibitors reduces major satellite repeat upregulation and (iii) 
treatment of HSF1 knockout MEFs only partly induces transcriptional activation of major 
satellite repeats; it is tempting to speculate that HSF1 together with other HSFs (eg HSF2, 
HSF3) could mediate the expression of the pericentromeric repeats in mice upon 
proteasome inhibition. Interestingly, in human cells, HSF2 was shown to form a 
heterotrimer with HSF1 and activate Satellite III expression upon heat shock (Sandqvist et 
al., 2009).  Furthermore, the HSF3, present in mouse and absent in human cells, was shown 
to activate the expression of non-classical heat shock genes including the PDZ domain–
containing protein (PDZK3) in response to heat shock (Fujimoto et al., 2010). If HSF3 could 
bind to the major satellite repeat it would be another candidate.  
Curiously, knockdown of HSF1 presented in this thesis was not capable of inhibiting the 
upregulation of pericentromeric repeats in response to proteasome inhibition whereas HSF1 
knockout and inhibition of HSF could inhibit this response in mouse fibroblasts. One 
possibility is that in the knockdown experiment transduction of both controls with lentivirus 
resulted in persistent upregulation of repeat expression following proteasome inhibition 
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indicating that the cells may have primed an additional chronic stress pathway which 
circumvents the requirement for HSF1 in specifically upregulating the pericentromeric 
repeats. However at this point it is worth mentioning that in a previous study in human cells 
HSF1 knockdown inhibited heat-shock induced upregulation of pericentromeric repeats 
(Eymery, Horard, et al., 2009).    
The similarities between the chromatin structural changes that take place as a result of both 
heat shock and proteasome inhibition suggest a common mechanism. For example, in non-
heat shocked HeLa and MCF-7 cells HP1β and HP1α were found to be accumulated at 
chromocentres respectively, whereas in heat shocked cells HP1β and HP1α were shown to 
display a rather homogenous nuclear distribution (Eymery, Horard, et al., 2009; Velichko, 
Kantidze, & Razin, 2011).  This is consistent with the results presented in this thesis (chapter 
4), where proteasome inhibition induced clear delocalisation of HP1α from chromocentres. 
Notably, both HP1α and HP1β are known to be repressors of pericentromeric 
heterochromatin (Mosch et al., 2011). Another example comes from Drosophila 
melanogaster, where heat shock was shown to induce marked redistribution and 
concentration of H3S10P at heat shock genes which form microscopically visible puffs on 
polytene chromosomes while the levels of H3 and H4 acetylation marks were largely 
unaffected (Nowak & Corces, 2000). The authors suggested that H3S10P is required for 
transcriptional activation of heat shock genes. Consistently, in this thesis treatment of cells 
with proteasome inhibition did no substantially change the levels of H3 acetylation (chapter 
4). Considering that (i) H3S10P was shown to mediate HP1 disassociation from the 
chromatin (Fischle et al., 2005; Hirota et al., 2005) and (ii) proteasome inhibition was shown 
in this thesis to delocalise HP1 from chromocentres, it would therefore be interesting to 
analyse the levels of H3S10P in pericentromeric regions in the presence and absence of the 
proteasome inhibitor. On the other hand, extensive analysis of changes of the histone 
modifications after heat shock in HeLa and MEFs (Fritah et al., 2009) revealed strikingly 
different results from the heat-shock puffs on Drosophila melanogaster polytene 
chromosomes. More specifically Fritah and colleagues reported that in Hela cells and MEFs 
heat shock induces (i) global histone deacetylation, (ii) reduction of H3S10P and H4K20me3 
levels and (iii) no obvious changes on H3K4me2, H3K4me3, H3K36me1, H3K36me3, 
H3K9me1, H3K9me2, H3K9me3 levels. Similarly, in another study histone (H2A, H2B, H3, 
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and H4) acetylation levels were also increased in stress-induced HSF1 granules and no 
change was found in H3S10P levels (Jolly et al., 2004b). These differences might relate in 
some way to the structural differences between the polytene chromosomes versus human 
chromosomes (Alberts, 2002). With reference to the results presented here following 
proteasome inhibition the fibroblast derived cells showed no changes in histone 
modification in common with the Drosophila melanogaster studies rather than the human 
studies. Moreover, these changes were previously seen in HSF1 granules, where acetylation 
was analysed by immunofluorescence in human but not mouse cells (Jolly et al., 2004b). 
This agrees with the results presented here in that no such granules were detected in 
murine cells (data no shown). It is possible however, that the failure to detect histone 
acetylation by IF or ChIP in the studies presented here reflects the possibility that only a 
small fraction of the pericentromeric repeats are affected. A similar argument could be 
applied to the lack of change in most histone modifications found in human cells following 
heat shock.  
Further studies are required in order to confirm the role of HSFs in regulation of 
pericentromeric repeats in mice. For example, knockdown of HSF2 in HSF1 knockout mice 
would assess whether HSF2 is required for the activation of the repeat transcription. Finally 
it is noteworthy to mention that transcriptional activation of human Satellite III under 
osmotic stress was shown to be independent of HSF1 and dependent on TonEBP 
transcription factor (Valgardsdottir et al., 2008). That study suggested that different stresses 
activate transcription of pericentromeric repeats via distinct transcription factors as was 
suggested by our study of lentiviral transduction which seemed to result in bypass of HSF1 
dependent transcriptional activation of pericentromeric repeats following proteasome 
inhibition. Therefore, stress induced through inactivation of proteasome function could also 
operate through transcription factors other than HSFs.  
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Following on from the findings presented in Chapter 4 this chapter examined the molecular 
mechanisms whereby proteasome inhibition might lead to de-repression and 
disorganisation of pericentromeric heterochromatin. The main findings were as follows: 
 The proteasome was found by ChIP to bind to the pericentromeric repeats 
consistent with its potential role in regulating transcription e.g by degradation of 
stalled RNAPII.  
 Inhibition of the proteasome led to accumulation of RNAPII within the nucleus by 
immunofluorescent microscopy but there was no increase in RNAPII detectable by 
ChIP on pericentromeric repeats which argues against significant degradation of 
RNAPII at this location. However, this highlights the need for further investigation 
between RNAPII degradation and pericentromeric silencing.  
 Proteasome inhibition led to upregulation of pericentromeric repeat expression 
which was apparently dependent on activation of the heat shock pathway. 
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5.4 Contributions  
Theona Natisvili performed all the experiments. Ms Giulia Emanuelli helped acquiring 
confocal images. Lorenzo Orietti analysed the binding of HSF1 to major and minor satellite 
repeats.  
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CHAPTER 6: CONCLUSION 
In order to understand how heterochromatin is silenced in a mammalian system, this PhD 
study initially focused on the pathologically silenced FXN gene and then pursued silencing of 
classical heterochromatin elements, including pericentromeric, centromeric satellite repeats 
and LINE L1 and SINE B1 retrotransposons. 
Here, nicotinamide was shown to reduce the heterochromatic mark H3K9me3 at the 
pathologically silenced FXN gene and upregulate its expression in vivo in patients with FRDA. 
This study suggested that altering a chromatin state by targeting epigenetic modifiers such 
as HDACs could provide a potential therapeutic avenue for FRDA and potentially a range of 
other diseases where the chromatin state of a causative gene is altered (eg. Fragile X 
syndrome, myotonic dystrophy).  
Another interesting phenomenon explored in this thesis was the role of the proteasome in 
the regulation of the FXN gene in FRDA. Here the proteasome was found to bind along the 
FXN gene, which was further confirmed to be heterochromatinised in cells derived from 
FRDA patients. This binding was shown to be at higher levels in patient cells and is 
consistent with the hypothesis, that in FRDA, proteasomal degradation of a stalled RNAPII 
might contribute to pathological FXN silencing. Instead, it was found that inhibition of the 
proteasome downregulated FXN transcription in cell lines, whereas the expression of the 
gene remained largely unaffected by proteasome inhibition in mice. This result might be 
explained by differences in the inhibitor used, the dose and bioavailability. Therefore the 
transcriptional effects of proteasome function might be pleiotropic, causing not only 
degradation of stalled RNAPII but also efficient transcriptional elongation of the FXN gene as 
has been suggest in yeast studies. Furthermore, inhibition of proteasome function was 
shown to result in upregulation of pericentromeric repeats transcripts which was dependent 
on ongoing transcription and appeared to be independent of cell-cycle perturbations. This 
transcriptional activation was found to be accompanied by changes in heterochromatin 
structure including delocalisation of HP1α from chromocentres and disruption of 
chromocentre clusters. Further investigation revealed that the mechanism underlying 
repression of murine pericentromeric repeats was apparently dependent on activation of 
the heat shock pathway, analogous to what was previously shown for various cellular 
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stresses in activating sub-classes of pericentromeric repeats in human cells (Eymery, 
Callanan, et al., 2009; Eymery et al., 2010; Jolly et al., 2004b; Valgardsdottir et al., 2008). In 
this thesis the investigation was restricted to HSF1, which was shown previously to mediate 
heat shock dependent activation of sub-classes of pericentromeric repeats in human cells 
(Eymery, Callanan, et al., 2009; Eymery et al., 2010) and was shown to partly mediate 
transcription of murine pericentromeric repeats. However, as different stresses were 
suggested to activate different transcription factors (Valgardsdottir et al., 2008), other 
factors might also be activated by proteasome inhibition and mediate transcription of 
mouse pericentromeric repeats. Further studies are required to analyse this hypothesis.  
In summary proteasome inhibition was shown here to regulate both transcription of the 
FXN and c-myc genes and repression of pericentromeric heterochromatin the latter of which 
was at least partially dependent on an intact heat shock pathway.  The data presented here 
suggests a model whereby proteasome inhibition activates HSF1 which invades 
heterochromatin, evicts HP1α which leads to disaggregation of centromeric clusters and 
activation of transcription of pericentromeric repeats (Figure 6.1).  
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Figure 6.1: Model of pericentromeric major satellite repeat activation with proteasome 
inhibition. (A) Inhibition of the proteasome by MG132 results in accumulation of misfolded 
and ubiquitynated proteins causing the release of HSF1 from the HSF1-HSP90 complex 
followed by HSF1 activation. The activated HSF1 (trimer) binds to its binding sequence 
within the major satellite repeat unit causing the release of HP1α from pericentromeres 
which becomes more accessible to the transcriptional machinery. The figure represents 
HSF1 only although other HSFs may also be involved. (B) Proteasome inhibition by MG132 
results in disaggregation of chromocentres thereby causing alteration of centromeric 
clusters structure.  
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CHAPTER 7: MATERIALS AND METHODS 
 
7.1  Cell lines  
All cell lines were incubated at 37 °C in a humidified atmosphere of 5% CO2. 
 
EBV-transformed cell lines 
Epstein-Barr virus (EBV)-transformed human lymphoblastoid cell lines derived from healthy 
individuals or FRDA patients were used in chapter 3.  
GM14926: Healthy 38 years old Caucasian male, GAA repeat in normal range (6-34 repeats)  
GM15850: Caucasian male with no age of onset specified, harbours 650 and 1030 GAA 
repeats on either alleles, blood sample taken at the age of 13 (FRDA_1) 
GM16234: Caucasian female with onset at 20 years, harbour 580 and 1030 GAA repeats on 
either alleles, blood sample taken at the age of 39 (FRDA_2) 
All EBV cell lines were obtained from Corriell Cell Repositories indicating the repeat lengths 
for each cell line.  
Culture conditions: All EBV cells lines were routinely cultured in RPMI medium with L-
glutamine (PAA laboratories GmbH) supplemented with Foetal bovine serum (Sigma) (10% 
v/v), Penicillin/Streptomycin (GIBCO ®) (1% v/v) and GlutamixTM-I 100x (GIBCO ®) (1% v/v). 
The cell number was adjusted between 0.2-0.5 x 10^6 cells/ml during the culture.  
 
NIH3T3 cell line  
NIH3T3 which is a standard mouse embryonic fibroblast cell line were used throughout the 
Chapter 4 and 5. This cell line was a kind gift from Dr Phill Wise (Imperial College London) 
Culture conditions: NIH3T3 cells were routinely cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) with L--glutamine (PAA laboratories GmbH) supplemented with Foetal 
bovine serum (Sigma) (10% v/v), Penicillin/Streptomycin (GIBCO ®) (1% v/v) and 
GlutamixTM-I 100x (GIBCO ®) (1% v/v).  
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Immortalised MEF HSF1+/+ and HSF-/- 
The wild type (HSF1+/+) and HSF1 null (HSF1-/-) immortalised MEFs (iMEFs) were generated 
and kindly provided from Prof Akira Nakai, Yamaguchi University School of Medicine, Japan. 
More information regarding the cells can be found in (Takii et al., 2015a).  
Culture conditions: iMEFs were routinely cultured in DMEM medium with L--glutamine (PAA 
laboratories GmbH) supplemented with Foetal bovine serum (Sigma) (10% v/v), 
Penicillin/Streptomycin (GIBCO ®) (1% v/v) and GlutamixTM-I 100x (GIBCO ®) (1% v/v).  
 
HEK293T cell line  
Human Embryonic Kidney 293T cells were used for lentiviral production for the knockdown 
experiment. This cell line was provided by KC Tan Un at Hong Kong University. 
Culture conditions: HEK293T were cultured in DMEM medium with L--glutamine (PAA 
laboratories GmbH) supplemented with Foetal bovine serum (Sigma) (10% v/v), 
Penicillin/Streptomycin (GIBCO ®) (1% v/v) and GlutamixTM-I 100x (GIBCO ®) (1% v/v).   
 
 
7.2  Transgenic YG8 mice containing human frataxin transgene (hFXN) 
The YG8 frataxin transgenic mice were generated by rescuing frataxin null mice with YAC 
FRDA transgene which contains an entire FXN gene with GAA repeats. These mice have two 
copies of the FRDA gene with 90+190 repeats (Table 4). More details can be found in “GAA 
repeat instability in Friedreich ataxia YAC transgenic mice” by Al-Mahdawi et al., published 
in Genomics 2004 (Al-Mahdawi et al., 2004).  
 
Transgenic 
line 
YAC transgene 
integrity 
FRDA copy 
number 
Founder GAA 
repeat length(s) 
Range of GAA 
repeats in offspring 
YG8 Complete 2 190 + 90 <9 to 223 
Table 4: Analysis of FRDA YG8 transgenic mouse line. Adapted from (Al-Mahdawi et al., 
2004) 
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7.3  Primary cells - Isolation of human peripheral blood mononuclear cells (PBMCs) 
Human PBMCs were extracted from blood samples taken from FRDA patients and healthy 
individuals (full ethical approvals were obtained from the local ethics committees at the 
National Hospital for Neurology and Neurosurgery and the Hammersmith Hospital, London) 
using the Ficoll-Paque™ PLUS (GE Life Sciences). The blood samples (~ 10ml) were added 
into 50ml falcon tubes containing 10ml of Ficoll and the samples were centrifuged at 
1500rpm in a benchtop centrifuge for 15min at room temperature. The interface buffy-coat 
containing PBMCs were transferred into new falcon tubes, diluted 2 fold with sterile PBS 
and centrifuged at 350g in a benchtop centrifuge for 15min at room temperature. The 
supernatant was discarded and the PBMCs pellet was either fixed for chromatin 
immunoprecipitation or stored in -80oC for RNA extraction. Usually 1ml blood contained ~1-
1.5X10^6 PBMCs.  
 
 
7.4  Drug preparation and treatments 
All drugs were prepared under sterile conditions under a cell culture-hood. The final drug 
concentrations are mentioned in the main text. MG132 (Sigma) was dissolved in DMSO to 
prepare a 20mM stock solution. A-amanitin (Sigma) was dissolved as 1mg/ml in culture 
medium. DRB (Sigma) was dissolved in DMSO to prepare a 10mM stock solution. ActD 
(Sigma) was dissolved in DMSO as 10mg/ml. PS341 (Velcade®, 3020μM) was kindly provided 
in a sterile bottle (in physiological saline) by Hammersmith Hospital (London) pharmacy. 
Quercetin (Sigma) was dissolved in DMSO to prepare a 100mM stock solution.  
A total of 3X10^6 EBV-transformed human lymphoblastoid cells from lines GM14926, 
GM15850 and GM16234 (see above) were treated in 3ml culturing medium (1X10^6/ml). 
The NIH3T3 and iMEFs cell lines were initially seeded on coverslips in culture plates 
(0.5X10^6 cells in 60mm culture plate or 1.5X10^6 in 100mm culture plate) at least 20h 
before adding the drug directly into a confluent culture plate. All the cell line treatments 
were performed by incubating the cells at 37 °C in a humidified atmosphere of 5% CO2.  The 
treatment of YG8 mice with PS341 was performed by Dr Mark Pook at Brunel University and 
the frozen tissues were obtained and then analysed in this thesis.  
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7.5  Genotyping for gender determination in NIH3T3 and iMEFs  
For genotyping 1X10^6 cells were lysed after overnight incubation at 55°C shaker in lysis 
buffer. The following day the DNA was extracted using phenol/chloroform. The genomic 
DNA was analysed by PCR, using the Biotaq PCR kit (Bioline) with primers designed that 
specifically amplify a region on exon 1 of the exclusively male SRY gene. The sequence of the 
primer is shown in Supplementary table S3. The PCR conditions used were: pre-heat at 94oC 
for 2min, 30 cycles of 94oC for 3min, 58oC for 20 sec and 72oC for 2min. Samples were run 
on a 3% gel at 140V for ~30min. The 194bp band is present only in males (Supplementary 
figure S1).  
 
7.6  Phenol/chloroform DNA extraction  
The DNA containing sample was vigorously mixed with an equal volume of phenol: 
chloroform. The sample was then centrifuged at 13000 rpm for 15 min at room temperature 
(RT) to separate the aqueous phase containing the DNA from the organic phase containing 
the proteins. The upper aqueous layer was transferred into a new tube and the DNA was 
precipitated by adding one tenth of sample volume of 3M sodium acetate (NaOAc pH=7) 
and 2.5X of the volume of 100% ethanol. The sample was incubated at -80°C for at least 1 
hour followed by centrifugation at 13000 rpm for 30min at 4°C. The supernatant was 
discarded and the pellet was washed with 1ml of 70% ethanol. The sample was further 
centrifuged at 13000 rpm for 15min at 4°C and the pellet was air dried and resuspended in 
DEPC water. DNA concentration was assessed using NANODROP ® Spectrophotometer ND-
1000 with ND-1000 v3.3.1 software.  
 
 
 
7.7  Chromatin immunoprecipitation (ChIP) 
Chromatin Immunoprecipitation was performed on chromatin derived from EBV 
lymphoblastoid cell lines or human PBMCs using the fast ChIP protocol described in (Nelson, 
Denisenko, & Bomsztyk, 2006), whereas in NIH3T3 cells the ChIP protocol used was that 
described in (Stock et al., 2007) both with some modifications.  
 
235 
 
ChIP on EBV cells/PBMCs  
The chromatin in 18X10^6 EBV cells in 25ml RPMI medium was cross-linked by incubating 
with 1ml of 37% w/v formaldehyde (Sigma) (final concentration 1.42%) for 10min at RT. The 
cross-linking was quenched by adding 141μl of 1M glycine per 1ml culturing medium (final 
concentration of glycine 125mM) followed by 5min incubation at RT. The incubation was 
followed by centrifugation at 2000g, 5min at 4oC. The fixed cell pellet was washed 2X with 
cold PBS and stored at -80oC.  
PBMCs were isolated from human blood as described previously and resuspendend in PBS. 
The cross-linking was performed by adding 40μl 37% w/v formaldehyde per 1ml of PBS (final 
concentration 1.42%) and incubating for 15min at RT. The fixing was quenched by adding 
141μl of 1M glycine per 1ml culturing medium (final concentration of glycine 125mM) 
followed by 5min incubation at RT. The incubation was followed by centrifugation at 2000g, 
5min at 4oC. The fixed cell pellet was washed 2X with cold PBS and stored at -80oC.  
Lysis was carried out for both EBV cells and PBMCs by resuspending the pellet in 1ml IP 
buffer containing proteasome inhibitor cocktail and PMSF (IP++ buffer) and pipetting up and 
down several times. This was followed by centrifugation at 12000g for 2min at 4°C. The 
pellet was washed once more with IP+++ buffer. The nuclear pellet was then resuspended in 
1ml IP++ buffer and sheared by sonication with the Bioruptor (Diagenode) for 1h, high 
energy (with intervals of 30sec on, 30sec off).  Next, the sonicated chromatin was 
centrifuged twice at 12000g for 15min at 4℃. Sheared chromatin in supernatant was snap-
frozen in liquid nitrogen and stored at -80℃. The sonication efficiency was visualised by 
reverse crosslinking 100µl of sheared chromatin, DNA extraction using phenol/chloroform 
and run on a 1.5% agarose gel. 
For immunoprecipitation, specific amounts of different antibodies (Supplementary table S4) 
were added to 200μl aliquot of sheared chromatin. One 200μl aliquot was used as a no-
antibody mock IP in order to monitor the non-specific binding (background). Furthermore 
50μl of sonicated chromatin material (input) was stored in -20oC.  Binding efficiency of the 
antibodies to their target epitopes was enhanced by incubating the samples in Biorupter 
(Diagenode) for 45 min, low energy (with interval of 30sec on, 30 sec off). Subsequently 
each sample was centrifuged at 12000g for 10min at 4oC.  The top 180μl of material was 
mixed with pre -washed 50μl Dynabeads ® Protein G (Invitrogen) and incubated overnight 
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on a rotating wheel at 4oC. Next day, the beads bound to antibody-chromatin complexes 
were washed six times with IP buffer and the DNA was isolated using 110μl Chelex-100 (10% 
w/v) (BIO-RAD) per sample.  Beads bound to antibody-chromatin complex and Chelex-100 
was mixed gently and heated 2X at 95°C for 7min with vortex in between. Then the samples 
were centrifuged at 12000g for 2min 4oC and the 80μl supernatant was transferred into a 
new tube. 200μl of sterile water was added to the Dynabeads, vortex and centrifuged at 
12000 g for 2 minutes at 4oC. The supernatant (200μl) was pooled with that previously 
obtained to make a final total of 280μl of ChIP DNA. The pre-stored input sonicated 
chromatin material (50μl) was mixed with 150μl 100% ethanol, incubated for 2min at RT 
and centrifuged at 12000g for 10min at 4oC. The pellet was then washed with 1ml of 70% 
ethanol. Upon centrifugation at 12000g for 5min at 4oC, the supernatant was discarded and 
the DNA was purified by using 110μl Chelex-100 (10% w/v) in the same way as with the ChIP 
samples described above.  
The DNA obtained was analysed by quantitative real time polymerase chain reaction (qPCR).  
 
ChIP on NIH3T3 cells  
The chromatin in 1X10^7 NIH3T3 cells were fixed by adding 540µl of 37% w/v formaldehyde 
(Sigma) directly to the 150mm culture dish containing 20ml of DMEM medium (final 
concentration of formaldehyde 1%) and incubating for 10min at 37°C. The formaldehyde 
fixation was quenched by adding 2820µl 1M glycine (final concentration of glycine 125mM) 
and incubating for 5min at RT. The cells were then washed 3X with cold PBS before the lysis.  
Lysis was carried out by adding 10ml of Swelling buffer (the NP-40 concentration was 
increased from 0.1% to 2.5% compared to the original protocol) containing protease 
inhibitor cocktail and PMSF to the cells and incubating for 10min at 4°C. Next, cells were 
collected by scraping and lysed using a Dounce homogenizer with a “Tight” pestle (~250 
strokes). The lysed material was centrifuged at 3000g, for 5min at 4°C. The nuclear pellet 
was resuspended in 1ml Sonication buffer (containing protease inhibitor cocktail and PMSF ) 
and sheared by sonication using a Bioruptor (Diagenode) for 20min, high energy (with 
intervals of 0.5min on, 0.5 min off). The sonicated chromatin was centrifuged twice at 
15000g for 15min at 40C. Sheared chromatin in supernatant was snap-frozen in liquid 
nitrogen and stored in -80℃. The sonication efficiency was visualised by reverse crosslinking 
237 
 
50µl of sheared chromatin, DNA was extracted using phenol/chloroform and run on a 1.5% 
agarose gel. 
For Immunoprecipitation, specific amounts of different antibodies (Supplementary table S4) 
were added to 200μl aliquots of sheared chromatin. One 200μl aliquot was used as a no-
antibody mock IP in order to monitor the non-specific binding (background). Furthermore 
10μl of sonicated chromatin material (input) was stored in -20oC. Binding efficiency of the 
antibodies to their target epitopes was enhanced by incubating the samples in a Biorupter 
(Diagenode) for 40 min, low energy (with intervals of 30sec on, 30 sec off). Subsequently 
each sample was centrifuged at 12000g for 10min at 4oC. The top 180μl of material was 
mixed with pre-washed 50μl Dynabeads Protein G (Invitrogen) or pre-washed 50μl 
Dynabeads Protein M (Invitrogen) specifically for the S2P-RNAPII antibody and incubated 
overnight on a rotating wheel at 4oC. Next day, Protein G Dynabeads bound to antibody–
chromatin complexed was washed by rotating for 5min at 4oC with 1ml of Sonication buffer, 
1ml Wash buffer A, 1ml Wash Buffer B and two times with 1ml of TE Buffer. Protein M 
Dynabeads bound to antibody-chromatin complexes were washed by rotating for 5min at 
4oC with the following buffer: twice with 1ml Sonication buffer, once with 1ml IgM antibody 
wash buffer and twice with 1ml TE buffer. The recovery of DNA from the 
immunoprecipitated protein/DNA complexes was performed using the Ipure Kit (Diagenode) 
following the manufacturer’s instructions.  
The DNA obtained was analysed by qPCR.  
 
7.8 Total RNA extraction 
Total RNA from EBV lympoblastoid cell lines/PBMCs, NIH3T3 cell line, HSF1+/+ and HSF1-/- 
Immortalised MEFs and mouse cerebellum/heart tissues was isolated using TRIZOL® 
Reagent (Invitrogen).  
The EBV cells/PBMCs were collected by centrifuge and resuspended in 1ml of Trizol. For the 
RNA extraction from the NIH3T3 cells and immortalised MEFs, lysis was performed by 
adding Trizol directly into the culture dish (1 ml per 10 cm2).  For tissue samples, frozen 
tissue was homogenised using the IKA ultra-turrax T25 homogeniser with 1ml Trizol. Next, 
the samples were incubated at room temperature for 5 minutes. 200 μl chloroform per 1 ml 
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Trizol was added, mixed by 20sec shaking and incubated for 5 minutes at room 
temperature. Samples were then centrifuged at 12000g, for 15min at 4℃ and the aqueous 
phase was transferred to a fresh tube. The pink organic phase was used to extract protein 
when necessary. Next, 500µl of isopropanol per 1ml of Trizol was added to the retained 
aqueous phase, mixed by vortex and incubated at room temperature for 10 minutes. 
Followed the incubation, the samples were centrifuged at 12000g for 15min at 4°C. 
Supernatant was removed and the pellet was washed by adding 1ml of 70% ethanol per 1ml 
of Trizol. Samples were vortex and centrifuged at 7500g for 5min at 4°C. Supernatant was 
removed and the RNA pellet was briefly air dried, followed by DNase treatment using a DNA 
free kit (Ambion). This was performed by adding 40µl master mix containing 33µl RNase free 
water, 2µl Superase, 4µl 10X DNaseI buffer and 1µl DNaseI followed by 20-30 min 
incubation at 37℃. 4µl of inactivation reagent was then added and mixed with each sample, 
followed by incubation at room temperature for 2min and centrifuged at 10000g for 2min at 
4oC. 35µl supernatant containing isolated RNA was retained for cDNA synthesis. RNA 
concentration was assessed using a NANODROP ® Spectrophotometer ND-1000 with ND-
1000 v3.3.1 software. The quality of RNA was determined by running a 1% agarose gel. RNA 
was stored at -80°C. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 
7.9  Complementary DNA (cDNA) synthesis 
Total RNA isolated was reverse transcribed into transcribed into complementary DNA with 
ThermoScript kit (Invitrogen) following the manufacturer’s instructions. For each reaction, 
50-250ng of random hexamers (primer) and 2µl of 10mM dNTP mix was mixed with 2.2µg of 
RNA and sterile water was added to make total volume of 12ul. For all the samples treated 
with proteasome inhibitor, 0.03µg of a ‘spike’ RNA with a unique sequence (generously 
provided by N. Dillon) was added per reaction as previously described (Szutorisz et al., 
2006). The reaction mixture was incubated for 5 min at 65°C and then placed on ice. 
Subsequently 1µl sterile DEPC-treated water, 4µl of 5X cDNA synthesis buffer, 1µl of 0.1M 
DTT, 1µl of ThermoScriptTM reverse transcriptase (15U/µl) and 1µl RNAseOUT 
(ThermoFischer) were added to each reaction mix giving final volumes of 20µl. Next, the 
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samples were incubated at 25°C for 10 minutes, 50°C for 50 minutes, 5 minutes at 85°C and 
finally 30 seconds at 4°C. Samples were stored at - 20°C. cDNA samples were diluted 7 fold 
and analysed by qPCR.  
 
 
7.10  Quantitative real time polymerase chain reaction (qPCR) 
qPCR was performed to analyse products generated by chromatin immunoprecipitation 
(ChIP) using the SYBR® Green JumpstartTM Taq ReadyMixTM (Sigma-Aldrich®) or SensiMixTM 
(Bioline) in low-profile 96-well white PCR plates (BIORAD). A single qPCR reaction composed 
by 10μl of SYBR® Green JumpstartTM Taq ReadyMix (Sigma) or 10μl SensiMixTM, 5μl primer 
mix containing 1mM of specific forward primer and 1mM of specific reverse primer 
(detailed primer sequences are shown in supplementary tables S2, S3) and 5μl DNA sample 
giving a total volume of 20µl. cDNA samples were prepared in triplicate and ChIP samples in 
duplicate. The PCR reaction was run using Chromo4 DNA engine (MRJ) with Opticon 
Monitor 3 (BioRad) software. The following PCR programmes were used for specific 
purposes:  
 
qPCR program for ChIP analysis: 
Initial step:                  95℃      10min   (incubation) 
40 cycles:                    95℃      30sec    (denaturation) 
                                      58℃      30sec    (annealing) 
                                      72°C      30sec    (extension) 
                                      Plate Read 
                                      80°C       1sec     
                                      Plate Read    
                                      82°C       1sec     
                                      Plate Read       
                                      85°C       1sec 
                                      Plate Read      
Melting curve read from 70℃ to 96℃, read every 0.5℃ - hold 1sec   
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qPCR program for RNA expression analysis: 
Initial step:                  94℃       2min   (incubation) 
40 cycles:                    94℃      30sec    (denaturation) 
                                      58℃      30sec    (annealing) 
                                      72°C      30sec    (extension) 
                                      Plate Read 
                                      80°C       1sec     
                                      Plate Read    
                                      82°C       1sec     
                                      Plate Read       
                                      85°C       1sec 
                                      Plate Read      
Melting curve read from 70℃ to 95℃, read every 0.5℃ - hold 1sec   
 
At the end of the amplification reaction, the threshold was arbitrarily set on the linear part 
of the logarithmic scale and the cycle threshold (Ct) values were imported from Opticon 
Monitor 3 to MS excel software upon checking the melting curves.  
All the relative RNA expression analysis was calculated using delta/delta-Ct method, in 
which the obtained Ct values were normalised to spike or housekeeping genes GAPDH or 
HPRT. The RNA expression analysis for all of the samples treated with proteasome inhibitor 
MG132 were normalised to spike as the treatment of cells with proteasome inhibitor caused 
a clear reduction of the examined housekeeping gene (GAPDH, HPRT, BACTIN) expression 
(data not shown). For all the remaining samples, (including mouse treated with PS341) the 
Ct values were normalised to GAPDH or HPRT (clinical trial). Normalisation to spike or 
GAPDH/HPRT was used (i) to improve the accuracy of quantification and (ii) as an internal 
control to correct for potential differences in reverse transcription efficiency.  
The ChIP analysis was calculated using delta/delta-Ct method in which the obtained Ct 
values were normalised to histone H3 occupancy or input along the examined locus. This 
value was further subtracted from the signal obtained from the no-antibody control. For the 
clinical trial, to internally control for variation in ChIP efficiency, enrichment levels were 
normalised against those obtained from heterochromatic ALRsat repeats for H3K9me3 
whereas normalisation for H3 pan-acetylation was performed by using the average 
enrichment levels of active housekeeping genes GAPDH, ALDOA, HMBS and HPRT. 
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The RNA half-lives were calculated after normalising to housekeeping genes, using a 
nonlinear regression model of multi-phase exponential decay which was run on MS Excel 
(PC, 2011) to obtain the best fit parameters. Fitted values were then plotted in Python 
(version 3.5) along with actual values which were represented as dots with error bars. 
 
7.11  Analysis of frataxin protein  
The organic pink phase containing protein was obtained after Trizol extraction of RNA. 
Frataxin (FXN) protein was quantified using Frataxin Dipstick Assay Kit (Mitosciences), 
following the manufacturer’s instructions. Absolute FXN values were obtained as pg using a 
standard curve generated by the recombinant FXN protein (Mitosciences #MSF42). Total 
protein concentrations were analysed using QuantiPro™ BCA assay kit (Sigma). Final FXN 
protein values calculated as pg of FXN per 1 µg of total protein. 
 
7.12  Western blot  
For adherent cells (~3X10^6), culture medium was aspirated from the culture plate and cells 
were washed 1X with PBS. The lysis of cells was performed by adding 500μl RIPA buffer 
directly to the culture plate followed by incubation for 5min at 4oC. Next, cells were gently 
scraped off the plate using a cell scraper and the cell lysate was transferred to an Eppendorf 
tube. The tube was then centrifuged at 12000g for 15min at 4oC and the supernatant was 
collected and stored at -20oC.  
For EBV cell lines, 10X10^6 cells were transferred to an Eppendorf tube and washed 2X with 
PBS. The lysis of EBV cells was performed by resuspending the cell pellet in 500μl of ice cold 
lysis buffer followed by rotation for 10min at 4oC. The sample was centrifuged at 12000g for 
15min at 4oC and the supernatant was collected and stored in -20oC.  
The protein concentration for each sample was determined by Bradford dye colorimetric 
assay (Bio-rad), following the manufacturer’s instructions. The protein concentration was 
calculated based on a standard curve of Bovine Serum Albumin (BSA) dilution standards.   
For protein denaturation, lysate samples with specific amounts of protein were mixed with 
6X Laemmli buffer (Alfa Aesar) followed by incubation at 100°C for 10min. 5-10μg of protein 
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and 5-10μl of Precision Plus Protein Dual colour Standard (Bio-Rad) molecular weight 
marker were loaded on a Polyacrylamide Gel (SDS-PAGE gel). The gel was then run in 1X 
running buffer (Bio-Rad) at 150 Volts.  
When the electrophoresis was completed, the proteins were electrotransferred from the 
SDS-PAGE gel to 0.2μm nitrocellulose membrane (Bio-Rad) (for HSF1) or methanol pre-
washed PVDF membrane (GE Healthcare) (for HP1α and RNAPII) in the presence of Transfer 
buffer containing 0%-0.05% SDS. After transfer, the membrane was blocked in TBST+5% 
non-fat milk (for HSF1), PBST+5% non-fat milk (for HP1α), blocking buffer+5% non-fat milk 
(for RNAPII) for 1h at RT. Next, the membrane was incubated with an appropriate dilution of 
the primary antibody (Supplementary table 3) in TBST+5% BSA (for HSF1), PBST+5% non-fat 
milk (for HP1α) and blocking buffer+5% non-fat milk (for RNAPII) on a rocking platform 
overnight at 4oC. Next day, the membrane was washed 3 times for 15min at RT each with 
TBST (For HSF1), PBST (for HP1α) or 1h at RT with blocking buffer+5% non-fat milk (for 
RNAPII). Subsequently, the secondary antibody conjugated with Horse Radish Peroxidase 
(HRP) was added at an appropriate dilution (see supplementary table S4) in TBST+5% non-
fat milk (for HSF1), PSBT+5% non-fat milk (for HP1α), blocking buffer+5% non-fat milk (for 
RNAPII) and incubated for 1h at RT. Following incubation, the membrane was washed 3 
times for 15min at RT each with TBST (for HSF1), PBST (for HP1α) or 2 times for 30 min in RT 
with blocking buffer and PBST (for RNAPII). The presence of HRP on the membrane was then 
detected using ECL Plus Western Blotting Detection Reagents (GE Healthcare) using the 
manufacturer’s instructions. 
 
 
7.13  Propidium Iodide (PI) staining for cell cycle analysis  
Adhering cells were trypsinised, washed with PBS and 1X10^6 cells and were resuspendend 
in 100μl of PBS. Drop by drop, cells were added into 1ml of ice cold 70% ethanol (pre-stored 
at -20oC) and incubated overnight at -20oC. The following day, the sample was centrifuged at 
600g for 5min at 4oC and supernatant was discarded. The fixed cell pellet was washed once 
with PBS and centrifuged at 600g for 5min at 4oC. Subsequently, the pellet was resuspended 
in 250μl PBS containing 5μl RNAse A (10mg/ml) and incubated at 37oC for 30min. Then cells 
were washed with 1ml PBS, spun down and resuspended in 350μl Propidium Iodide (PI) 
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solution (50μg/ml) (Millipore). Cells were analysed with fluorescent activated cell sorter 
(FACS) LSR (10000 events per sample) and gated according to single-cell population and to 
DNA content representative of the cell cycle.  
 
 
 
7.14  Counterflow centrifugal elutriation  
Cell cycle separation was conducted using an elutriation system with JE-5.0 elutriator rotor 
(Beckmann Coulter Inc) equipped with Avanti J-26 XP centrifuge (Beckmann Coulter Inc) and 
a pump. This system consists of a device that uses constant centrifugal force and gradually 
increases the counterflow rate in order to separate cells based on their size, which 
correlates well with the cell cycle stage (Banfalvi, 2008).  
2X10^8 cells were harvested and washed twice with Elutriation buffer. In order to obtain a 
single cell suspension the cell pellet was resuspended in 40ml Elutriation buffer and passed 
twice through an 18-gauge needle (25G) syringe. Next, the sample was loaded into the pre-
assembled elutriation chamber. Throughout the elutriation process the centrifuge was 
maintained at a constant speed of 1700rpm at 4oC. To obtain elutriation fractions, the flow 
rate of the elutriation buffer (regulated by a pump connected to the chamber) was 
increased from 8ml/min to 20ml/min by 1ml/min increments. Consecutively 200ml effluent 
volumes were collected from the centrifuge for each flow rate and cells were pelleted by 
centrifugation at 300g for 5min at 4oC. To assess the quality of synchronization in each 
elutriated fractions, cells were stained with PI followed by FACS analysis (see above). Based 
on the cell cycle profile similarity, elutriation fractions were further pooled and categorised 
into 5 different fractions. From each fraction (i) RNA was isolated followed by q-RT-PCR 
and/or (ii) cells were stained by DRAQ5 followed by imaging using Imagestream. The 
experimental workflow is shown in Figure 7.1.  
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Figure 7.1: Experiment workflow for elutriation. NIH3T3 cells were harvested and 
fractionated by cell size using centrifugal elutriation. The different fractions obtained were 
pooled and categorised based on their cell cycle similarity which was measured by PI 
staining into 5 distinct fractions. From each fraction RNA was extracted followed by q-RT-
PCR or/and the cells were stained with DRAQ5 followed by imaging using Imagestream. The 
image was adapted and modified from (Ly et al., 2014) 
 
 
7.15  Immunofluorescence  
NIH3T3 cells were grown and treated when necessary, directly on coverslips placed into a 
culture plate. Subsequently coverslips were transferred from culture plate to petri dish and 
washed twice with cold PBS. To fix the cells, coverslips were incubated in 4% 
paraformaldehyde (PFA) diluted in PBS containing 0.1% (v/v) Triton X100 for 15 min at RT. 
Following incubation, the fixative was aspirated and coverslips were washed with 2XPBS for 
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three times and 1XPBS twice. Next, fixed cells were permeabilised with 0.5% (v/v) Triton 
X100 diluted in PBS for 30min at RT. This was followed by three washes in 1X PBS and 
incubation of coverslips in 20mM Glycine dissolved in PBS for 30min at RT. Then the non-
specific antibody binding sites were blocked by incubating the coverslips in PBS+ blocking 
solution for 1h at RT. Subsequently, cells on the coverslip were incubated with 80μl of 
primary antibody appropriately diluted (Supplementary table S4) in PBS+ in a dark 
humidified chamber overnight at 4oC. On the following day, the coverslips were washed by 
immersing in 3 consecutive cups containing PBS+. Next, cells were incubated in 
fluorochrome-conjugated (Alexa488 or Alexa568) secondary antibody diluted to the 
required concentration in 1XPBS for 1h at RT in a dark humidified chamber. Coverslips were 
washed by immersing in 9 consecutive cups containing PBS. Each washed coverslip was 
further incubated with DAPI diluted in 1:1000 in PBS for 15min at RT in the dark. Finally the 
coverslips were washed three times in 1XPBS for 3min each and mounted on the 
microscope slides using Vectashield mounting medium (Vector Laboratories).  
Images were acquired with Leica Microsystems SP5 confocal microscope and Leica FISH 
microscope. Analysis of images was performed by Fiji Image J software.  
 
 
7.16 RNA in situ hybridization (RNA-FISH)  
RNA in situ hybridization (RNA-FISH) was performed using ViewRNATM ISH Cell Assay kit 
(Affymetrix Panomics) following the manufacturer’s instructions. The images were acquired 
with a 63X oil-immersion lens using a Leica Microsystems SP5 confocal microscope. Analysis 
of images was performed by Fiji Image J software. 
RNA probe:  
Major satellite RNA probe set was designed and produced by Panomics (Affymetrix) probe 
developers. This probe was V00846 – Mouse Satellite DNA sequence – type 1 (conjugated 
with Alexa546).  
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7.17  Chromocentre cluster analysis by Imagestream X  
The ImageStreamX (Amnis, Seattle, Washington) is a combination of a flow cytometer and a 
digital fluorescence microscope that allows living cells to be directly imaged individually in 
suspension.  
5X10^5 cells were pelleted and washed twice in cold PBS containing 1mM EDTA and 0.02% 
(w/v) Sodium Azide (PBS++). Next cells were resuspended in 100µl of 1µM DRAQ5 dissolved 
in PBS++. Samples were placed on ice and kept in the dark until imaging. 20000 cells were 
collected at 40X magnification using 658nm laser wavelength.  Results were quantitated 
using the associated Image Data Exploration and Analysis software (IDEAS Amnis). After 
single cell and DRAQ5 fluorescence gating, the number of chromosome clusters per cell was 
determined by computing the intensity of localized bright spots within the image that were 
greater than 2.75 pixels in radius. Results were transferred to Microsoft Office Excel 2013, 
and plotted for analysis. Detailed analysis of the gating strategy is shown in Supplementary 
figure S2.  
 
 
7.18  Lentivirus-mediated short hairpin RNA (shRNA) knockdown  
HSF1 shRNAs, Scramble shRNA (unspecific shRNA) cloned into the pGIPZ vector as well as 
pGIPZ vector without any shRNA (GE Dharmacon) were provided as E.coli stock cultures. A 
single colony from each stock culture was picked and streaked on a different petri dish 
containing LB Agar growth medium supplemented with 100μg/ml Ampicillin. The petri 
dishes were incubated overnight at 30oC. Following incubation, a single colony was tooth-
picked from each dish and placed into a 15ml snap falcons containing 2ml Low salt LB 
medium supplemented with 100μg/ml Ampicillin and 25µg/ml Zeocin. Samples were 
incubated on a shaking platform overnight at 30oC. Next day, 500µl of each sample was 
used to extract the vector DNA using a MiniPrep kit (Qiagen) according to the 
manufacturer’s instructions. Constructs were then digested with SacII restriction enzymes 
and run out on a gel. If the digestion pattern was as expected (band sized:  1259 bp, 2502 
bp, 7927 bp), 500µl of “snap” culture samples were transferred into 2L flasks containing 
500ml Low salt LB with 100μg/ml Ampicillin. Cultures were then incubated on a shaking 
platform (~150rpm) overnight at 30oC. The following day samples were centrifuged at 5000 
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rpm for 15min at 4oC. The constructs were purified using High-speed Maxi extraction kit 
(Qiagen) following the manufacturer’s instructions and further checked via SacII digestion.  
Lentivirus particles were produced in the HEK293T cell line culture in 100mm culture dishes. 
The transfection of HEK293T cells was performed using transfection mix containing 20µg of 
construct, 2µg of the envelope vector (pMD2.G), 8µg of packaging vector (psPAX2) and 90µl 
of polymer PEI (1mg/ml) in a final volume of 1ml. The mix was initially incubated for 20min 
at RT before adding to HEK293T cells. Cells were then incubated with transfection mix for 5h 
at 37oC. Following incubation, the mix was replaced with fresh DMEM culture medium and 
incubated overnight at 37oC. The following day medium was again replaced with 8ml of 
fresh DMEM culture medium. 48h after transfection, cells were examined for GFP under the 
fluorescence microscope (Supplementary figure S4) and if a green signal was detected, the 
medium from culture dish was collected and filtered in a 0.45μm filter. ~7 ml of virus 
containing medium was supplemented with PEG to a final concentration of 8μg/ml. The mix 
was used to transduce NIH3T3 cells cultured in a 6-well plate (~1X10^5 cells per well). After 
an overnight incubation, the medium was replaced. 48h after infection, cells were examined 
for GFP under the fluorescence microscope (Supplementary figure S5) and if green signal 
was detected, transduced cells were then selected with 2µg/ml of puromycin.  
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7.19  Materials and Reagents  
1X Phosphate buffered saline (PBS): 171mM NaCl, 3.3M KCl, 10.1mM Na2PO4, 1.8 mM 
KH2PO4 
Tris-buffered saline (TBS): 50 mM Tris-Cl, pH 7.5, 150 mM NaCl 
Lysis buffer for genotyping: 0.1M Tris HCl (pH 8.0), 5mM EDTA (pH 8.0), 0.2M NaCl, 0.2% 
SDS, proteinase K (Roche,200 μg/ml, freshly added each time) 
IP buffer: 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, NP-40 (0.5% vol/vol), Triton 
X-100 (1.0% vol/vol). When necessary, add freshly 0.5μl P8430 Protease inhibitor cocktail 
(Sigma) and 5μl 0.1M PMSF in isopropanal per 1 ml of IP buffer.  
Swelling buffer: 25 mM HEPES pH 7.9, 1.5 mM MgCl2 , 10mM KCl, 2.5% NP-40. Adjust pH to 
7.9. When necessary, add freshly 0.5μl P8430 Protease inhibitor cocktail (Sigma) and 5μl 
0.1M PMSF in isopropanal per 1 ml of Swelling buffer.  
Sonication buffer: 50 mM HEPES pH 7.9, 140 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% 
Na-deoxycholate, 0.1% SDS. Adjust pH to 7.9. When necessary, add freshly 0.5μl P8430 
Protease inhibitor cocktail (Sigma) and 5μl 0.1M PMSF in isopropanal per 1 ml of Sonication 
buffer. 
Wash buffer A: 50 mM HEPES pH 7.9, 500 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% Na-
deoxycholate, 0.1% SDS. Adjust pH to 7.9  
Wash buffer B:  20 mM Tris pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Na-
deoxycholate. Adjust pH to 8.0. 
IgM antibody wash buffer: 2 mM Tris pH 8.0, 0.02 mM EDTA, 50 mM LiCl, 0.1% NP-40, 0.1% 
Na-deoxycholate. Adjust pH to 8.0  
TE buffer: 10 mM Tris pH 8.0, 1mM EDTA 
RIPA buffer: 50mM Tris pH 8.0, 150mM NaCl, 0.5% Na-deoxycholate, 1% NP-40, 0.1% SDS. 
Freshly were added 0.5μl P8430 Protease inhibitor cocktail (Sigma) and 5μl 0.1M PMSF in 
isopropanal per 1 ml of RIFA buffer.  
Lysis buffer (western blot): 50mM Tris-HCl pH 7.5, 1mM EDTA, 10% glycerol, 50mM NaF, 
5mM sodium pyrophosphate, 1% Triton. Add freshly 1mM DTT (stock 1M, 1:1000 dilution), 
0.1mM PMSF (stock 0.1M, 1:1000 dilution), Na3VO4 in a 1:100 dilution.  
Running buffer: 25 mM Tris pH8.3, 190 mM glycine, 0.1% SDS 
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Transfer buffer: 25mM Tris pH 8.3, 190mM glycine. Add freshly 20% (v/v) methanol and if 
necessary 0-0.05% (v/v) SDS.  
Blocking buffer: 10mM Tris HCl pH8, 150mM NaCl, 0.1% Tween 20  
PBST: 0.1% (v/v) Tween 20 in 1X PBS 
TBST: 0.1% (v/v) Tween 20 in 1X TBS 
Elutriation buffer: 3.4mM EDTA and 1% FBS in 1X PBS.  
PBS+ Blocking Solution: 1%BSA, 10% Casein, 5% Fish Skin Gelatin in 1X PBS. pH7.8-8.  
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SUPPLEMENTARY FIGURES 
Supplementary figure 1   
 
 
Figure S1: Sex determination in (A) NIH3T3 cells and (B) HSF1+/+ and HSF1-/- iMEFs. Lane 
ladder represent DNA size marker (MassRuler, Fermentas); lane (-) control represent the 
negative control (reaction with all the reagents except the genomic material); lane 
(+)control represent a positive PCR reaction from the genomic DNA derived from a known 
male mouse. The presence of 194bp band indicated male sex SRY gene (NIH3T3 and HSF1-/-
), whereas the absence of the band shows female (HSF1+/+) sex.  
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Supplementary figure 2 
 
       
 
     
 
Figure S2: Gating strategy for the ImageStreamX analysis. The single cell population was 
gated, followed by gating of focused cells and further gating of stained cells. The number of 
chromocentres was determined by computing the intensity of localized bright spots within 
the image that were 2.75 pixels in radius. Results were transferred to Microsoft Office Excel 
2013 and plotted for analysis. 
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Supplementary figure 3  
        
 
 
 
 
 
Figure S3: Alignment of a portion of (A) pericentromeric major satellite and (B) centromeric 
minor satellite consensus sequence with the canonical binding sequence of the HSF1 
transcription factor. Capital letters define the most important bases and n=T, C, A or G. 
 
A 
B 
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Supplementary Figures 4 and 5 
 
               
                
Figure S4: Representative images of the HEK293T transfection with shRNA vector containing 
GFP gene for assessing the efficiency of transduction. The GFP signal was checked 48h after 
transfection by fluorescence microscope.  
 
 
 
   
Figure S5: Representative images of NIH3T3 cells after lentiviral infection. The GFP signal 
was checked 48h after infection by fluorescence microscope.  
 
 
 
 
       Brightfield                                 GFP                             Brightfield and GFP 
              Brightfield                                     GFP                               Brightfield and GFP 
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SUPPLEMENTARY TABLES 
Supplementary table 1: A summary from chromatin features of the FXN gene. Adapted and 
modified from (Yandim et al., 2013).   
Region 
Paper  
Promoter/5UTR Upstream of GAA repeats Downstream of GAA 
repeats 
Li et al., 2015 
 
 Fibroblast cell line  
H4K5ac  
H4K20me1  
H4K20me3  
Fibroblast cell line  
H4K5ac  
H4K20me1  
H4K20me3  
Evans-Galea et al., 2012  
 
Human Primary cells 
DNA methylation   
Human Primary cells 
DNA methylation  
Human Primary cells 
DNA methylation  
Kim et al., 2011 
 
Lymphoblastoid cell lines  
H3K4me2  
H3K4me3  
H3K36me3  
H3K79me2   
H3K9ac  
H3K14ac  
H3K9me3  
H4K20m3  
H3K27me3  
Lymphoblastoid cell lines  
H3K4me2  
H3K4me3  
H3K36me3  
H3K79me2  
H3K9ac  
H3K14ac  
H3K9me3  
H4K20m3  
H3K27me3  
 
HEK293 cell line inserted with 
GFP_(GAA)^  construct  
H3K9ac  
H3K14ac  
H3K9me3  
H3K4me3  
H3K79me2  
Lymphoblastoid cell lines  
H3K4me2   
H3K4me3   
H3K36me3  
H3K79me2  
H3K9ac  
H3K14ac  
H3K9me3  
H4K20me3  
H3k27me3  
 
HEK293 cell line inserted 
with GFP_(GAA)^  construct 
H3K9ac  
H3K14ac  
H3K9me3   
H3K4me3   
H3K79me2  
Kumari et al .  2011 
 
Lymphoblastoid cell lines  
H4K16ac  
H4K5ac  
H3K9ac  
H3K14ac  
H3K4me2  
H3K36me3  
Lymphoblastoid cell lines  
H4K16ac  
H4K5ac  
H3K9ac  
H3K14ac  
H3K4me2  
H3K36me3  
Lymphoblastoid cell lines  
H4K16ac  
H4K5ac  
H3K9ac  
H3K14ac  
H3K4me2   
H3K36me3  
Punga et al., 2010 
 
 
 
Lymphoblastoid cell lines  
H3K9me3  
H3K4me2     
H3K36me3   
Lymphoblastoid cell lines  
H3K9me3  
H3K4me2   
H3K36me3  
Lymphoblastoid cell lines  
H3K9me3   
H3K4me2  
H3K36me3  
De Biase et al., 2009 
 
 
FRDA Fibroblast cell line  
H3K9me3  
H3K27me3  
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Al-Mahdawi et al., 2008  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human Brain tissue  
DNA methylation   
H3K9ac  
H3k14ac  
H4K5ac   
H4K8ac   
H4K12ac   
H4K16ac  
H3K9me2  
H3K9me3  
 
Human Heart tissue  
DNA methylation  
 
 
 
 
 
 
FXN transgenic mouse brain 
tissue  
DNA methylation   
H3K9ac  
H3K14ac   
H4K5ac  
H4K8ac  
H4K12ac  
H4K16ac  
H3K9me2   
H3K9me3  
 
FXN  transgenic mouse 
heart tissue  
DNA methylation  
Human Brain tissue   
DNA methylation  
H3K9ac   
H3K14ac   
H4K5ac   
H4K8ac  
H4K12ac   
H4K16ac  
H3K9me2  
H3K9me3  
 
Human Heart tissue  
DNA methylation  
 
Human cerebellar tissue 
DNA methylation  
 
FXN transgenic mouse 
cerebellar tissue  
DNA methylation  
 
FXN transgenic mouse brain 
tissue  
DNA methylation  
H3K9ac  
H3K14ac  
H4K5ac  
H4K8ac  
H4K12ac  
H4K16ac   
H3K9me2  
H3K9me3   
 
FXN transgenic mouse heart 
tissue  
DNA methylation  
Human Brain tissue    
DNA methylation  
H3K9ac   
H3K14ac   
H4K5ac   
H4K8ac   
H4K12ac   
H4K16ac   
H3K9me2   
H3K9me3  
 
Human Heart tissue  
DNA methylation  
 
 
 
 
 
 
FXN transgenic mouse brain 
tissue  
DNA methylation  
H3K9ac  
H3K14ac  
H4K5ac  
H4K8ac  
H4K12ac  
H4K16ac   
H3K9me2   
H3K9me3   
 
FXN  transgenic mouse heart 
tissue 
DNA methylation  
Soragni et al 2008  
 
 HEK293 cell line inserted with 
GFP_(GAA)^  construct  
H3K9ac  
H3K14ac  
H4K5ac  
H4K8ac  
H3K9me3   
HEK293 cell line inserted 
with GFP_(GAA)^  construct  
H3K9ac  
H3K14ac   
H4K5ac  
H4K8ac  
H3K9me3  
Herman et al., 2006 
 
Lymphoblastoid cell lines  
H3K9ac   
H3K14ac  
H4K5ac  
H4K8ac  
H4K12ac  
H4K16ac  
 
Lymphoblastoid cell lines  
H3K9ac  
H3K14ac  
H4K5ac  
H4K8ac  
H4K12ac  
H4K16ac  
H3K9me1  
H3K9me2  
H3K9me3  
Lymphoblastoid cell lines  
H3K9ac  
H3K14ac  
H4K5ac  
H4K8ac  
H4K12ac   
H4K16ac  
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Supplementary table 2: List of primers for Chapter 2 and 3 
Purpose Primer name primer sequence (5' to 3') 
RNA expression FXN_F (clinical trial) 
FXN_R (clinical trial) 
CCCGCCGCGCAAGTTC 
CTGCAAGGTCTTCAAAAAACTCTG 
FXN_F  
FXN_R  
ATGTCTCCTTTGGGAGTGGTGTCT 
CCCAGTCCAGTCATAACGCTTAGGT 
Primary FXN_F 
Primary FXN_R 
AGCCCCACATTCTCAGACAC 
ACGCACCAAAGGGTAACTTG 
YG8 mouse FXN_Ex3Ex4_F 
YG8 mouse FXN_Ex3Ex4_F 
ATGTCTCCTTTGGGAGTGGTGTCT 
CCCAGTCCAGTCATAACGCTTAGGT 
Human GAPDH_F 
Human GAPDH_R 
GGAGCGAGATCCCTCCAAAAT 
GGCTGTTGTCATACTTCTCATGG 
c_MYC_F 
c_MYC_R 
AAACACAAACTTGAACAGCTAC 
ATTTGAGGCAGTTTACATTATGG 
Mouse GAPDH_F 
Mouse GAPDH_R 
AACTTTGGCATTGTGGAAGG 
ACACATTGGGGGTAGGAACA 
Major_F 
Major_R 
GACGACTTGAAAAATGACGAAATC 
CATATTCCAGGTCCTTCAGTGTGC 
Minor_F 
Minor_R  
CATGGAAAATGATAAAAACC 
CATCTAATATGTTCTACAGTGTGG 
HPRT_F 
HPRT_R 
CCCTGGCGTCGTGATTAGT 
GAGCACACAGAGGGCTACAA 
Spike_F 
Spike_R 
GAGGGCCATACATGGTGGT 
CTCTAACCACTGGCGCCTTA 
ChIP 
 
 
 
 
 
 
ChIP 
FXN_UpsP1_F 
FXN_UpsP1_R 
GGGATTTCTTTTCCCCAGAG 
ACCTTGCAGGACACCAAAAC 
FXN_U2_F 
FXN_U2_R 
CCCCACATACCCAACTGCTG 
GCCCGCCGCTTCTAAAATTC 
FXN_Ex1_F 
FXN_Ex1_R 
GGAGCAGCATGTGGACTCTC 
CGGCGCGGATACTTACTG 
FXN_IntP1_F 
FXN_IntP1_R 
CTCCCGGTTGCATTTACACT 
GTGACAAGCATGGAGACAGC 
FXN_IntP2_F 
FXN_IntP2_R 
CTGACCCGACCTTTCTTCCA 
TGGGCGTCACCTTTATCTTC 
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FXN_IntP3_F 
FXN_IntP3_R 
GAAACCCAAAGAATGGCTGTG 
TTCCCTCCTCGTGAAACACC 
FXN_IntP4_F 
FXN_IntP4_R 
CTGGAAAAATAGGCAAGTGTGG 
CAGGGGTGGAAGCCCAATAC 
FXN_IntP5_F 
FXN_IntP5_R 
CCCTTGCACATCTTGGGTAT 
GAGAAAAGGGTGGGGAAGAG 
FXN_IntP6_F 
FXN_IntP6_R 
AGCCCCACATTCTCAGACAC 
ACGCACCAAAGGGTAACTTG 
β_globin_F 
β_globin_R 
GCTGGTGGTCTACCCTTGGA 
AGGTTGTCCAGGTGAGCCAG 
GAPDH_ChIP_F 
GAPDH_ChIP_R 
CACCGTCAAGGCTGAGAACG 
ATACCCAAGGGAGCCACACC 
ALDOA_F 
ALDOA_R 
CTCCTCCCTGAAGAGCCTTT 
CCCTGCCCAACTTCAAATAG 
HMBS_F 
HMBS_R 
CTCTGCGGAGACCAGGAGT 
CGCTTGGAAAGTAGGCTGTG 
HPRT_ChIP_F 
HPRT_ChIP_R 
CCCTCAGGCGAACCTCTC 
CTGACTGCTCAGGAGGAGGA 
ALRsat_F 
ALRsat_R 
AACTCACAGAGTTGAACGATCC 
ACCTCAAAGCGGCTGAAAT 
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Supplementary table 3: List of primers for Chapter 4 and 5 
 Primer name primer sequence (5’ to 3’) 
Genotyping 
 
SRY_F 
SRY_R 
GCAGGTGGAAAAGCCTTACA 
GTCCCACTGCAGAAGGTTGT 
RNA expression  
 
 
Spike_F 
Spike_R 
GAGGGCCATACATGGTGGT 
CTCTAACCACTGGCGCCTTA 
GAPDH_F 
GAPDH_R 
AACTTTGGCATTGTGGAAGG 
ACACATTGGGGGTAGGAACA 
c_MYC_F 
c_MYC_R 
GCCCAAATCCTGTACCTCGTCC 
CTCTTCTCCACAGACACCACATCA 
HSP70_F 
HSP70_R 
GGTGGTGCAGTCCGACATG 
TTGGGCTTGTCGCCGT 
HSP90_F 
HSP90-R 
AAAGGCAGAGGCTGACAAG 
AGGGGAGGCATTTCTTCAGT 
HSF1_F 
HSF1_R 
TGCTGGACATTCAGGAGCTT 
AAGTAGGAGCTCTCCCCCAG 
ChIP   
 
promoter GAPDH_F 
promoter GAPDH_R 
AGTCCGTATTTATAGGAACCCGGATGGTGG 
ATGAGAGAGGCCCAGCTACTCGCGGCTTTA 
gene body GAPDH_F 
gene body GAPDH_R 
GAGCCCTCCCTACTCTCTTGAAT 
ACACCGCATTAAAACCAAGGA 
MOG_F 
MOG_R 
AATATCTGGCAAGGGTGACG 
TATGGTTACCGGGGACAGAG 
HSP70_F 
HSP70_R 
CACCAGCACGTTCCCCA 
CGCCCTGCGCCTTTAAG 
RNA and ChIP  Major_F 
Major_R  
GACGACTTGAAAAATGACGAAATC 
CATATTCCAGGTCCTTCAGTGTGC 
Minor_F 
Minor_R 
CATGGAAAATGATAAAAACC 
CATCTAATATGTTCTACAGTGTGG 
LINEL1_F 
LINEL1_R 
TTTGGGACACAATGAAAGCA 
CTGCCGTCTACTCCTCTTGG 
SINEB1_F 
SINEB1_R 
GTGGCGCACGCCTTTAATC 
GACAGGGTTTCTCTGTGTAG 
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Supplementary table 4: List of Antibodies 
Antibody/clone name Purpose Company cat # 
Histone H3 ChIP (6μg per sample) Abcam  Ab1791 
H3K9me3 
 
ChIP (6μg per sample)  
IF (1:100) 
Millipore 17-625 
H3K4me3 ChIP (6μg per sample) Abcam  Ab8580 
H3K36me3 ChIP (3μg per sample) Abcam Ab9050 
H3ac (K9+K14+K18+K23+K27) ChIP (6μg per sample) Abcam Ab47915 
HP1α IF (1:50) 
WB (1:500) 
Millipore  
Millipore  
05689 
MAB3446 
HSF1 ChIP (10μg per sample) 
WB (1:1000) 
Santa Cruz 
Cell Signalling  
sc-9144X 
4356 
Proteasome 20S β6 ChIP (8μg per sample) 
IF (1:100) 
Enzo Life  BML-PW9000 
Proteasome 20S C2 ChIP (8μg per sample) Abcam Ab3325 
S5P-RNAPII (4H8) ChIP (8μg per sample) 
IF (1:1000) 
WB (1:10000) 
Millipore  05-623 
S2P-RNAPII (H5) ChIP (18μg per sample) 
IF (1:50) 
Covance 
  
MMS-129R 
RNAPII (8WG16) WB (1:200) Abcam  Ab817 
Gapdh WB (1:100000) Abcam Ab22555 
α-Tubulin  WB (1:2000 and 1:10000) Sigma  T5168 
HRP-goat anti mouse WB (1:20000) Life Technologies G21040 
HRP-goat anti rabbit WB (1:20000) Santa Cruz  SC2004 
Alexa488 Goat Anti-Mouse 
 
IF (1:600) Life Technologies A11001 
Alexa568 Goat Anti-Rabbit IF (1:600 and 1:200) Life Technologies A11011 
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